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ABSTRACT
In the course of the work presented in this thesis, the construction of solid 
matrix-antibody-antigen (SMAA) complexes as vaccines was further developed. In 
particular, it was demonstrated that it is feasible to assemble SMAA complexes using 
a short oligopeptide tag (Pk) attached to the C-termini of antigens and a Pk tag- 
specific mAb SV5-P-k. In order to facilitate the purification of recombinant proteins 
for immunization purposes, a second affinity tag was attached to the antigen 
N-termini. Initially, the N-terminal tag was 26-lcDa-large thrombin-removable 
glutathione 5-transferase (GST), which pemiitted first-step purification on 
immobilized glutathione. However, because of problems with protein insolubility and 
the proteoly tical removal of GST from the hybrid proteins, the GST domain was 
substituted by an N-terminal 12-amino acid-long tag (His) containing an array of 
6 histidines. The His tag was small and thus did not require removal prior to 
immunization, and allowed purification of His-linked proteins on a nickel-affinity 
column. Moreover, it was possible to preform nickel-affinity chromatography under 
protein denaturing conditions, which allowed purification of insoluble or aggregated 
proteins. In addition, novel prokaryotic expression vectors were constructed for 
a single-cloning-step addition of these N- and C-terminal tags to proteins of interest. 
These vectors were used to individually express all non-glycosylated products 
encoded by the simian immunodeficiency virus (SIV) in E. coli. The SIV envelope 
glycoprotein gpl60 with the Pk tag attached to its C-terminus was expressed in insect 
cells and first-step purified on a lentile lectin column. Following the first purification 
step on either nickel or lentile columns, all SIV proteins were purified and 
successfully incorporated into SMAA complexes using anti-Pk tag mAb SV5-P-k. 
Thus, efficient purification protocols were developed, which purified recombinant 
proteins via two different affinity tags attached to their N- and C-termini and isolated 
predominantly full-size proteins. As a stage in achieving the goal of human 
multivalent vaccines, the SV5-P-k mAb was humanized and is currently being 
expressed in Chinese hamster ovary cells.
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INTRODUCTION
The work presented in this thesis is part of a long term effort to develop 
a universal strategy for construction of multivalent subunit vaccines, and potentially 
vaccines against human immunodeficiency virus (HIV). The vaccine, that is being 
developed in our laboratory, is constructed as solid matrix-antibody-antigen (SMAA) 
complexes.
Part A of the Introduction presents adaptive immune responses generated to 
viral infections, i.e. branches of immunity the induction of which is primarily targeted 
in vaccination. Although antibodies represent important antiviral immune responses, 
part A mainly focuses on antigen processing and presentation to T cells. This is for 
several reasons: (i) it is an exciting and currently quickly advancing area of 
immunology; (ii) these processes are believed, in the majority of instances, to be 
central to the ability of an individual to mount virus-specific effector functions; 
furthermore, (iii) evidence seems to emerge, that cell-mediated immune responses in 
humans and the macaque model of HIV infection and acquired immunodeficiency 
syndrome (AIDS) correlate with protective immunity against immunodeficiency 
viruses; and, finally, (iv) antigen presentation is the part of immunity, that is believed 
to be primarily impaii*ed in patients with AIDS. Part B of the Introduction discusses 
how the knowledge of these pathways is influencing our views on the control of virus 
infections and, more specifically, the design of anti-viral vaccines. Part C introduces 
some molecular aspects of HIV infection and AIDS, in which the HIV genome 
organization, life cycle, pathogenesis and animal models of infection and disease, 
focusing predominantly on the simian immunodeficiency vims (SIV) infection of 
macaques, are discussed. Finally, part D states the objectives of the work.
A. IMMUNE RESPONSES TO VIRAL INFECTIONS.
The nonadaptive defence systems of organisms include external skin and 
internal circulating cells such as phagocytes or natural killer cells, which serve as 
a first-line defence against viruses. In vertebrates, there is a second-line protection 
due to a dual system of humoral and cell-mediated immune responses. These immune 
responses are generated by a cascade of molecular and cellular associations and 
interactions. They are adaptive, specific and display a long-term memory. The 
effectors of humoral responses are antibodies produced by B cells, the binding of 
which to usually extracellular antigens initiates a variety of elimination responses. 
Virus-infected cells are more effectively cleared by processes involving 
T lymphocytes, which are capable of killing cells displaying virus-derived peptides.
A description of the generation of antigen-specific cell-mediated immune responses 
with particular emphasis on viral proteins and a shorter section on humoral responses 
follow below.
A.I. General description of processing and presentation of viral 
antigens to T cells.
A.1.1. T cell subpopulations.
T-cells recognize antigens on the surface of antigen-presenting cells (APC) in 
association with molecules encoded by genes of either the class I or class II major 
histocompatibility complex (MHC) (Zinkemagel and Doherty, 1975), a phenomenon 
known as MHC restriction. Cluster designation markers CD4 and CDS distinguish 
two major populations of T cells, CD4 CD8+ and CD4+CD8", found in the peripheral 
blood of all vertebrate species. These phenotypes correlate to some extent with T cell 
functions. MHC class I-restricted T cells (CD8+) function as cytotoxic T-lymphocytes 
(CTL), which, upon recognition of MHC-antigen complexes, kill the target antigen- 
presenting cells, e.g. virally infected cells. MHC class H-restricted T cells (CD4+) 
play several key roles in the generation of immune responses. By producing soluble
3
factors termed cytokines, they ’help' to carry out the effector functions of the antigen- 
specific immune responses, i.e. they ’stimulate' both antigen-activated MHC class I- 
restricted CTL to kill virus-infected cells and antigen-activated B cells to produce 
antibodies. They also stimulate cells of the non-specific immune responses such as 
macrophages, granulocytes or eosinophils. Depending on the local cytokine 
environment created by cells of the innate immunity early in the response, CD4+
T lymphocytes can differentiate into Thl or Th2 subsets (reviewed by Scott, 1993). 
Thl cells produce predominantly tumour necrosis factor and interferon-yand are best 
at activating macrophages. Th2 cells make predominantly interleukins IL-4, IL-5, 
IL-6 and XL-10 and preferentially activate B cells. Some MHC class H-restricted 
T cells can function as CTL and as such may have an important role in controlling 
certain virus infections, for example, those of measles and herpes simplex viruses.
A.1.2. Cellular handling of antigens for presentation to T cells.
Pioneering work on antigen presentation demonsti'ated that internal proteins 
(e.g. the nucleoprotein), rather than surface glycoproteins, of influenza virus were the 
major target antigens for influenza virus-specific class I-restricted CTL (Townsend et 
fl/., 1984). This was followed by the observation that only part of the gene for 
influenza virus nucleoprotein (NP) sufficed to sensitize hansfected cells to NP- 
specific CTL lysis (Townsend et a/., 1985). The finding that T cells recognize 
peptides rather than whole native antigens, as is the case with antibodies, was finally 
demonstrated by the ability of synthetic peptides to sensitize target cells to CTL 
(Townsend et al., 1986).
During processing for presentation to T cells, antigens are first denatured and 
partially degraded into peptide fragments. Some of these peptides associate with 
MHC molecules and the resulting MHC-peptide complexes are transported to and 
displayed on the cell surface. There are two distinct intracellular pathways, 
endogenous and exogenous, used for processing antigens for MHC class I- and 
class Il-restricted presentation, respectively. In MHC class I presentation, cytosolic 
proteins are degraded by proteases and the resulting peptides enter the lumen of the
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endoplasmic reticulum (ER) where they become associated with newly synthesized 
MHC class I molecules. These complexes are then transported through the Golgi 
apparatus to the cell surface for presentation to specific MHC class I-restricted 
T cells. For the MHC class II presentation, antigens enter acidic vesicles 
(endosomes/lysosomes), usually following their capture by specialized cells (see 
below), where they undergo partial proteolysis. In this compartment, some of the 
resulting peptides become associated with MHC class II molecules and are 
transported as MHC-peptide complexes to the cell surface. The intracellular 
trafficking of MHC molecules and antigens is described in more detail below and is 
schematically illustrated in Fig. 1.
The primary interactions between T cell receptors and MHC-peptide 
complexes (Fig. 2 and below) are essential for the eventual generation of both 
adaptive immunity and some aspects of innate immunity. The parts of peptides 
participating in the T cell recognition of antigen-presenting cells are called T cell sites 
and consist of an epitope and an agretope (Sette et a/., 1987). Amino acid residues 
that physically contact a T cell receptor form an epitope and those binding an MHC 
molecule are called an agretope. However, T cell sites and T cell epitopes are often 
used interchangeably.
A.1.3. MHC polymorphism.
There is a number of gene clusters encoding MHC class I (e.g. HLA-A, B and 
C in humans, and H2-K, D and L in mice) and MHC class II (e.g. HLA-DR, DQ and 
DP in humans; and H-21-A and I-E in mice) molecules. Every individual expresses 
four to six different class I molecules. Not every peptide generated by proteolysis has 
affinity for a given MHC molecule (below). As a result, only a selected set of 
peptides ('-1%) will be presented to T cells. It has been estimated that each MHC 
molecule can present approximately 1000 different peptides on a cell, with each 
species of MHC molecule presenting a different set of peptides. As will also be 
discussed latter, MHC molecules are highly polymorphic (different alleles of MHC 
genes are designated with superscript letters, e.g. H 2Kb or H-2Kd, or by additional
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Figure 1. Cellular handling of antigens.The diagram schematically illustrates the life cycle of a virus (in this case the influenza virus) and how the virus proteins can enter the eiidogenous (MHC class I) and exogenous (MHC class II) antigen processing and presentation pathways in an antigen-presenting cell. Following partial proteolytic degradation, certain virus- derived peptides associate with either MHC class I or II molecules. The MHC-peptide complexes are then transported to the cell surface where they are specifically recognized by T cells bearing T cell receptors.
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Figure 2. Molecular interactions in antigen-specific T cell recognition of antigen- presenting cells.The left-hand side of the figure depicts the interactions during the recognition of 
peptides associated with MHC class I molecules by TCR on a CD8+ T cell (usually a cytotoxic T lymphocyte). The right-hand side of the figure illustrates the recognition 
of MHC class U-peptide complexes by a CD4+ T cell (a helper or possibly a cytotoxic T cell). The key determinant of T cell specificity is the T cell receptor (TCR). The TCR is closely associated with the CD3 complex and either a CD8 or CD4 molecule. The CD3 complex is involved in signal transduction across the plasma membrane following TCR engagement and so are most likely the CD8/CD4 molecules.
numbers and letters, e.g. HLA-Aw68 or HLA-B27) and, as a consequence, different 
individuals in an outbred population will present different sets of peptides to T cells. 
If 1000 different peptides do indeed bind to one MHC molecules, then every 
individual should be able to mount a T cell response to any given virus. Nevertheless, 
for reasons not clear, it appears that non-responding alleles can be found even for 
complex viruses (Bennink and Yewdell, 1988).
The MHC polymorphism has arisen in evolution by selection of individuals 
resistant to different infectious diseases. The extent of MHC polymorphism has been 
carefully adjusted as a result of two antagonistic processes, the ability to present
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peptides vs. positive selection of sufficient variety of T cells in the thymus. An 
excessive MHC polymorphism would not leave, after negative selection of T cells, 
broad-enough specificity of the T cell population for the organism defense. The same 
two antagonistic processes have also determined the length of peptides presented by 
MHC molecules (below).
A.1.4. Antigen-presenting cells.
Cells, which process antigen for presentation to T cells, are termed antigen- 
presenting cells (APC). Virtually every nucleated cell expresses MHC class I 
molecules and thus, when infected, can act as a target for activated CTL. MHC 
class n  molecules are constitutively expressed primarily on haematopoietic cells, but 
a variety of other cells, e.g. epithelial cells in a number of organs, can express MHC 
class n  molecules when activated by cytokines such as interferon 7.
Although any nucleated cell may act as a target cell for MHC class I-restricted 
T cells, it appears that the initial activation of resting virgin T cells may require 
additional factors that can only be supplied by specialized antigen-presenting cells. 
Thus not every antigenic MHC-peptide complex delivered to the cell surface for 
presentation to T cells is necessarily immunogenic. This has been demonstrated in 
several studies of diabetes involving transgenic mice (Ohashi et a/., 1991; Oldstone et 
a/., 1991; Schonrich et al.y 1991). In one of these studies, mice were made transgenic 
for lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) so that they 
expressed the LCMV GP only in pancreatic isle T cells. The mice were 
phenotypically normal and did not develop diabetes. Neither did the offspring arising 
from a cross of these mice with other mice that were transgenic for a T cell receptor 
specific for LCMV GP and thus had a large proportion of T cells that were capable of 
recognizing MHC-LCMV GP complexes. However, when both the single and double 
transgenic mice were infected with LCMV, they rapidly developed lethal diabetes 
(Ohashi et al.y 1991). It thus appears that although pancreatic cells can act as target 
cells for CTL, they are not capable of providing the initial stimuli to activate CTL. 
However, following virus infection, specialized antigen-presenting cells may activate
8a CTL response to LCMV GP resulting in destruction of pancreatic cells and the 
development of diabetes.
The number of MHC molecules present on the cell surface depends on the cell 
type and activation state of the cell, which in turn depends on the presence of 
interferons and other cytokines. It has been estimated that an antigen-presenting cell 
has to display a minimum of 200 antigenic complexes to be recognized by activated 
CTL (Christink e t  al.y 1991). The overall avidity of cell-to-cell interactions may be 
lessened by a negative charge resulting from extensive cell surface glycosylation 
(Boog e t  al.y 1989). However, in addition to the formation of the MHC-peptide-T cell 
receptor (TCR) complexes, other auxiliary interactions between cell surface 
molecules contribute to the intercellular signalling between APC and T cells, e.g. 
interactions of CD8 and MHC class I or CD4 and MHC class II molecules (Fig. 2), 
LFA-1 and ICAM-1, LFA-3 and CD2 (for review see Springer, 1990), CD28 and B7, 
and CD5 and CD72 (Linsley et  al.y 1991; Vandevelde eta l.y  1991). Interactions of 
these molecules increase the overall strength of the T cell binding to APC. These 
interactions also provide necessary additional signals absent in 'non-professional'
APC for the priming of resting T cells, i.e. inducing the progression of T cells from 
Go to G1 phases of the cell cycle, their proliferation, terminal differentiation and 
expression of full T cell functions. Because the affinity of TCR for MHC-peptide 
complexes is very low, the Kd being in the range of 10-4-10-5 M (Matsui et al.y  1991; 
Weber et al.y  1992), it has been suggested that an antigen-independent adhesion 
precedes the TCR engagement (Williams and Beyers, 1992).
While any cell infected with virus may act as a target cell for CTL, only 
specialized antigen-presenting cells may be able to prime CTL. The most potent cell 
type in this respect seems to be the dendritic cell (Young and Steiman, 1990; 
Macatonia et al.y  1989 and 1991). For example, in vitro experiments showed that 
dendritic cells incubated with T cell site peptides were able to prime CTL responses 
to influenza virus while similarly treated macrophages or spleen cells failed to do so 
(Carbone et al.y  1988). The special effectiveness of dendiitic cells in CTL priming
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may be due to their low levels of surface glycosylation (Boog et al., 1989) and high 
levels of expression of surface adhesion molecules (Freudenthal and Steiman, 1990).
A.2. Antigen presentation by MHC class I molecules.
MHC class I molecules are heterodimers consisting of a transmembrane heavy 
chain (or a  chain) and p^-microglobulin (Fig. 2). They can present peptides derived 
from all proteins synthesized in the cell, including those encoded by mitochondria 
(Loveland et al., 1990; Shawar et ah, 1991) as well as proteins targeted or delivered 
to cytosol by in vitro manipulations (Moor et al., 1988). These antigens may include 
self- and viral proteins or proteins originating from intracellular pathogenic bacteria 
that enter cytosol (Brunt et al., 1990). Peptides become associated with MHC class I 
molecules in the ER and/or the Golgi apparatus. The presentation of peptides by 
MHC class I molecules can be specifically abrogated by treatment of antigen- 
presenting cells with drug brefeldin A (Misumi et al, 1986). In these cells, 
biefeldin A blocks the movement of newly synthesized membrane proteins from the 
endoplasmic reticulum to the Golgi apparatus, while endocytosis and protein 
synthesis are not inhibited.
A.2.1. Calnexin, an accessory molecule for MHC class I biosynthesis.
When the biogenesis of MHC class I molecules was studied in three murine 
tumour cell lines, a novel protein of 88 kDa (p88) was identified and partially 
characterized (Degen and Williams, 1991). Murine p88 and its human counterpart 
IP90 (Hochstenbach et a l, 1992) were later shown to be identical to calnexin, 
a Ca2+-binding protein present in the ER (Ahluwalia et al, 1992). Calnexin rapidly 
and quantitatively associates with newly synthesized MHC class I heavy chain and 
the rate of dissociation of these complexes correlated well with the rate of transport of 
MHC class I heavy chain from ER to the Golgi. However, calnexin also associates 
with other nascent proteins in the ER and seems to assist generally with correct 
protein folding.
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Not all newly synthesized MHC class I heavy chains and Pi-microglobulins 
assemble into stable complexes and excess free P2-microglobulin is secreted out of 
the cell (Neefjes and Ploegh, 1988). This suggests that there are limiting amounts of 
peptides in the ER. Such a situation would ensure that bystanding cells are not 
sensitized to CTL lysis following capture of secreted antigenic peptides by their 
unloaded cell surface MHC molecules.
A.2.2. Interaction of peptides with MHC class I molecules and analysis of
naturally processed MHC class I-associated peptides.
A landmark in elucidating the way how peptides bind to MHC heterodimers 
was the determination of crystal structure of human HLA-A2 molecule (Bjorkman et 
al„ 1987). It revealed a single peptide-binding groove on the MHC heavy chain 
formed by two a-helices and a p-pleated floor. It was only recently, that the atomic 
details of peptides bound to MHC class I molecules were determined. Three virus- 
derived synthetic peptides of different lengths and sequences were bound to the 
murine H-2K^ molecule in an extended P-structure (Fremont et aL, 1992; Matsamura 
et al., 1992; Zhang et al., 1992). The peptides appeared anchored by their termini in 
the groove with a certain amount of freedom in their central portions. Crystal 
structures of two human class I molecules, HLA-Aw68 (Silver et al., 1992; Guo et 
al., 1992) and HLA-B27 (Madden et al., 1992) containing antigenic peptides were 
also resolved and supported the same general principles for interaction of peptides 
with class I heavy chain. Peptides bind the groove in the same orientation with their 
N- and C-termini buried within conserved pockets at the ends of the binding cleft. 
The pockets hold peptides by bonds made to the peptide main chain of the first two 
and last two amino acids as well as to the terminal a-amino and carboxyl groups. 
These interactions are tight, involving a network of van der Waals and hydrogen 
bonds, and completely exclude solvent molecules from the intermolecular surfaces. 
Peptide side chains interact with four other pockets in the middle of the binding 
groove and determine the MHC allele specificity. The middle portion of the peptides
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is less constrained by the MHC cleft, which can accommodate longer peptides by 
bulging away from the binding groove.
These principles may not apply to all MHC class I molecules, or, 
alternatively, just one end of the antigenic peptide may, in some cases, form 
sufficiently antigenic complexes. Thus the murine MHC class IH-2L^ molecule was 
reported to present efficiently two different five-amino acid-long peptides derived 
from murine cytomegalovirus (Reddehase et al., 1989) and lymphocytic 
choriomeningitis virus (Whitton et al., 1989). It was shown independently, that the 
latter peptide, GVYMG, overlapped the most effective nonapeptide RPQASGVYM, 
and even a four-residue peptide GVYM still, although inefficiently, sensitized target 
cells to CTL lysis (Schulz et al., 1991).
In order to analyze directly natural peptides bound to MHC molecules, two 
groups of workers purified murine class I molecules from virally infected cells and 
acid eluted the bound peptides. Firstly, a vesicular stomatitis virus-derived peptide 
was isolated that associated with H -2 K h , but did not bind to H -2 D b  molecules (Van 
Bleek and Nathenson, 1990). The second study identified different naturally 
processed influenza peptides presented by either H -2 D h  or H -2 K ^  molecules 
(Rotzschke et al., 1990). The eluted peptides contained 8 or 9 residues and their 
fidelities were confirmed by highly efficient recognition of their corresponding 
synthetic analogues by CTL.
A.2.3. MHC class I molecules present self-peptides.
The observation that viral peptides stabilize the association of MHC class I 
heavy chain with p2~inicroglobulin and enhance the transport of this complex out of 
endoplasmic reticulum (Townsend et al., 1989 and 1990) led to the proposal that in 
uninfected cells, MHC class I molecules are loaded with peptides derived from self­
proteins. This notion was in agreement with several X-ray crystallographic studies 
showing significant electron densities in the binding groove of three human MHC 
class I molecules, which were hard to resolve, possibly because of the variety of 
potential self-peptides present in the same protein crystal (Bjorkman et al., 1987;
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Garrett et a l, 1989; Madden et al, 1991). These speculations were proved correct by 
eluting pools of heterogeneous self-peptides from H-2K^, KP, and HLA-A2.1 
molecules (Falk et al, 1991). The majority of these peptides was 8 or 9 amino acids 
long. The pools of peptides were microsequenced as a mixture and abundances of 
amino acids at each peptide position revealed agretope motifs characteristic for each 
MHC molecule. The origins of self-peptides were first identified by separating 
peptides eluted from HLA-B27 on HPLC and sequencing each peptide individually 
(Jardetzky eta l, 1991). By comparing the peptide sequences with database 
sequences, 7 out of 11 peptides was possible to identify as being derived from 
abundant cytosolic or nuclear proteins such as histones, ribosomal proteins and 
members of the 90K heat-shock protein family. Obviously, mechanisms inducing 
self-tolerance must have ensured that MHC molecules presenting self-peptides did 
not induce deleterious immune responses against 'self. Since then, many allele- 
specific motifs for MHC class I molecules have been identified (Rammensee et a l, 
1993).
A.2.4. Prediction of MHC class IT  cell sites.
The finding that short synthetic peptides sufficed to sensitize target cells to 
CTL lysis in vitro and could indeed induce specific CTL in vivo created high 
expectations for peptide vaccines and initiated a number of studies identifying 
immunodominant T cell sites. Several computer algorithms were developed which 
attempted, with varying degrees of success, to predict T cell sites from the protein 
amino acid sequences based either on the ability of a particular amino acid stretch to 
form an amphipathic structure (DeLisi and Berzofsky, 1985) or on the best fit to 
a consensus sequence common to known T cell sites (Rothbard and Taylor, 1988). 
With increasing amounts of data, it became apparent that neither approach would be 
entirely satisfactory. However, from the sequences of the peptides eluted from MHC 
class I, it was possible to identify MHC allele-specific motifs, i.e. agretope amino 
acids important for binding to an MHC molecule (Jardetzky et al, 1991; Falk e ta l, 
1991; Hunt etal, 1992; Chicz etal., 1992). Since then, consensus agretope motifs for
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a number of MHC molecules have been determined and summarised by Rammensee 
and colleagues (1993). The MHC class I binding agretope usually consists of one 
position in the carboxyl-terminus of peptides requiring a certain amino acid side 
chain, and one position with strong amino acid preferences elsewhere depending on 
the MHC allele (Maryanski et aL, 1989 and 1990; Madden et ah, 1991; Fremont et 
al,, 1992). The remaining positions within the peptide are fairly unrestricted. On the 
other hand, some amino acids at certain positions in peptide ligands might be 
’forbidden’.
Â.2.5. MHC locus as a cassette for antigen processing and presentation.
MHC class I molecules present peptides derived predominantly from 
cytoplasmic proteins. Because protein degradation is thought to occur at least initially 
in the cytoplasm, peptides must cross a membrane to enter the lumen of the ER for 
association with newly synthesized MHC class I molecules. Genes in the MHC locus 
code for at least two other classes of proteins that may be involved in antigen 
processing. These are subunits of a cytoplasmic proteasome thought to be involved in 
antigen degradation and putative peptide transporters involved in the transport of 
peptides from the cytosol to the lumen of the endoplasmic reticulum.
Â.2.6. Proteolytic degradation of antigens for MHC class 1 presentation.
It has been suggested that a set of processing-associated genes within the 
MHC class n  locus relates to the proteolytic degradation of antigens for MHC class I 
presentation (Monaco and McDevitt, 1982,1984 and 1986). At least two genes in this 
region, LMP2 and LMP7, code for subunits of a special type of cytoplasmic 20S 
proteasomes (or multicatalytic protease complexes) called the low molecular weight 
polypeptide (LMP) complex (Brown etal., 1991). LMP consists of about 13-15 
polypeptides encoded by distinct sets of genes. Both of the LMP2 and LMP7 genes 
from MHC have been cloned, but recent evidence showed that these proteasome 
subunits were not essential for presentation of antigenic peptides from influenza virus 
and intracellular proteins (Arnold et al., 1992). However, these data did not exclude
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a more subtle contribution of the LMP complex to peptide generation. In fact, very 
little is known about the proteolytic degradation of antigens for class I presentation 
and alternative mechanisms to proteolysis for generation of peptides have been 
discussed (Fetten et al., 1991; Boon and Van Pen, 1989).
A.2.7. Transport of peptides from the cytosol to the lumen of the ER and
association of peptides with MHC class I molecules.
Studies on mutant cell lines, in which MHC class I heavy chain and 
p2-microglobulin were efficiently synthesized, but the MHC heterodimers did not 
seem to reach the cell surface, have suggested a role for peptide transporters in the 
translocation of peptides from the cytosol to the lumen of the endoplasmic reticulum. 
In these cells, the surface expression of MHC molecules was significantly increased 
by addition of virus-derived peptides, even though the same virus previously failed to 
sensitize the mutant cells to CTL (Townsend et ah, 1989). Further analysis of the 
phenotypic defect indicated that the presence of peptides was critical for association 
of the MHC class I heavy chain with P2-ttiicroglobulin (Cerundolo et al., 1990; 
Ljunggren et al., 1990; Hosken and Bevan, 1990). Some of the cell lines with 
presentation defect had been previously characterized as having deletions in the 
class n  region of the MHC locus (Townsend et al., 1990; Ljunggren et al., 1990). 
Two of the missing genes, TAP^I and TAP-2 (for transporter associated with antigen 
presentation), belonged to the ’ATP-binding cassette’ (ABC) superfamily (Monaco et 
al., 1990; Deverson et al., 1990; Trowsdale et al., 1990). All members of this family 
contain a domain homologous to a putative ATP-binding site and transport molecules 
ranging from metal ions and small sugars to proteins, some over 100 kDa, across 
biological membranes. Reconstitution studies of the mutant cell lines revealed that 
a defect in either the TAP-1 or TAP-2 gene alone resulted in a defect in antigen 
presentation and a loss of surface expression of MHC class I molecules (Spies and 
Demars, 1991; Attaya et al., 1992). It has been suggested that the products of the 
TAP-1 and TAP-2 genes form heterodimers that transport peptides across the ER 
membrane.
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Direct evidence for the proposed role for the products of TAP genes the 
peptide transmembrane transport is still awaited. Relatively convincing functional 
arguments came from an elegant experiment involving a minigene expressing a T cell 
site from influenza virus matrix protein introduced into an MHC class I-defective cell 
line T2 (Anderson et al., 1991). Transfected T2 cells were recognized by class I- 
restricted CTL only if the matrix T cell site was linked to a signal sequence that 
targeted the hybrid oligopeptide to the lumen of the ER via the signal-recognition 
particle-dependent transport mechanism. Thus, if peptides reach the lumen of the ER, 
T2 cells possess all the machinery required for transporting stable MHC-peptide 
complexes to the cell surface. Additional support for the role of peptide transporters 
came from studies which demonstrated that the transporters themselves were 
polymorphic and could influence the selection of peptides finally displayed on the 
cell surface by MHC class I molecules (Powis et al., 1992).
On the other hand, several observations question the proposed role for the 
peptide transporter function of the TAP proteins. Spherical vesicles made from 
membranes of rough ER called 'rough microsomes' are generally impermeable to 
proteins lacking the signal sequence. However, short peptides of up to ten residues 
could enter microsomes generated from the ER of T2 cells (Levy et al., 1991). Since 
these peptides entered the microsomes in the absence of ATP, it was concluded that 
ATP-dependent transporters were not involved in this translocation. Although the 
absence of ATP in preparations is always a disputable point, so far there have been no 
reports of the binding of nucleoside phosphates to TAP proteins (Gaskins et al.,
1992).
There is also some debate as to whether peptides of appropriate length 
(octapeptides and nonapeptides) for association with MHC class I molecules are 
generated in the cytoplasm prior to or during the transport into the lumen of the ER, 
or whether larger peptides are trimmed by proteases in the ER to the appropriate size, 
possibly after their association with MHC molecules (Wallny et al., 1992). The 
evidence for trimming of peptides is indirect. It is known that T2 cells can present 
a limited set of endogenous peptides. Wei and Cresswell (1992) sequenced three such
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peptides and found that two, a 9-mer and an 11-mer, were derived from putative 
signal sequences that would have entered the ER via normal signal-recognition 
particle-dependent transport. The third peptide of unknown origin was a 13-mer. The 
presence of correct nonapeptides (in addition to the longer peptides) suggests that 
some trimming may have occurred in the ER to generate the peptides of the 
appropriate length (see also Henderson et al., 1992). Specific antigenic peptides can 
not be detected in cells unless the MHC molecules to which they bind are also present 
(Falk et al., 1990; Wallny et al., 1992). Thus, if the right-size peptides are generated 
in the cytoplasm prior to or during the transport into the ER, peptides in the ER 
unprotected by binding to MHC molecules must have a very short half-life. By the 
same token, the peptide short half-life in the ER argues for the presence of a strong 
proteolytic activity in the lumen of the ER.
A.2.8. Non-classical MHC class I molecules.
All the above work has concerned classical MHC class I, i.e. class la, 
molecules. The MHC loci in humans and mice also contain clusters of non-classical 
class I heavy chain genes designated as MHC class Ib molecules (H-2Q, T and M in 
mice.) Both class la and Ib heavy chains associate with p2-microglobulin. MHC 
class Ib molecules display much less polymorphism than class la and class II 
molecules. The allelic differences in the sequences of class Ib genes are only about 
1%, which is typical for most other genes and differs markedly from 15% of the 
class la genes. The immunological function of MHC class Ib molecules is largely 
unknown. Originally, it was suggested that they may simply serve as a sequence pool 
for generating class la polymorphism (Flavell et al, 1986), Evidence for an immune 
function of MHC class Ib molecules involved several T cell clones bearing yS T cell 
receptors that were restricted by H-2T molecules (Bluestone et al, 1991). 
Subsequently, it was shown that class Ib-containing MHC complexes could present 
foreign peptides derived from intracellular bacteria and that H-2M3 molecules 
specialized in presentation of N-formylated peptides (Loveland et a l, 1990; Shawar 
et a l, 1991). The first MHC allele-specific motif was determined for H-2Qa-2
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molecules (Rotzschke et al., 1993). The extrapolation of these studies would be that 
other class Ib molecules can also present foreign peptides, however, no function in 
combating viral infections has yet been reported.
A 3. Antigen presentation by MHC class II molecules.
MHC class n  molecules (HLA-DR, DQ and DP in humans and H-21-A and I- 
E in mice) are heterodimers consisting of transmembrane a  and (Î (heavy) chains 
(Fig. 2) and, in association with antigenic peptides, stimulate CD4+ T lymphocytes. 
As outlined above, the pathway of antigen processing for presentation to class II- 
restricted T cells is clearly different from that for MHC class I presentation. A central 
role in the MHC class II pathway is played by the acidic vesicles 
(endosomesAysosomes) of the cell. It is in these vesicles where the class II antigenic 
peptides are generated and become associated with MHC class II molecules. The two 
different processing and presentation pathways reflect the fact that antigens 
synthesized within the ceil (usually derived from the cytosol of an AFC) are 
presented by MHC class I molecules, while any antigen, that reaches the 
endosomal/lysosomal compartment (usually via receptor mediated endocytosis, 
phagocytosis or pinocytosis), is processed for MHC class II presentation. In this way, 
antigens for class II presentation never enter the cytosol and remain inside vesicles 
within the cell. Processing of antigens for class n  presentation is sensitive to 
lysosomotropic agents such as chloroquine, which buffer the acidic environment of 
the late endosomal/lysosomal compartment and thus prevent the lowering of internal 
pH necessary for dénaturation and catabolism of internalized antigens.
A 3.1. Binding of peptides to MHC class ÎI molecules.
The molecular details of the MHC class II binding groove-peptide interactions 
were resolved by determining the crystal structure of peptide-containing HLA-DRl 
(Brown et al., 1993). The structure confirmed the validity of the MHC class II 
structure model based on MHC class I crystallographic data. Differences were
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observed in that the ends of the two side a-helices leave the cleft more 'open'.
Peptides did not appear to be buried in the groove as in the case of MHC class I 
molecules, but rather lay straight in the groove projecting from both ends with no 
apparent kink in the central region. There was a non-polar pocket near one end of the 
groove in which an anchoring amino acid side chain resided. Interestingly, the crystal 
structure suggested a dimerization of HLA-DRl ap heterodimers.
Peptide-binding assays suggest that class II molecules bind peptides with high 
affinities reaching 10'^ M (Roche et al, 1991) and that strongly binding peptides 
share allele-specific structural motifs (Jardetzky e ta l, 1990; O'Sullivan e ta l, 1991). 
Site-directed mutagenesis studies of MHC molecules and single-residue substitutions 
in peptides have provided further information on the importance of individual amino 
acids in the MHC class II-peptide-TCR interactions (Krieger et a l, 1991).
In an analogous series of experiments to the characterisation of naturally 
occurring peptides bound to MHC class I molecules, peptides have been acid eluted 
from purified MHC class II molecules and microsequenced. Peptides generated by 
natural processing and presented by MHC class II complexes were first identified for 
mouse I-Al) and I-Eb molecules (Rudensky e ta l, 1991a). They ranged from 13 to at 
least 17 amino acid residues and this study suggested that the peptides where 
precisely defined at their N-termini while their C-termini varied. Since then, data has 
become available on peptides isolated from several other MHC class II molecules 
(Hunt et a l, 1992; Nelson et al, 1992; Kropshofer et a l, 1992; Chicz et al, 1992). 
The size of naturally processed peptides ranged from 12 to 25 amino acids long, 
depending on the particular class II molecule. In contrast to earlier work, these studies 
suggest that there seems to be an allele-specific core sequence involved in binding the 
peptide to the groove of the MHC class H molecule (Hunt et al, 1992; Chicz et al, 
1992) and variable length sequences extending at both the N- and C-termini. The 
'ragged' ends of peptides argues against the instructive role of MHC class II 
molecules, i.e. against the trimming of peptides after binding to MHC class n  
heterodimers.
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As with class I molecules, antigenic peptides may contribute to the stability of 
MHC class n  ap heterodimers (Sadegh-Nasseri and Germain, 1991; Germain and 
Hendrix, 1991). Two forms of murine class II molecules have been reported in 
unboiled spleen immunoprecipitates that differed in stability and potentially in 
conformation. The more stable form remained associated on SDS-PAGE, while the 
less stable dissociated into a  and p monomers. The relative amounts of the two forms 
varied for different haplotypes and class II molecules. Pre-incubation of spleen cells 
with antigen (hen egg-white lysozyme; HEL) significantly increased the levels of the 
stable form and produced a conformational change detectable by a monoclonal 
antibody. Other studies showed that the stability of class II aP chain-peptide 
complexes is also influenced by pH (Jensen, 1990) and the phospholipid composition 
of membranes harbouring MHC molecules (Roof et a i, 1990).
A.3.2. Contact of TCR with MHC-peptide complexes.
Similarly to the antibody variable regions, each a  and p chain of TCR contains three 
hypervariable complementarity-determining regions (CDR) (Davis and Bjorkman,
1988). The conformations of the MHC and TCR complexes suggested that the 
residues of TCR contacting the peptide epitopes predominantly reside in CDR3, that 
is in the CDR closest to the constant domain (Chothia et al., 1988; Claverie et al.,
1989). The study that supported this model (Jorgensen et al., 1992) involved injecting 
a series of peptides with a single amino acid substitution in the epitope, i.e. changes 
affecting the TCR recognition but not the MHC binding, into transgenic mice 
carrying genes for either the a  or P chains of TCR of a T cell line recognizing the 
original peptide (see Fig. 2). After each immunization of these 'half transgenic mice, 
hybridomas were prepared using the responding T cells and genes for their 
endogenous TCR chains were sequenced. This approach revealed that substitutions in 
the peptide were reflected by reciprocal substitutions in CDR3 of the 'endogenous' 
chains.
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A.3.3. Prediction of MHC class H T cell sites.
Since the binding of peptides to class H molecules does not appear to be as 
selective as the binding of peptides to class I MHC molecules, it may prove difficult 
to predict agretopes that facilitate the binding of peptides to class H molecules. On the 
other hand, since the binding of peptides to class II molecules appears to be more 
permissive than the binding of peptides to class I molecules, the parameters used for 
predicting class IIT  cells sites may not need to be so rigid.
A.3.4. Proteolytic degradation of antigens for MHC class II presentation
and its subcellular localization.
The exact subcellular compartment involved in antigen degradation for MHC 
class n-restricted presentation continues to generate some dispute. It has been shown 
for at least some antigens, that unfolding is a prerequisite for efficient proteolysis 
(Collins eta l, 1991; Jensen, 1991). For example, generation of peptides from HEL 
capable of binding to I-A^ requires the reduction of HEL's four disulphide bonds.
This reduction occurred in lysosomal but not in membrane/endosomal fractions 
(Jensen, 1991). The importance of lysosomes in processing protein antigens was also 
demonstrated in experiments involving liposomes of various chemical compositions 
used to deliver four different proteins to either lysosomes or endosomes. In every 
case, antigens were much more immunogenic when targeted to lysosomes (Harding et 
al.y 1991a and 1991b). Although these results did not exclude endosomal processing 
for other antigens, lysosomes were the primary catabolic compartment for the tested 
antigens. In contrast, an ultrastructural study using immunogold labelling of MHC 
class n  demonstrated that endosomes have all the properties required for processing 
and presentation of antigens (Guagliardi et al., 1990), In essence, there seems to be 
a late endosomal/lysosomal compartment where degradation of antigens and coupling 
of the resulting peptides to MHC class II molecules occurs. At present, there is little 
data available on how MHC class E-peptide complexes are transported out of such 
a compartment to the cell surface.
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Experiments addressing the proteases involved in antigen degradation for 
MHC class n  presentation proved to be largely difficult to interpret, mainly because 
of the diverse effect of protease inhibitors on APC. The conclusion was that a number 
of proteases, in particular cathepsin D (Van Noort et al., 1991) and E (Bennett et al., 
1992), residing in the endocytic pathway subtly contributed to the proteolysis 
depending on the cell type and the particular route by which antigens reached the 
lysosomal compartment. Indeed, the observations that peptides of different lengths 
and with poorly defined termini can be isolated from MHC class II molecules 
suggests that they might have been generated by different proteases. This in turn may 
reflect a multiplicity of routes by which the peptides reached the 
endosomal/lysosomal compartment. It should also be noted that although MHC 
class n  molecules become loaded with self-peptides (Rudensky et al., 1991a and 
1991b; Hunt et al., 1992; Nelson et al., 1992; Kropshofer et al., 1992; Chicz et al.,
1992), it appears that a higher proportion of unloaded MHC class II molecules 
(1-20%) reaches the cell surface compared to MHC class I molecules (<0.3%; Chen 
and Parham, 1989).
A.3.5. The role of MHC class H-associated invariant chain.
The trafficking of MHC molecules and antigenic peptides within the cell is the 
key to the differential presentation of peptides by the two classes of MHC molecules. 
The intracellular pathways and association of MHC class II heterodimers with 
peptides is in part regulated by a molecular 'chaperon' termed the invariant chain 
(Teyton et al., 1990). The invariant chain forms a homotrimer and as such 
temporarily interacts with three MHC class II ap chain dimers (Roche and Cresswell, 
1991a). In doing so, it fulfils two critical functions: it prevents newly synthesized 
MHC class n  molecules from binding antigenic peptides during the early stages of 
their assembly and transport in the ER (Roche and Cresswell, 1991b), and it directs 
the assembled MHC class II molecules to the acidic endocytic compartment (see 
Fig. 1). In this compartment, the invariant chain is proteolytically degraded and 
releases 'empty' class n  ap  dimers which are now available for peptide binding
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(Roche and Cresswell, 1991b). Both signals, the first that retains the invariant chain 
in the ER until its association with the MHC class H molecules and the second 
responsible for delivering class E-invariant chain complexes into endosomes, are 
located in the cytoplasmic tail of the invariant chain (Bakke and Dobberstein, 1990; 
Lotteau et al, 1991).
A.3.6. Presentation of endogenous antigens by MHC class 11 molecules.
Studies involved in the processing and presentation of the surface antigen of 
hepatitis B virus (Jin et aL, 1988) and antigens of measles and influenza viruses 
(Jacobsen et aL, 1989) demonstrated that MHC class E molecules can present 
endogenous antigens, although less efficiently than the MHC class I molecules. For 
this presentation to occur, the endogenous antigens still have to follow the 
endosomal/lysosomal pathway, for example by internalization of membrane proteins. 
A series of studies using immunoglobulin X light chain (Weiss and Bogen, 1989 and 
1991) and HEL (Brooks et ah, 1991; Moreno et al., 1991) showed that peptides of 
endogenous origin may also be introduced into the MHC class E pathway by being 
targeted to particular cellular compartments. Thus peptides derived from mutated 
X chains retained in the vacuolar system by preventing the formation of a disulphide 
bond in the X variable region, or held in the ER by addition of the KDEL sequence 
were presented by MHC class II molecules. The same T cell site did not associate 
with MHC class II molecules when retained in the cytosol or nucleus, or when 
secreted out of the B cells.
Â.4. Viral mechanisms interfering with antigen processing and 
presentation.
The importance of cell-mediated immunity in controlling virus infections can 
also be inferred from the different molecular mechanisms viruses have evolved to 
interfere with the processing and presentation of antigens to T cells. These 
mechanisms may include a general 'shut off of host protein synthesis, which is likely
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to contribute to the overall decrease of cell surface expression of MHC complexes, as 
well as more specific mechanisms. To illustrate this point, a few examples of the 
ways in which adenoviruses, pox viruses and herpesviruses have evolved to evade the 
immune response will be briefly described.
Striking examples of evasive strategies have been developed by human 
adenoviruses, which carry in their genomes a cassette of genes protecting infected 
cells from the immune response. Most of these genes are clustered in an early 
transcriptional region E3. Functions of all the gene products from this region have not 
been elucidated, but, for example, glycoprotein 19K binds newly synthesised MHC 
class Î heavy chains and blocks their transport from the ER (Kvist et ah, 1978; Paabo 
et a i, 1986; Jefferies and Burgert, 1990), thus preventing the adenovirus-infected 
cells from displaying MHC class I-peptide complexes (Burgert et al., 1987; Rawle et 
al., 1989). However, deletion of E3 resulted in disease exacerbation, probably due to 
increased immunopathology (Ginsberg etal., 1989). Two other proteins from E3 and 
one from ElB regions protect infected cells against cytolysis induced by tumour 
necrosis factor. In addition, a protein encoded by El A region has been demonstrated 
to down-regulate transcription of the MHC class I gene (Schrier et al., 1983; Bernards 
etal., 1983).
Different anti-antiviral tactics have been developed by certain poxviruses. 
Vaccinia virus, for example, possesses genes (B13R and B24R) that code for proteins 
of the serine-protease inhibitor family (serpins) (Kotwal and Moss, 1989; Smith et 
al., 1989). A putative function of viral serpins is that they inhibit cellular proteases, 
some of which are involved in antigen degradation, and thus reduce the presentation 
of virus-specific peptides. It is known that recombinant vaccinia viruses which 
express antigens under the control of early promoters can induce CTL responses, 
while those expressed under the control of late promoters tend only to induce 
antibody responses (Coupar et al, 1986). Since serpins are expressed late, they may 
be involved directly in interference with antigen processing and presentation at late 
times in infection, although direct evidence for their role is still awaited. The 
production of seipins appears to be only one of a battery of molecules that poxviruses
•I
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produce that interfere with the immune response. For example, vaccinia virus also 
produces soluble homologues to the interleukin-1 (IL-1) and IL-6 receptors (Smith 
and Chan, 1991; Alcami and Smith, 1992). Since IL-1 and IL-6 have a broad 
spectrum of effects and are known to play important roles in the regulation of 
immune responses, it has been suggested that the vaccinia virus homologues can 
interfere with the immune response by blocking the effects of these cytokines. It has 
also been suggested that the serpins may interfere with the conversion of pro-IL-lp to 
the active form, IL-ip (Ray etal., 1992).
Herpesviruses also appear to have developed a number of specific 
mechanisms for interfering with antigen processing and presentation. Human 
cytomegalovirus interferes with the transport of MHC class I molecules from the 
endoplasmic reticulum to the cell surface and, in addition, encodes a protein of high 
homology with the MHC class I heavy chain capable of binding the human 
P2-microglobulin (Browne et al., 1990). The proposed function of this protein in vivo 
is to prevent the assembly of MHC class I complexes by sequestering 
P2-microglobulin, and so render the cytomegalovirus-infected cell unrecognizable by 
CTL.
A.5. Superantigens.
A separate class of immunogenically potent molecules presented by MHC 
class II complexes and recognized by T cell receptors is termed 'superantigens'
(White et al., 1989). The most distinct feature of superantigens is that a single 
superantigen can stimulate a large proportion of ap TCR-bearing T cells, for some 
reaching up to 30% of the entire T cell population. This hyperimmunogenicity is 
because the MHC class Il-superantigen complexes are recognized only by Vp (the 
variable region of P-chain), or in some cases Vy, of T cell receptor, while MHC 
class II molecules complexed with conventional antigenic peptides are contacted by 
all the variable elements of TCR (Va, Ja, vp. Dp and Jp). This results in a much 
higher specificity of T cells recognizing conventional antigens. Indeed, the frequency
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of T cell responses to a peptide antigen ranges usually from 10"^  to 10"^ . The fact that 
superantigens interact with specific regions of the TCR distinguishes them from 
polyclonal T cell mitogens, such as concanavalin A. Furthermore, superantigens bind 
the MHC molecule at sites distinct from the peptide-binding groove (Dellabona et al.,
1990) [and different staphylococcal toxins bind to distinct sites on an MHC class II 
molecule (Scholl et al., 1989)], they do not require intracellular processing (Fraser et 
al., 1989) and their recognition is only marginally restricted by the MHC allele. 
Interactions between MHC molecules and superantigens (Dellabona et ah, 1990), 
MHC molecules and Vp of TCR (Fleischer et ah, 1991), and superantigens and Vp 
(Pullen et ah, 1990; Gascoigne and Ames, 1991) have been demonstrated and shown 
to be involved in the generation of T cell responses. The sole binding of some 
superantigens to MHC class II molecules can induce transcriptional activation and 
increase in MHC-bearing cell adhesiveness (Trede et ah, 1991), and may synergize in 
lymphocyte proliferation (Fuleihan etal., 1991).
A.5.1. Classification and manifestation of superantigens.
Superantigens can be divided into to two categories: foreign and self. The 
former comprize many bacterial products including e.g. staphylococcal enterotoxins, 
causative agents of food poisoning and toxic shock syndrome, or streptococcal toxins, 
whose involvement in multiple autoimmune diseases and immunodeficiencies in 
humans have been suggested (Heber-Katz and Acha-Orbea, 1989). The latter are 
exemplified by endogenous antigens found in mice - minor lymphocyte-stimulating 
determinants (Mis; Festenstein, 1973). There are two major manifestations of self­
superantigens. Firstly, certain self-superantigens eliminate during T cell selection in 
thymus those T cells, which carry TCR VP chains specific for these superantigens. 
Secondly, they cause an extensive proliferation in a mixed-lymphocyte assay, i.e. they 
are seen as ’alloantigens' in mixed cultures of spleen cells isolated from mouse strains 
that carry identical MHC genotypes, but differ in their Mis loci.
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A.5.2. Retroviral superantigens.
Self-superantigens have recently acquired a virological dimension. Although 
the Mis loci are unlinked to MHC, they co-segregate with integrated genomes of 
endogenous retroviruses, murine mammary tumour viruses (MMTV; Frankel et al., 
1991; Woodland et al., 1991; Dyson et al., 1991). In addition, an exogenous MMTV 
encodes a maternally inherited superantigen (Marrack and Kappler, 1991). The 
superantigen was transmitted from an infected mother to her offspring after birth 
(presumably in the milk) and caused a deletion of Vpl4+ T cells in the progeny. 
Further analysis located the superantigen gene to an open reading frame in the 3' long 
terminal repeat (LTR ORF) of MMTV (Choi et al., 1991). This finding was 
confirmed by depletion of Vpl4+T cells in mice transgenic for both the whole 
MMTV and for just the LTR ORF. LTR ORF comparison of different MMTV 
variants located the vp  specificity to the C-terminal of the gene product (Acha-Orbea 
et al., 1991). Another and potentially more important finding was a demonstration of 
a Vp5“Specific superantigen expressed by a defective murine leukaemia virus, which 
induces an AIDS-like disease in mice (Hugin et al., 1991). B cell lymphomas 
presenting this retroviral superantigen caused a VP5+ T cell proliferation, which was 
possible to block by gag p30-specific antibodies. Thus, superantigens may represent 
yet another mechanism for perturbation of the fine equilibrium of our immune 
system, potentially contributing to the development human AIDS.
A.5.3. What is the biological function of superantigens?
What is the function of superantigens that preserved them through the 
evolution? There are probably 20 to 30 integration sites for MMTV in mice, these are 
relatively recent in evolution and may not have their counterparts in other mammals 
as e.g. no endogenous superantigens have yet been detected in humans. In mice. Mis 
could evolve to delete bacterial toxin-responsive T cells (Marrack et al., 1990). On 
the other hand, subtle changes in either the Mis loci or the respective Vp regions were 
found in wild mice, preventing the negative selection of Vp+ T cells during the 
maturation in thymus (Cazenave et al., 1990). In addition to negative selection, a role
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of Mis in positive selection has been also observed (Benoist et al., 1989) as well as 
their ability to potentiate conventional antigen presentation (Janeway et al., 1983). 
This led to the suggestion of a co-ligant function for superantigens (Janeway et al.,
1989), whereby Mls-like structures would in special cases stabilize or orient the TCR- 
MHC interactions. Also, because bacterial superantigen stimulation does not require 
the CD4 molecule (Fleischer and Schrezenmeier, 1988; Sekaly et al., 1991), these 
superantigens may substitute for the CD4 function. These properties could be 
exploited for potentiating immune responses induced by vaccines. In any case, 
superantigens in mice exert a strong influence on the shaping of the T cell repertoire. 
Their true biological function and role in autoimmune and immunodeficiency 
diseases, however, remains obscure.
A.6. Humoral immune responses.
Humoral immune responses defend an organism primarily against the 
extracellular phase of viral infections. They are mediated by antibodies, which 
circulate throughout the body in the lymph and in the blood serum. Antibodies are 
produced by B lymphocytes, which upon recognition of a foreign antigen differentiate 
into antibody-secreting plasma or memory B cells. For most antigens, these processes 
are assisted predominantly by helper Th2 cells (above). Once produced, antibodies 
can bind to a virtually unlimited number of surface structures on the virus and 
neutralize it by either preventing attachment to and/or penetration into the host cells, 
or opsonizing the virus for efficient phagocytosis by macrophages. In some instances, 
these processes may happen more efficiently in the presence of complement.
Antibodies recognize small antigenic determinants called epitopes, which can 
be continuous or discontinuous (Barlow et al, 1986). Discontinuous epitopes depend 
on the tertiary and quaternary protein structures and are always conformationally 
sensitive, i.e. are destroyed upon antigen dénaturation or proteolytic degradation. 
Continuous epitopes consist of a linear array of amino acids and are usually 
conformationally sensitive. Epitopes are defined operationally, that is by recognition
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by antigen-binding sites on antibodies, called paratopes. It is assumed that all epitope- 
paratope interfaces involve a surface area of approximately 700 Â2, as it was shown 
in the case of lysozyme (Amit et ah, 1986). From the known folding patterns of many 
globular proteins, this assumption implies, that no surface epitope region is likely to 
contain only a single continuous stretch of amino acid residues. Thus, 'continuous 
epitope', in fact, usually represents only part of a larger discontinuous determinant. It 
follows that linear peptide fragments are likely to have only a across-reactive 
antigenicity with the native protein, from which they were derived. As discussed 
below, this raises some theoretical questions about peptide vaccines. Several 
computer programmes have attempted to predict linear cross-reactive fragments from 
the primary protein structures (Barlow et al., 1986; Blundell et al., 1987). But, as it is 
with the prediction of T cell sites, these algorithms predicted well some 'continuous' 
epitopes, while they failed to identify others.
B. CONTROL OF VIRAL DISEASES.
The spread of many viral diseases has been controlled through primary health 
care and immunoprophylaxis, which involves either active (vaccines) or passive 
(antisera) immunization. The advances in molecular biology are also resulting in 
increasingly effective chemotherapies, which in turn put increasing demands on rapid 
and specific diagnosis.
The severity of virus infection and disease of an individual depends in part on 
whether the speed of induction of protective immune responses is faster or slower 
than the virus replication. Among the factors, that may influence the final outcome of 
virus infection, are the type of virus and the virulence of a particular virus variant, 
route of infection, previous exposure to the same or similar viruses/antigens, 
genotype and immune status of an individual, and presence of other compromising 
factors.
Immunization has been the most reliable means of preventing virus diseases. 
Predominantly, it is used to protect individuals against the first exposure to pathogens
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by increasing the efficiency of protective reaction. While passive immunization 
supplies virus-specific antibodies, the aim of vaccination is to induce an individual's 
own natural immunity. This acquired immunity is generated by pre-exposing the 
immune system to appropriate antigens, which results in a clonal expansion of 
antigen-specific lymphocytes and generation of circulating antigen-specific memory 
cells. Most, if not all, of the anti-viral vaccines used to-date prevent viral disease 
rather than infection. The various types of vaccines and their advantages and 
disadvantages are discussed below.
B .l. Traditional approaches to virus vaccines.
The conventional method of vaccination utilizes inactivated [e.g. 
poliomyelitis (Salk), influenza, hepatitis B or rabies] or live-attenuated [e.g. 
poliomyelitis (Sabin), measles, mumps, rubella or yellow fever] viruses. These 
approaches are successful, but there are certain concerns or disadvantages associated 
with their use. Killed virus vaccines require extreme care during the inactivation 
process to make certain, that no live virus is present and yet that the structure of viral 
antigens is preserved. The immunity conferred by killed virus vaccines is short and 
requires additional boosts causing concern about hypersensitivity reactions. In 
addition, inactivated viruses cannot induce responses to non-structural proteins and 
the CTL responses are generally poor. Live attenuated vaccines consist of wild type 
viruses, which are restricted in some critical step in pathogenicity of disease. The 
necessary considerations with these vaccines are their potential reversion to greater 
virulence, contamination with agents latently infecting the tissue culture substrates 
(e.g. simian virus 40, avian leukosis virus or simian cytomegalovirus), establishment 
of latent infections and limited viability after storage.
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B.2. New approaches to viral vaccines.
In certain instances, deleterious rather than beneficial immune responses were 
primed with the traditional antiviral vaccines. For example, children vaccinated with 
inactivated measles (Rauh and Schmidt, 1965) or respiratoiy syncytial (Kim et al., 
1976) viruses developed exacerbated diseases after natural infections with these 
viruses (for review see Randall and Souberbielle, 1990). A great effort is therefore 
being made to develop alternative vaccination strategies and to improve the efficacy 
and safety of the existing vaccines. These more or less rational interventions may, 
however, require more profound understanding of the basis of immune responses to 
virus infections as well as the biology of virus replication.
B.2.1. Subunit vaccines.
Vaccination with subunit vaccines represents one of the modern antiviral 
strategies, which involves immunization of individuals with 'harmless' viruses - either 
chimeric or expressing foreign antigen(s) of interest, purified or more likely 
recombinant viral antigens, or immunogenic peptides. Unfortunately, small 
oligopeptides and antigens by themselves are weak immunogens unless they naturally 
polymerize, as it is in the case of hepatitis B surface antigen (Valenzuela et al., 1982). 
New formulations and ways of how to increase the efficiency of presentation of 
poorly immunogenic subunit monomers to the cells of the immune system have been 
suggested: the use of immunostimulators, such as aluminium gels (Glenny et al., 
1926) and muramyl dipeptide (Ellouz et al., 1974), or an assembly of poorly 
immunogenic monomers into defined multimeric structures, such as the matrix of the 
adjuvant Quil A of immunostimulating complexes (ISCOMs) (Morein et al., 1984), 
liposomes (Allison and Gregoriadis, 1974)), solid matrix-antibody-antigen (SMAA) 
complexes (Randall and Young, 1991), Ty particles (Adams et al., 1987) and many 
others (reviewed in Gupta et al., 1993). In addition, sustained or timed release of 
immunogens can mimic booster injections after a single vaccine administration (Tice,
1993).
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To induce long lasting protective immunity to many viruses, it may be 
necessary to induce broad antibody and T cell responses. For the induction of T cell 
responses, there is a number of problems which have to be considered. Firstly, there 
are two major pathways for processing antigen for presentation to MHC class I- and 
class n-restricted T cells. A major problem is how to direct 'non-replicating* antigen 
to the cytosol of appropriate antigen-presenting cells for the induction of MHC 
class I-restricted T cells. In some cases involving both viral and non-viral proteins, 
non-replicating antigens could indeed prime MHC class I-restricted T cells in vivo. 
HIV glycoprotein gpl60, influenza haemagglutinin and ovalbumin incorporated into 
ISCOMs stimulated CD8+ class I-restricted CTL after either subcutaneous injection 
or oral immunizations (Takahashi etal., 1990; Mowat etal., 1991). Simian virus 5 
antigens incorporated into SMAA complexes (Randall and Young, 1991), heipes 
simplex virus glycoprotein D- and influenza virus-derived peptides attached to a fatty 
acid as a lipid anchor (Watari et al., 1987; Deres et al., 1989), and soluble ovalbumin 
(Staerz et al., 1987) have all been reported to induce MHC class I-restricted T cells. 
The precise mechanisms by which these antigens enter the MHC class I presentation 
pathway are not known. It remains a possibility that there is a specialized APC that 
can specifically process exogenous antigen for MHC class I presentation. It has also 
been suggested that inactivated virus may induce MHC class I-restricted T cells if the 
inactivated viruses can enter the cell by fusion with the plasma membrane rather than 
via a low-pH fusion in endocytic vesicles (Bolognesi, 1990). The ability of 
exogenous antigens to induce MHC class I-restricted CTL is of obvious interest for 
vaccine design, because safer non-replicating agents would be able to generate 
immune responses both against virus particles (neutralising antibody) and infected 
cells (CTL).
B.2.2. Peptide vaccines.
The consequence of MHC polymorphism in terms of cellular immunity is, that 
different individuals within an outbred population may recognize different T cell-sites 
on a given protein. Thus, if peptide vaccines are to be developed, it is recognized that
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they would have to contain a cocktail of peptides to ensure that a reasonable 
proportion of individuals would respond to the vaccine. It was estimated, that pools of 
about six carefully selected CTL sites derived from a particular pathogen could be 
reactive in nearly the whole population (Mills et al., 1989). For practical purposes, 
prediction of T cell sites from the amino acid sequences of protein antigens will most 
likely have to depend solely on the identification of MHC allele-specific agretopes. 
This approach may be accurate enough to give useful information about potential 
T cell sites on a protein for possible peptide vaccine development providing the MHC 
phenotype of a target population has been determined. However, the relevance of 
these T cell sites to the host immune defence also requires further consideration. The 
presence of an agretope motif in the amino acid sequence of an antigen does not 
guarantee that this peptide will associate with MHC molecules, form an antigenic 
complex and induce a T cell response. The patterns of T cell responses may be 
influenced by a number of factors other than MHC molecules, including proteins 
involved in antigen processing (proteasomes and peptide transporters), other immune 
response genes and also by other background genes (Gammon et al., 1987; Vidovic 
and Matzinger, 1988).
For similar reasons, identifying peptides for incorporation into potential 
vaccines by screening for their ability to induce T cell response is also not completely 
satisfactory. Immunogenic peptides may not be relevant in immune protection for 
a variety of reasons. The corresponding peptides may not be efficiently generated 
and/or presented by the natural processing of the native proteins by APC. Thus, after 
vaccination, peptide-induced T cells specific for such ’cryptic'T cell sites would be 
irrelevant, because these T cells may never 'find' the MHC-peptide complexes, which 
they are specific for, on cells infected during the course of natural infection. For 
example, CTL generated in vitro by priming with ovalbumin fragments were unable 
to recognise target cells transformed with the whole ovalbumin gene (Carbone et al., 
1988). In a more complicated experiment, HLA-A2-restricted CTL specific for 
residues 58-68 of influenza virus A matrix protein were shown to cross-react with the 
same peptide associated with HLA-Aw69. Since HLA-Aw69 is normally a non­
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responding allele, this observation suggests that although the HLA-Aw69 molecule 
can bind the peptide, it does not present the peptide for other reasons during natural 
influenza vims infections (Bodmer et ah, 1989). Thus, the processing machinery of 
APC limits the number of T cell sites presented and in turn restricts the complexity of 
naturally induced T cell responses.
In this respect, there are studies clearly demonstrating a strong bias of 
immune responses towards particular immunodominant sites over other 'accessible'
T cell sites of the same or other viral proteins (Allan and Doherty, 1985). Moreover, 
'silencing' the response to a previously immunodominant T cell site can cause a shift 
of the immune response to the next T cell site in the hierarchy. The mechanisms 
underlying these immunodominance hierarchies are not yet clearly understood.
Immunization of experimental animals with synthetic peptides, e.g. peptides 
derived from foot-and-mouth disease (Bittle et al, 1982), poliomyelitis (Emini et ah, 
1983) or herpes simplex (Cohen et al,. 1984) viruses, elicited in a number of instances 
virus-neutralizing antibodies. Despite these encouraging results, design of peptides 
for the induction of virus-neutralizing antibodies requires much more research to be 
undertaken. The first limitation of this approach comes from the belief, that most of 
the antibody epitopes on viral proteins are discontinuous (Barlow et ah, 1986; Van 
Regenmortel, 1989) and cannot be mimicked by a single peptide composed of an 
array of unmodified amino acids residues. Thus, only 'continuous epitopes' can be 
easily incorporated into peptide vaccines, which are bound to induce cross-reacting 
antibodies (see above). Secondly, even linear epitopes are conformational. Although 
flexibility enables peptides to be more antigenic, it may decrease the epitope 
immunogenicity, as good immunogenic structures may have to be rigid in order to 
allow for affinity maturation of antibodies. In one study, looping of a 30-amino acid 
peptide by a disulphide bond increased the peptide immunogenicity compared to its 
linear form (Leonard et ah, 1990), presumably by generating a tertiary structure 
and/or restricting the side-chain mobility. Finally, antibody epitopes in peptide 
vaccines may have to be linked to a T helper cell site, because majority of B cells are 
dependent on the T cell 'help'.
@
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B.2.3. DNA immunization.
A novel immunization technique is being developed, in which DNA 
constructs are directly introduced into mammalian tissue in vivo (Nabel et al., 1990; 
Wolff et al, 1990). This gene inoculation can be regarded as a form of subunit 
vaccination and has generated great hopes for both vaccinology (Wang et al., 1993) 
and gene therapy (Wilson, 1993). From the vaccine point of view, injection of 
a normal functional gene mimics features of vaccination with live attenuated viruses. 
This was shown to induce both neutralizing antibodies to HIV-1 envelope and HIV 
envelope-specific proliferative responses (Wang et al., 1993). Some of the areas that 
need further investigation are the efficiency of DNA uptake by cells and the 
possibility to target the DNA to particular antigen-presenting cells. Examples of the 
approaches used to stimulate the plasmid DNA uptake are a bupivacaine pretreatment 
of the injected muscle (Thomason and Booth, 1990), receptor-mediated endocytosis 
of transferrin-polylysine-DNA conjugates into hematopoietic cells (Zenke et al,
1990) and construction of liposome-DNA complexes (Hyde et al, 1993) or 
adenovirus-polylysine-DNA conjugates for introducing genes into airway epithelium 
(Gao et al, 1993a). Obviously, there is a lot to be learned about gene inoculation 
before this technology becomes generally acceptable for human vaccination.
B.2.4. A case for multivalent vaccines.
For the formulation of subunit vaccines, the cellular handling of antigens has 
several important consequences which argue for the incorporation of multiple 
antigens. Firstly, any viral protein, including surface, internal or non-structural 
proteins, may contain important T cell sites. Thus, multiple viral antigens may have 
to be included in an effective anti-viral vaccine. Secondly, several antigens may have 
to be included in a vaccine in order to induce balanced immune responses, as the 
induction of only appropriate combination of humoral and cell-mediated responses 
may be desirable to avoid deleterious consequences of vaccination itself and/or 
exacerbated pathology after subsequent infection with the virus. Thirdly, several 
factors discussed above, including polymorphism of the proteins involved in the
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processing and presentation of antigens, limit the number of T cell sites that can be 
presented by a single individual, again arguing that several viral antigens may have to 
be used for vaccination to protect all or most individuals in a target population. The 
final problem for vaccine design is the antigenic variation of viruses. During the 
course of infection, viruses are under strong selective pressure imposed upon them by 
the host immune responses. Thus to cover the most common or even predicted escape 
mutants, efficient prophylactic and therapeutic vaccines may have to include more 
then one variant of the same viral antigen.
B.3, Solid matrix-antibody«antigen (SMAA) complexes as multivalent 
subunit vaccines.
Construction of solid matrix-antibody-antigen (SMAA) complexes has been 
suggested to be a means of producing effective antiviral vaccines (Randall, 1989). 
Multispecific immunization with SMAA complexes can be achieved either by 
incorporating different virus antigens into the same SMAA complex using a mixture 
of mAbs (Randall and Young, 1989) or by making monospecific SMAA complexes 
and mixing them prior to injection (Fig. 3).
B.3.1. Immunogenicity of SMAA complexes.
SMAA complexes are highly immunogenic inducing both vigorous humoral 
and cell mediated immune responses (Randall and Young, 1988). The immunogenic 
nature of SMAA complexes results in part from the fact that antigens are presented to 
the cells of the immune system in a stable, particulate and repetitive form. The 
immune response to SMAA complexes may be also enhanced by the presence of 
antigen-bound antibodies, which may facilitate the uptake of antigens by APCs via Fc 
or complement receptors.
Immunization of mice with SMAA complexes that contained either internal or 
external structural proteins of the paramyxovirus, simian viras 5 (SV5), enhanced the 
speed of clearance of virus from immunized mice (Randall et aL, 1988). The effector
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Figure 3. SMAA complexes as multivalent vaccines.A - Different mAbs are attached to independent solid matrices prior to the binding of antigens. The resulting SMAA complexes may be combined together before being used as immunogens. B - Solid matrix is saturated with a mixture of mAbs prior to the addition of antigens. C - A single tag-specific mAb and tag-linked antigens are used for the construction of SMAA complexes. D and E - The same as C, only Fab of single chain Fv fragments of antibodies, respectively, are employed. Also, additional mAb to host cell antigens and/or immunostimulating proteins, such as cholera toxin subunit B, may be included to enhance particular type of immune responses (not shown). Modified from Randall (1989).
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cells primarily responsible for virus clearance were shown to be CD8+ lymphocytes. 
This together with the demonstration, that SMAA complexes induced class I- 
restricted cytotoxic T cells (as measured in vitro) suggested, that the effector cells 
responsible for the clearance of virus in vivo were indeed CD8+ cytotoxic T cells 
(Randall and Young, 1991). This set of experiments demonstrated that antigens 
introduced on SMAA complexes, i.e. non-infectious exogenous agents, can enter 
intracellular processing pathways leading to an induction of MHC class I-restricted 
T lymphocytes, although this induction of T cells was less efficient compared to the 
infectious virus.
B.3.2. Construction of SMAA complexes.
B.3.2.L Solid matrix.
a) 'Fixed' and killed S. aureus cells.
Initially and mainly for practical purposes, preparations of heat-killed and 
formalin-hardened Staphylococcus aureus Cowan A cells (Kessler, 1975) were used 
as a solid matrix. S. aureus cells have a consistently high cell surface density of 
protein A, which is covalently linked to the peptidoglycan layer of the cell wall 
(Sjoquist et al, 1972), is stable over a wide range of pH, is quite resistant to 
denaturing agents and heat (Sjoholm, 1975) and has at least three, but probably no 
more than four, highly homologous Fc-binding regions (Sjodahl, 1976).
For the construction of SMAA complexes, particulate solid matrices are 
saturated with specific monoclonal antibodies (mAb), which in turn are satiu*ated with 
their respective antigens. Practically this means that, in the first step, mAb are 
concentrated and purified from either ascitic fluids or tissue culture supernatants, and 
the solid matrix-antibody complexes are used in the next step to purify antigens fi^ om 
crude cellular lysates. The resulting SMAA complexes are used as immunogens.
b) Alum gels.
Immunization of animals with alum-antigen complexes is a well established 
method for inducing humoral immunity (Klaus and Humphrey, 1977). In this 
technique, the purified antigen is non-specifically absorbed onto preformed alum
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precipitates (aluminium phosphate or hydroxide) or is trapped into the gel during 
precipitation, a method first described more then 60 years ago (Glenny et al, 1926) It 
has been shown in our laboratory, that incorporation of antibodies into these alum 
precipitates, i.e. production of alum-antibody-antigen complexes, further increases the 
immunogenicity of antigens compared to those of just alum-antigen complexes 
(Randall et al, 1993b). Thus, the binding of protein to alum via an antibody linkage 
may increase the efficiency of binding to alum, preserve the protein's native structure, 
and the antibody may help to trigger certain immunological processes that will 
enhance the immune responses to alum SMAA complexes. In addition, alum is non- 
immunogenic and the use of alum gels have been licensed for use in man.
B.3.2.2. Antibodies.
To date we have only used mouse mAb in the construction of SMAA 
complexes. It is unlikely that it will be possible to use mouse mAb for producing 
vaccines for general use in humans. SMAA complexes used as human vaccines will 
have to include human antibodies in order to i) minimize immune responses directed 
against the antibody component and ii) improve the possible interactions with the 
human immune system and effector cells. Humoral responses against the murine 
determinants of the antibody component of the SMAA complexes could significantly 
reduce the half-life of SMAA complexes in human body, hamper any subsequent 
immunizations with SMAA complexes, interfere with diagnostic tests involving 
murine mAb or induce hypersensitivity reactions. The human hybridoma technology 
has been a considerable technical challenge compounded by immunizing humans and 
even the best procedures are time-consuming and unreliable, and derived hybridoma 
may be unstable. Here, recombinant DNA techniques offer a solution. It is possible to 
construct hybrid antibodies by substituting the genetic information for antigen- 
binding regions of human heavy and light chains with their rodent counterparts of 
desired antigen specificity (Fig. 4; Winter and Milstein, 1991). The whole humanized 
antibody can then be produced in suitable eukaryotic cells (Reichmann et al, 1988; 
Verhoeyen et a l, 1988; Tempest et al, 1991; Page and Sydenham, 1991). However, 
if the Fc portion of mAb were dispensable for efficient uptake and presentation of
scFv
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Figure 4. Engineering of antibodies.i) Antigen-specific heavy and light chain variable regions of a rodent mAb can be expressed in E. coli as Fab or Fv fragments of antibodies, the former having human- derived constant regions, ii) Rodent mAb can be completely reshaped by grafting only the antigen-binding complementarity-deternriining regions onto a human framework. Modified from Winter and Milstein (1991).
antigens by antigen-presenting cells, Fab or Fv fragments could substitute for the 
whole antibody in SMAA complexes (Fig. 3). Incorporation of Fab or Fv fragments 
into SMAA complexes would have the advantages of a reduced chance of adverse 
immune reactions and the availability of bacterial expression systems (Boulot et al, 
1990; Skerra étal., 1991).
B.3.2.3. Purification of antigens.
Ideally, successful subunit vaccines will contain recombinant proteins rather 
than antigens from infected cell lysates, thereby eliminating health risks during both 
the production and use of the vaccine. Unfortunately, there are no straightforward 
recipes to follow for protein purification, as each protein has unique physico­
chemical properties. Many procedures have been developed over the years and used 
in various combinations, on one the hand to overcome protein insolubility, proteolytic 
degradation or aggregation, and on the other to preserve protein structure. Efficiency 
is yet another important aspect of purification protocols, which is frequently
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compromised for purity. Generally, the more purification steps involved, the cleaner 
is the final product, but the lower the yield. Recombinant DNA technology has again 
been instrumental in opening new ways of protein purification. Thus, fusion of an 
affinity tag to one end of the protein of interest may facilitate protein purification and 
increase protein stability. The tag-based purification procedures may exploit a variety 
of specific interactions, e.g. between antigenic oligopeptide tags and tag-specific 
antibodies, enzymes or specific enzyme domains and their substrates, ligands and 
their receptors, metal-binding amino acid residues and chelated metal ions (reviewed 
in Sassenfeld, 1990).
C. HIV INFECTION AND AIDS.
The global endemic of human immunodeficiency virus (HIV) continues to 
grow. According to the World Health Organization statistics, there are 14 million 
people infected with HIV and 2.5 million have developed acquired immunodeficiency 
syndrome (AIDS). If the HIV infection continues to spread at the present rate, 30 - 40 
million people world-wide will have been infected with HIV by the year 2000. It is 
likely that most of these people will eventually die of AIDS. At present, the only safe 
way for altering course and scale of this human disaster is, undoubtedly, in 
educational campaigns inducing people to modify their high-risk behaviour. 
Practically, the best hope is in mass vaccination programmes.
C .l. HIV classification.
Human immunodeficiency virus (HIV) is a member of the family of 
Retroviridae (the retroviruses), the genus of Lentivirinae. HIV is a small RNA virus, 
whose virions are of about 80 - 130 nm in diameter and consist of a lipid envelope 
surrounding an icosahedral nucleocapsid. Currently, there are two well-characterized 
subtypes of the virus, HIV-1 and HIV-2, both of which cause disease (Clavel et ah, 
1987).
i
t
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C.2. HIV genome organization.
HIV genome is composed of two identical copies of a positive-sense single- 
stranded RNA. The RNA molecules are non-covalently bound and their size is 
approximately 9,300 nucleotides. The HIV genome consists of 3 large genes encoding 
polyproteins essential, but not sufficient, for virus replication (see also Fig. 6). These 
are the gag gene coding for the structural proteins of the virion, the pol gene, which 
encodes the various enzymes involved in tite processes of reverse transcription, 
integration of proviral DNA into host chromosomes and virion maturation, and the 
env gene, which encodes glycoproteins present on the virion surface responsible for 
binding to and penetration into the appropriate target cells. In addition to these 
3 genes, HIV carries at least six other genes coding for auxiliary viral proteins nef, 
rev, tat, vif, vpr and vpu known to play critical roles in both the regulation of HIV 
gene expression and in morphogenesis and release of infectious virus particles 
(reviewed e.g. in Haseltine, 1991)
C.3. HIV lifecycle.
The replication cycle of HIV begins by virus entry into the target cell. Once 
inside the cell, the virus genomic RNA is converted into double-stranded DNA that 
integrates into the host cell genome as a proviral DNA. HIV then ’hijacks' the pre­
existing cellular machinery of transcription and translation for production of viral 
genomes and proteins, which assemble into new nucleocapsid particles. These 
particles acquire a phospholipid envelope containing viral glycoproteins during egress 
out of the cell, which results in a release of new fully-infectious virions.
C.3.1. Virus entry.
The initial events of virus infection are the virus binding and penetration of 
target cells. The virus attachment is facilitated by a high-affînity interaction between 
the outer portion of virus glycoprotein, gpl20, and cellular receptor CD4 (Stein et al..
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1987), a surface glycoprotein found on a variety of cells of hematopoietic origin 
(Dalgleish et al., 1984). However, the gpl20/CD4 interaction may not be necessary 
(Clapham et al., 1989; McKeating et al., 1990) nor sufficient (Tersmette et al., 1989a; 
Hovanessian et al., 1993) for efficient virus entry. The potential requirement for the 
cleavage of the third hypervariable domain (the V3 loop) in gpl20 lead to an 
indication, that there may be a requirement for an essential surface co-receptor with 
proteolytic activity. Hovanessian and colleagues (1993) recently demonstrated, that 
anti-CD26 mAb or inhibition of its peptidase activity by peptides blocked 80-90% of 
HTV entry into target cells. Following attachment (and cleavage of the V3 loop), entry 
of HIV occurs by fusion of the virus phospholipid envelope with the plasma 
membrane of the cell. Fusion is mediated by the transmembrane portion of the virus 
glycoprotein, gp41, (Lifson et al., 1986) and is pH independent (Stein et al., 1987).
C.3.2. Synthesis of HIV nucleic acid and provirus integration.
After release of the HTV genome into the cytoplasm, the single-stranded RNA 
is converted into a double-stranded DNA intermediate. These steps are carried out by 
virally encoded RNA-dependent DNA polymerase (reverse transcriptase) and 
ribonuclease H, enzymes characteristic for the retrovirus family, which are delivered 
to the cytoplasm together with the genome by the infectious particle (Varmus and 
Swanstrom, 1985). The poor fidelity of reverse transcriptase (Meyerhans et al., 1989) 
is one of the major problems in the battle with HTV, because it provides a means of 
escaping both antiviral chemotherapies and immune responses. The double-stranded 
DNA form of the virus genetic information, now flanked by long terminal repeats 
(LTR) at both ends, is inserted into the host genomic DNA by another virus-specified 
enzyme integrase, which is also packed within the virus particle (Famet and 
Haseltine, 1990). Once integrated, the proviral DNA becomes permanently associated 
with the host chromosomes and is vertically transmitted during subsequent cell 
divisions.
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C.3.3. Expression of HIV genes.
Expression of HIV genes is a complex process controlled by both host and 
viral factors. The production of viral proteins begins with the synthesis of a complete 
RNA copy of the proviral DNA. Transcription is initiated from the 3’-end of the 5' 
long terminal repeat and its rate is largely controlled by cellular proteins. The HTV 
genome contains 4 spice-donor and 6 known splice-acceptor sites resulting in more 
than 30 distinct processed mRNA species found in infected cells, among which 
almost every viral gene is positioned as the first open reading frame (ORE) (Schwartz 
et al., 1990). The mRNA molecules can be either unspliced, or singly or doubly 
spliced. The exceptions are the pol gene, which is translated as a result of a ribosomal 
ffame-shift during translation of the gag-pol mRNA (Jacks et ah, 1988), resulting in a 
gag-pol polyprotein, and the env gene, which appears to be translated from a 
bi-cistronic mRNA that also encodes the vpu gene product (Schwartz et ah, 1990). 
The gag-pol polyprotein precursor is proteolytically cleaved into functional products 
by the virus protease.
C.3.4. Nucleocapsid assembly and release of infectious particles.
The capsid precursor protein and the capsid precursor of the replicative 
enzymes co-as semble at the inner surface of the cell membrane. These proteins have 
myristic acid attached to their N-termini and insert themselves into the cell membrane 
(Veronese et ah, 1988). The capsid precursor protein contains two copies of a viral 
RNA-binding motif, so called cysteine-histidine box (Marie and Spahr, 1986). This 
cysteine-histidine box specifically recognizes the T  packaging signal located at the 
5'-end of the genomic RNA and ensures, that the RNA is incorporated in the resulting 
closed spherical particles (Lever et ah, 1989). Assembled nucleocapsids bud through 
the cell membrane, which contains the already digested virus glycoprotein 
gp41/gpl20. Late maturation events include the proteolytic cleavage of capsid protein 
and replicative enzyme precursors (Oroszlan and Luftig, 1990).
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Figure 5. Schematic course of HIV infection and AIDS.
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C.4. HIV infection and disease.
HIV is a sexual and blood-bom pathogen, the infection of which can have 
a number of diverse manifestations ranging from subclinical abnormalities to 
opportunistic infections and malignacies that define the acquired immunodeficiency 
syndrome (AIDS), the end-stage disease (reviewed by Levy, 1993). The course of 
HTV infection is schematically depicted in Fig. 5. From the very first description, 
AIDS has been associated with the depletion of CD4+ T-lymphocytes in the 
peripheral blood (Gottlieb et al., 1981). However, the CD4"*" T helper cells are not the 
only cells infected, as HIV has been also demonstrated to infect other cells such as
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monocytes, macrophages and certain glial cells of the central nervous system. The 
mechanisms of how HIV causes the immunodeficiency are not entirely clear (Weiss, 
1993), but they are driven by a persistent HIV infection (Pantaleo etal., 1993; 
Embretson et a/., 1993). There is an increasing body of evidence suggesting, that the 
decrease in the CD4+ lymphocyte due to viral infection does not solely account for 
the collapse of the immune system seen in AIDS patients. The central problem seems 
to be in defective antigen presentation and inappropriate signalling by antigen- 
presenting cells resulting in T cell anergy and priming cells for activation-induced 
death (Stanley and Fauci, 1993; Meyaard et al.^  1993). One purely theoretical 
scenario for the immune system defeat follows. In brief: (i) dormant HTV proviruses 
integrated in the host chromosomes are activated in stimulated lymphocytes during 
other infections (Tong-Starksen et al.y 1989) (ii) the HIV envelope by mimicking 
allogeneic stmctures (Wahren et aL, 1989; Habeshaw etal., 1992) and/or HIV- 
associated superantigen (Soudeyns et a/., 1993) non-specifically activate lymphocytes 
and render them susceptible to apoptosis because of the absence of a correct co-signal 
(Meyaard etal.^ 1992; Ameisen and Capron, 1991); (iii) antigen-presenting cells 
produce aberrant cytokine signals, that may affect the overall homeostasis of T cell 
populations, e.g. by relative dominance of Th2 over Thl cell subsets (Stanley and 
Fauci, 1993); (iv) HIV probably kills memory cells faster than they are replenished, 
which may be one of the consequence of the above malfunctioning of antigen- 
presenting cells (Helbert et aL, 1993); (v) during persistent replication in the lymph 
nodes, HIV develops sequential escape mutants that are one step ahead of the 
immunosurveillance; (vi) the accumulation of new HTV antigenic variants eventually 
overcomes the immune system; and (vii) the fast HTV evolution results in emergence 
of virulent cytopathic variants (Tersmette et al„ 1989b).
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C.5. Strategies for the control of HIV infection.
C.5.I. An ideal HIV vaccine.
An ideal anti-HIV vaccine is (i) antigenicly appropriate, i.e. induces protection 
against different subtypes and variants of HIV. It (ii) induces mucosal and systemic 
immunities to maximize the likelyhood of protection, and this protection is achieved 
by (iii) an optimal balance between humoral and cell-mediated immune responses.
The protection the vaccine induces is (iv) long-lasting and (v) achieved by a minimal 
number of doses. The vaccine is (vi) heat stable and (vii) easy to administer, i.e. 
orally. Finally, the vaccine, that is to have a chance to successfully combat the world­
wide HIV epidemic, has to reach the target population, that is to be (viii) affordable 
for everybody.
C.5.2. Problems with HTV vaccine development.
There is a number of difficulties specific to HIV in the rational development 
of effective vaccines, (i) Due to the low fidelity of reverse transcriptase, HIV has an 
ability to rapidly change its genomic sequence. In this way, mutants escaping both 
immune and drug attacks emerge, (ii) The likely vehicle of transmission is an infected 
cell rather than a cell-free virus, (iii) HIV can spread directly fi’om cell-to-cell without 
the need to release an infectious particle. After integration into the host chromosome, 
HIV can (iv) establish a latent infection, i.e. no expression of viral proteins, and (v) be 
vertically carried from cell-to-cell as an integrated provirus, (vi) HIV infects the very 
immune cells upon which the action of vaccine depends. The last point is not 
a problem for prophylactic vaccines.
After more then a decade of intense effort, there is no cure for AIDS nor is 
there an effective vaccine against HTV. Before such a vaccine is developed, a number 
of key questions must be answered. The problem number one is to determine the 
correlates of human protection, i.e. what are the specific immune responses vaccines 
have to evoke in order to protect individuals fi'om HIV infection and/or disease. It 
needs to be established which HTV antigens should constitute the basis of a vaccine,
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how the virus antigenic variability can be overcome and how the antigens should be 
presented to the immune system. Furthermore, reliable surrogate markers for the 
disease progression need to be identified. Finally, more accurate knowledge is 
required of how HTV is transmitted and what causes the immune system to collapse.
C.5.3. Non-vaccine strategies for controlling HIV replication.
Vaccination is only one of the possible approaches to controlling the HIV 
infection and replication. Any step in HTV life cycle and any HIV-derived protein or 
nucleic acid involved in the virus replication are potential targets for antiviral therapy. 
The candidate 'hot-spots' for an anti-HIV intervention and some of the corresponding 
drugs are shown in Table 1. The most favourite target of anti-HIV drugs is the reverse 
transcriptase. However, to overcome or avoid resistance resulting from the fast 
generation of escape mutants, a successful chemotherapy may have to be 
a combination of drugs inhibiting several steps in virus replication at once. No 
therapeutics targeting DNA synthesis of the second strand, transport of the viral 
dsDNA from the cytoplasm to the nucleus and integration of the dsDNA into host 
chromosomes have yet been suggested.
C.6. Animal models of HIV infection and AIDS.
Several animal models have been developed in order to provide a scientific 
basis for designing vaccination and chemotherapeutic trials in man. These model 
systems are very helpful for studying both the pathoaetiology of diseases caused by 
virus infections and for the evaluation of novel anti-viral drugs and potential vaccines. 
They may provide insights into both the humoral response (including the production 
of virus-neutralizing antibodies) and the induction of T cell proliferative and MHC- 
restricted cytotoxic T cell responses.
Table 1. Targeted steps in HIV life cycle and some of the corresponding interfering agents.
Attachment •sCD4, (Daar et al., 1990)• CD4-Ig (Capon etaL^ 1989)•SCD4-PE40 [Pseudomonas aeruginosa exotoxin A (Ashorn et al., 1990)]•CD4-peptides, dextran sulphate, mAbs
Uncoating •Hypericin
Reverse transcription Nucleotide analogues:•AZT* [zidovudine, Retrovir (Mitsuya et al, 1985)] •ddC* (DDC, zalcitabine, HIVID)•ddl* (didanosine, Videx)•d4T [Stavudine (Gao et al., 1993b)]•FLT [3-halo-dideoxypyridine (Matthes et al., 1988)] •PMEA [an acyclic adenine (Balzarini et al., 1989)] •3TC [Lamivadine (Coates etal., 1992)] Non-nucleotide inhibitors:•BHAPs [U-87201E, Atevirdine Mesylate, ATV (Romero et a/., 1991)]•U-90,152 (Dueweke etal., 1993)
•R-89439 [a-APA derivative (Colebunders et al., 
1992)]•L-697,661 (Saari et al., 1991)•TIBO [R82913 (Pauwels et al., 1990)]•BIRG-587 [nevirapine (Merluzzi et al., 1990)]
RNAseH degradation of template •AZTMP (Tan et al., 1991)
Viral transcription •Ro 24-7429 [tat inhibitor (Hsu et al., 1993)] •TAR decoys (Sullenger et al, 1991a)
RNA splicing and transport •RRE decoys (Sullenger et al, 1991b) •transdominant rev
Protein synthesis •Antisense mRNA (Izant and Weintraub, 1985)
RNA stability •Ribozymes (Hasseloff and Gerlach, 1988)
Protein glycosylation •N-butyl DNJ
RNA packaging and virion assembly •Myristic acid analogues (Heuckeroth et al, 1990) •transdominant gag, antisense/ribozyme, protease inhibitors
Virus budding •Interferon a  (Pitha et al, 1979; Ho et al, 1985)
Maturation •A-77003 [protease inhibitor (Erickson et a l, 1990)] •Ro 31-8959 [protease inhibitor (Roberts eta l, 1990)]
Other Immunomodulators:•Trental [pentoxifylline, inhibits TNF (Fazely et a l, 1991)]•IL-2 [increase in CD4+ and proliferative responses (Schwartz e ta l, 1991)]•THF and TP5 [augments CMI (Kouttab et al, 1992)]
See Abbreviations for the chemical names of individual drugs; * Approved for human therapy
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C.6.1. Search for an animal model.
Since HIV was isolated from patients with AIDS (Popovic et al., 1984), there 
has been an intensive search for suitable animal models of AIDS. So far the most 
useful model has proved to be the simian immunodeficiency virus (SIV) infection of 
several varieties of macaques (reviewed in Schultz and Hu, 1993). A lot of attention 
has been also focused on the feline immunodeficiency virus (FIV) infection of cats. 
Although it is possible to giow HIV-1 in mice with severe combined 
immunodeficiency (SCID) following their reconstitution with human lymphocytes 
and in chimpanzees, these models are of a limited use because an AIDS-like disease 
is not produced and the host animals are either rare or difficult to maintain. The 
relatively recent finding by Agy and colleagues (1992), that pig-tailed macaques can 
be infected with HIV-1, even though the infection is also non-pathogenic, may 
provide a better system to test anti-HIV vaccines.
A great amount of attention in HIV vaccinology has been focused on the 
envelope glycoprotein and its hypervariable V3 loop. However, incorporation of the 
whole env products into vaccines may be somewhat controversial. In addition to the 
antigenic variability, the sole presence of gpl60 or its parts in organism has been 
implicated in several pathogenic mechanisms potentially contributing to the 
development of AIDS. These include sensitizing of uninfected CD4+ cells to 
cytotoxic T lymphocyte lysis (Siliciano et al., 1988), induction of CD4+ cell fusion 
(Lifson et al., 1986), immunosuppression (Weinhold et al., 1989; Manca et al., 1990), 
immunological tolerance (Haynes et al., 1993) and apoptosis (Ameisen and Capron, 
1991; Szawlowski et al., 1993). Moreover, HIV-1 gpl20 expression in astrocytes of 
transgenic mice resulted in brain neuropathological lesions characteristic of AIDS 
dementia (Oldstone, 1993).
C.6,2. Studies on simian immunodeficiency virus vaccines.
In 1985, a lentivirus, SIVmac, was isolated and shown to induce AIDS in 
rhesus macaques (Letvin et al., 1985). Subsequently, other strains of SIV were
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Figure 6. Derivation of SIVmac viruses.Squares represent a passage of virus isolates through an animal and ovals individual virus isolates or clones. Where a dotted line is used, the exact derivation was impossible to trace. Modified from Schultz and Hu (1993).
isolated: SIVsm from sooty mangabeys (Fultz et al., 1986), SIVmne from pig-tailed 
macaques (Benveniste et al., 1988), SIYagm from African green monkeys (Fukasawa 
et al., 1988) and SIVmnd from mandrills (Tsujimoto et ai, 1988). Fig. 6 shows the 
derivation of SIVmac isolates.
Simian and human immunodeficiency viruses and their infection of hosts have 
some remarkable similarities including virus morphology, genome organisation, (see 
also Fig. 7) life cycle, tropism, and pathology of disease they cause. The drawback of 
the SIV system is, that the SIV and HIV envelope glycoproteins are relatively 
distinct. Nevertheless, the model of SIV infection of macaques has been instrumental 
for testing a variety of vaccination strategies against lentiviruses, some of which are 
discussed below.
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Figure 7. Particle and genome organization of simian immunodeficiency virus.
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C.6.2.1 Whole inactivated virus vaccines.
Initially, the traditional vaccination approach was taken using tlie whole 
inactivated SIV vaccines. These early vaccinations delayed or even prevented the 
onset of disease and successfully protected a proportion of animals against infection 
(Desrosiers et aL, 1989; Sutjipto et al., 1990; Murphy-Corb et al., 1989.) The animals 
were challenged with 10 to 50 units of 50% of monkey infectious doses (MID50) of 
a homologous SIV and the protected ones remained virus free for over a year (Stott et 
al., 1990; Putkonen etal., 1991; Johnson et al., 1992a and b). Protection was also 
achieved against heterologous strains of SIV, but it did not extend to HIV-2 (Cranage 
et al., 1992; Gardner and Murphy-Corb 1990; Johnson et al., 1992a). However, when 
vaccination experiments were carried out using virus-infected cells, approximately 
half of the control animals vaccinated with uninfected cells were protected as well 
(Stott et al., 1991). It was also found, that the vaccinated animals were protected 
against challenge with SIV grown in human, but not in simian cells (Langlois et al., 
1992; Cranage et al., 1992,1993). Thus, although there was an increased protection 
after vaccination with virus-infected compared to uninfected cells, the protection 
observed with whole inactivated virus vaccine and infected cells was almost certainly 
due to immune responses against cell components of the vaccines rather than against 
tire viios antigens themselves (Stott etal., 1993; Cranage et al., 1992,1993).
So which host cell proteins are responsible for the protection and what is their 
role in inactivated virus vaccines? The incorporation of MHC molecules into 
retrovirus particles has been known for some time (Bubbers and Lilly, 1977) and was 
confirmed for HIV and SIV (Gelderblom et al., 1987). More recently, the heavy chain 
of HLA class I and both the a  and p chains of HLA class II were identified in HIV-1 
and SIV vaccine preparations (Cranage et al., 1993). It was even estimated, that there 
is a 2-3:1 ratio of HLA DR:gpl20 on the surface of purified virions (Arthur et al., 
1992). Antibodies specific for HLA class I, but not class II, molecules were found in 
animals vaccinated with inactivated virus preparations (Chan et al., 1992; Cranage et 
al., 1993). However, immunizations with mouse cells expressing either HLA class I 
or class n  molecules protected against a human-grown SIV infection only one half of
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the mouse cell/HLA class Il-vaccinated macaques, while the other animals became 
infected (Stott, 1993). Passive transfer of sera from inactivated virus-immunized 
animals did protect naive recipients (Stott, 1993) and antibodies to HLA molecules, 
including P2-inicroglobulin, do inhibit infection by HIV and SIV (Arthur etaL,
1992). It remains to be explained, why antibodies against host cell components 
present on the virus particles protected, while neutralizing antibodies against gpl20 
did not. On the other hand, sera from uninfected human cell-immunized and protected 
animals failed to neutralize the challenge SIV stock (Stott et al., 1991). Thus, despite 
the puzzling data so far, the significance and potential of these observations for the 
development of human HIV vaccines should not be overlooked.
C.6.2.2 Live attenuated vaccines.
Live attenuated SIV vaccines were used in several instances. Immunization 
with live attenuated molecular clone la l l  derived from SIVmac did not protected 
rhesus monkeys against infection with 100 to 1000 MID go of pathogenic STVmac251, 
but delayed disease and death (Marthas et al., 1990). Similar results were reported 
after infection of cynomolgus macaques with avirulent strain of HIV-2 and 
a subsequent challenge with 10 to 100 MIDgo of pathogenic SIVsm (Putkonen et al., 
1990). Nine months after the SIV challenge, the virus could be recovered from the 
lymph nodes of monkeys, but no disease developed. By large the most impressive 
protection against lentivirus infection has been achieved by vaccination with live 
attenuated SIVmac239, which carried a deletion in the ne/gene (Daniel et al., 1992). 
The animals were initially challenged with 10 MQDgo of either virulent SIVmac239 or 
uncloned SIVmac251. The virulent viruses were never recovered from the vaccinated 
animals, which all remained healthy for 9 months. Two of the protected animals were 
re-challenged with 100 to 1000 MIDgo of uncloned SIVmac251 with identical results. 
This efficient protection represents a unique opportunity to study and determine the 
correlates of protection, and identify the critical viral components for its induction.
C.6.2.3 Subunit vaccines.
SIV vaccine formulations based on recombinant proteins have been largely 
unsuccessful. In summary, SIVmac-derived gag, gag p55, p27, gpl60 or gpl20
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produced in bacteria, yeast, insect cells, CHO cells or expressed by recombinant 
vaccinia virus have been used as immunogens, some induced strong T helper 
responses or neutralizing antibodies, but all have uniformly failed to induce 
protection against infection (reviewed in Stott, 1993). In this respect, the SIVmne 
virus seems to be exceptional, possibly due to the fact that SIVmne induces 
somewhat slower disease progression than the other SIV strains (Benveniste et al., 
1988). Thus, a combined vaccination scheme using a live vaccinia virus expressing 
gpl60 followed by a boost with purified gpl60 produced in the baculovirus system 
protected macaques against subsequent challenge with 1 to 9 MID50 of SIVmne (Hu 
et al., 1992). However, this protection failed to be repeated in SIVmac (Mills et al., 
1992,1993; Giavedoni et al., 1993). In a second SIVmne study, immunization with 
four peptides corresponding to conserved SIV and HIV regions of g p l^  fused to 
P-galactosidase did not prevent infection of SIVmne, but protected animals from 
disease progression for at least 3 years (Shafferman et al., 1991). Moreover, the 
infection could not be transferred by inoculation of naive macaques with viable 
lymph node cells nor peripheral blood lymphocytes isolated from immunized and 
challenged animals (Shafferman et al., 1992). In an extension of this work, 
inactivated plasma from the peptide-vaccinated or SIV-infected animals protected 
naive recipients from SIVmne infection and the same study suggested, that of the four 
peptides present in the vaccine mixture, the two originating from gp41 were 
responsible for inducing neutralizing (and anti-syncytial) activity (Lewis et al., 1993). 
In all the above SIVmne experiments, the vaccine and challenge viruses were 
genetically matched.
Recently, chimeric SIV viruses carrying HIV-1 tat, rev, vpu and env genes 
were constructed and shown to replicate, although poorly, in cynomolgus macaques 
(Shibata et al., 1991; Li et al., 1992; Sakuragi et al., 1992), Such chimeras used as 
challenge viruses, and even more so as immunogens, offer a system for testing or 
comparing efficacy of HIV-1-based vaccines in macaques and determining the 
correlates of protection.
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D . O b je c t iv e s  o f  t h e  w o r k .
Successful vaccines against HIV may have to invoke both mucosal and 
systemic immunities probably by inducing both humoral and cell-mediated immune 
responses. The mechanisms underlying antigen processing and presentation to T cells 
together with the antigenic variability of HIV argue for incorporating more than one 
immunogenically relevant HIV determinant, i.e. more than one T cell site and/or 
antibody epitope, into such a vaccine. Thus, there is a need for vaccine design, that 
allows certain flexibility in terms of which and how much of HIV proteins the 
vaccine delivers. Also, the vaccine may have to incorporate engineered immunogens, 
which would avoid the undesirable determinants causing e.g. induction of Th2 at the 
expense of Thl T cell subsets, immunosuppression, apoptosis or tissue damage. 
Moreover, should the vaccine contain non-replicating antigens, these will have to be 
introduced into the MHC class I presentation pathway for induction of MHC class I- 
nestricted T cell responses. Finally, but not lastly, the vaccine should be relatively 
stable, cheap and easy to prepare. The use of solid matrix-antibody-antigen (SMAA) 
complexes as vaccine may have the potential to meet all the above requirements. 
Using the SIV model, the availability of separately prepared SIV antigens 
incorporated into SMAA complexes may allow both the evaluation of the efficacy of 
such complexes in preventing infection and/or disease in experimental animals and 
studying the roles of individual SIV proteins in induction of beneficial immune 
responses. Moreover, purified SIV proteins provide tools for analysis of humoral and 
T-helper response specificities induced during natural SIV infection and by any 
current or future protective vaccination schemes.
The work presented in this thesis has three principal aims: i) to develop 
SMAA complexes as a universal vaccine vehicle for delivery of antigens, ii) to clone 
all SIV genes, express the respective proteins and develop protocols for protein 
purification, and iii) to develop this vaccine design for potential use in humans, which 
involves humanizing the antibody used for the construction of SMAA complexes.
5 6
There will be no attempt to scale up the production of SIV antigens nor of the 
reshaped antibody.
In the first part, the feasibility of construction of SMAA complexes using 
a single tag-specific monoclonal antibody and multiple tag-linked antigens was 
demonstrated. It was shown that a 14-amino acid oligopeptide, present in the phospho 
(P) and V proteins of simian virus 5 (SV5) and designated Pk, retained its 
antigenicity when attached to the C-terrainus of two 'foreign' proteins [p27 of SIV 
and glutathione-S-transferase (GST)] such, that these proteins could be incorporated 
into SMAA complexes using mAb SV5-P-k that had been originally raised against 
the native SV5 P and V proteins.
Secondly, all SIV unglycosylated proteins were cloned and expressed in 
bacteria. The expressed SIV proteins were flanked at their N-termini with either GST 
or a small histidine tag, and at their C-termini with the Pk tag. The two-tag protocol 
for purification significantly improved the purity of isolated proteins and assured 
their full-size. The second purification step involving the Pk tag and a tag-specific 
mAb incorporated the recombinant SIV proteins into complexes used as 
immunogens. Tlie SIV env gene was inserted into a baculovirus vector such that the 
expressed virus glycoprotein was coupled at its C-terminus to the Pk tag.
The aim of this part of the work is to evaluate the importance of individual 
SIV antigens incorporated into SMAA complexes for inducting of protection of 
macaques against SIV challenge. Supposing vaccination with the mixture of all SIV 
proteins in SMAA complexes is protective, this simple and versatile system could be 
used to determine the minimum formula for a protective vaccine.
Finally, genes for the variable domains of heavy and light chains of S V5-P-k 
mAb were cloned. The variable regions were expressed in bacteria as Fab and Fv 
antibody fragments and their Pk tag specificities were confirmed in an ELISA assay. 
The murine complementarity-determining regions of the SV5-P-k mAb were then 
grafted onto suitable human frameworks and the whole reshaped mAb, now of the 
human IgGl isotype, is currently being expressed in CHO cells.
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MATERIALS AND METHODS
1. Plasmids.
Plasmid pBK28-SIV (Kornfeld et al., 1987) containing the SIV (macaque) 
proviral DNA, derivative of the Mm251 isolate, inserted in pUC18 was kindly 
provided through the MRC AIDS Reagent Project. Plasmids pBluescript containing 
rev, tat and gpl60 of SIVmac251(32H)(pJ5) were generous gifts of E. Rud 
(Wellcome Research Labs, Beckenham, Kent). Plasmids pGEX-2T and pQE-9 were 
purchased from Pharmacia (Milton Keynes, U.K.) and QIAGEN (Hybaid, Middlesex, 
U.K.), respectively. Vectors for the expression of Fab and scFv antibody fragments in 
bacteria were obtained from G.Winter (MRC Laboratory of Molecular Biology, 
Cambridge) and the eukaryotic vectors expressing immunoglobulin genes were gifts 
from B. Harris (Scotgen, Aberdeen).
2. Recombinant DNA.
Plasmid DNAs were prepared using the alkaline lysis method of Birnboim and 
Doly (1979) and treated by standard protocols (Maniatis et al., 1982), of which some 
selected methods are described below. Enzymes used for recombinant DNA work 
were purchased from New England Biolabs. Inc. (NEB; Bishop's Stortford, Herts), 
Promega (Southampton), Bethesda Research Laboratories (Paisley) or Boehringer 
Mannheim (Lewes, East Sussex) and used according to the vendors' 
recommendations.
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3, Agarose-gel electrophoresis.
DNA samples were analyzed by horizontal agarose-gel electophoresis. The 
concentration of agarose (Sigma) reconstituted in TBE buffer (90 mM Tris-borate,
2 mM EDTA pH 8.0) ranged from 0.8 to 4% (w/v) depending on the size of DNA 
analyzed. The size of the gel was 10 x 10 x 0.5 cm. DNA samples were mixed 
1:5 (v/v) with 6x loading buffer [0.25% (w/v) bromophenol blue, 30% (v/v) glycerol] 
and loaded into the wells. The DNA species were gel-separated at 100 V for required 
times, stained with 1 p-g.ml"^  ethidium bromide in TBE buffer and visualized on a UV 
transilluminator.
4. Recovery of DNA fragments from agarose gels.
Stained agarose gels were placed onto a UV transilluminator and 
approximately 1-mm wide well was excised just in front of the desired DNA band. 
Gels were returned into the gel rig and TBE buffer was poured into the electiode 
tanks and gel wells, so that it did not overflow the surface of the gel. DNA band of 
interest was then electroeluted by 7 to 9 sequential 100-V 30-second pulses, each 
followed by removing and refilling the buffer from the excised well. The progress of 
electroelution was monitored on UV illuminator. The DNA-containing buffer aliquots 
were pooled, phenol/chlorofoim extracted, ethanol precipitated and dried. For vector 
fragments, the DNA was incubated with alkaline phosphatase (Boehringer 
Mannheim) for 1 hour at 37 °C prior to phenol/chlorofoim extraction in order to 
prevent recircularization during subsequent ligation reactions. Dried DNA was 
resuspended in 20 pi of water and a 2-pl sample was used to estimate the level of 
DNA recovery by gel electrophoresis.
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5. Primers and DNA linkers.
Oligonucleotides used in this work were synthesized using an Applied 
Biosystems oligonucleotide synthesizer and phosphoramidite chemistry. Primers 
annealing at the 5'- and 3'-ends of SIV genes are designated -BACK (backward) and 
-FOR (forward), respectively, and their sequences are as follows; nucBACK 5'-GTG 
CAG GGA TOO ATG TTC TTG GAA AAG ATA GAG CCA GCA CAA G-3', 
nucFOR S'-C TAG CTG AAT TCC TGC CAC CTC TCT AGC CTC TCC GG-3', 
nefBACK 5 -GTG CAG TGA TCA ATG GGT GGA GCT ATT TCC ATG AGG-3', 
nefFOR 5'-C TAG CTG AAT TCC GCC TTC TTC TAA CCT CTT CCT C-3', 
ISBACK 5 -GTG CAG GGA TCC ATG GCA GAA GCC CTG AAA GAG GCC-3', 
15FOR 5'-C TAG CTG AAT TCC CTG GTC TCC TCC AAA GAG AGA ATT 
GAG-3', 17BACK 5 -OTG CAG GGA TCC ATG GGC GCG AGA AAC TCC GTC 
TTG-3’, 17F0R 5'-C TAG CTG AAT TCC GTA ATT TCC TCC TCI GCC GCT 
AGA TGG-3', 27BACK 5'-GCT CAG TGA TCA ATG CCA GTA CAA CAA ATA 
GGT-3', 27FOR 5'-GAG ACA GGA TCC TAA TCT TGC CTT CTG TCC TGG-3', 
polBACK 5 -GTG CAG GGA TCC ATG GTG TTG GAA TTG TGG GAA GGA 
GGG ACA C-3’, protBACK 5 -CTG CAG GGA TCC ATG CCT CAA TTC TCT 
CTT TGG AGG AGA CCA G-3', protFOR 5 -C TAG CTG AAT TCC AAG ATT 
TAG AGA CAT CCC CAG AGC-3', revBACK 5 -GTG CAG GGA TCC ATG 
AGC AGT CAC GAA AGA GAA GAA G-3', revFOR 5'-C TAG CTG AAT TCC 
GTC CTG AGG ACT TCT CGA CTT CTC-3', rtBACK 5 -GTG CAG GGA TCC 
ATG CCC ATA G(T AAG GTA GAG CCT GTA AAA GTC-3', rtFOR 5'-C TAG 
CTG AAT TCC GAG AAC TTG TCT AAT CCC CTG AC-3', tatBACK 5 -GTG 
CAG GGA TCC ATG GAG ACA CCC TTG AGG GAG-3', tatFOR 5'-C TAG 
CTG AAT TCC TCT GAA AAG GCC AGG AGC TGT TGC C-3', vifBACK 5'- 
CGT GAT GGA TCC ATG GAG GAG GAA AAG AAG TGG-3', vifFOR 5 -C 
TAG CTG AAT TCC TGC CAG TAT TCC CAA GAC CTT TGC-3', vprBACK 
5 -CGT GAT GGA TCC ATG GAA GAA AGA CTT CCA GAA AAT GAA 
GGC-3', vprFOR 5'-C TAG CTG AAT TCC AGA GGG CGG TAT AGT TGA
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GAG-3', vpxBACK 5 -CGT GAT TTA TCC ATG TCA GAT CCC AGG GAG AGA 
ATC CC-3', vpxFOR 5'-C TAG CTG AAT TCC TGA TAGTCC TGG AGG GGG 
AGG-3' and GEXFOR 5'-C GCT CTG TCG ACG CGC GCA AGC TTC AGA TCG 
TCA GTC AGT CAC GAT TAA TT-3'. Mutagenic primers used for the inactivation 
of protease were mutprotB ACK 5'-A GTC TTA TTG AAT ACA GGG GC-3' and 
mutprotFOR 5'-GC CCC TGT ATT CAA TAA TAC T-3'. Oligonucleotides of 
positive and negative senses used for generation of the Pk tag-coding DNA linkers 
were: GEXnPkpos 5 '-GA TCT GGA AGG CCG ATC CCA AAC CTT TTG CTG 
GGA TTG GAC TCC ACC G-3', GEXnPkneg 5'-GA TCC GGT GGA GTC CAA 
TCC CAG CAA AGG GTT TGG GAT CGG CTT TCC A-3', GEXcPkpos 5'-A ATT 
CCA GGA AAG CCG ATC CCA AAC CCT TTG CTG GGA TTG GAC TCC ACC 
TOA-3', GEXcPkneg 5'-A ATT TCA GGT GGA GTC CAA TCC CAG CAA AGG 
GTT TGG GAT CGG CTT TCC TTG -3', HisPkpos 5 -GA ATT CTC GGA AAG 
CCG ATC CCA AAC CCT TTG CTG GGA TTG GAC TCC ACC TAG-3’ and 
HisPkneg 5'-AG CTT CTA GGT GGA GTC CAA TCC CAG CAA AGG GTT TGG 
GAT CGG CTT TCC GAG ATT TCT GCA-3'. The PCR BACK primers annealing 
to the leader sequences of the immunoglobulin chains were described previously by 
Jones and Bendig (1991) and the FOR primers used to amplify the variable regions 
were tcFOR 5'-GGA TCC CGG GTG GAT GGT GGG AAG ATG-3' for the mouse 
K light chain and MoIgG2aFOR 5’-GGA TCC CGG GAG TGG ATA GAC CGA 
TGG-5' for the mouse IgG2a heavy chain.
The primers used for the reshaping of the heavy chain were: HI 5'-CTG TCT 
CAC CCA GTG CAT TCC AAA ACT GGT GAA GGT ATA G-3', H2 5’-GTT CTT 
GGG GTT GTC TAG CGA TAT TGT AAA TCT GCC CTT CAC TGT GTC TCC 
ATA GTA GAT GGT AGT ACT GTC AGT ATT ATT GTA TGC AAC CCA 
CTC-3', H3 5'-CCC TTG GCC CCA GTA GTC AAA GCC GTA GTA AGG GCC 
CGC GCT TGC ACA AAA ATA G-3' and H2.2 5'-GTT GTC TCG CGA TAT TGT 
AAA TCT GCC CTT CAC TGT GTC TCC ATA GTA GAT GGT AGT ACT GTC 
AGT ATT AAT GTA TGC AAC CCA CTC AAG ACC-3'. The oligonucleotide H2, 
in addition to grafting CDR2, mutated Ser75 of the human framework to Pro.The
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primers for reshaping of the light chain were: L I CTG CTG GTA CCA ATA CAA 
ATA AGT GAT GCC ATT ACT ATG TAC GAG ACT CTT ACT AGA CCT ACA 
GGT GAT GGT CAC-3', L2 5 -GCT TGG CAC ACC TGA GGC AAG GCT GGA 
CAT CTG GTA GAT CAG CAG-3' and L3 5 -CCC TTG GCC GAA CGT GAA 
TGG AAG TTC TAG AAT TTG ACC GCA GTA GTA GGT G-3’. The primers used 
for the construction of chimeric immunoglobulin genes were: H-Pst 5’- C ACC GCT 
CTC CTG CAG TTG GAC CTC-3’, L-PvuBACK 5 -GAT ATT CAG CTG ACG 
CAG GCT G-3', L-BamFOR 5 -CGC GGA TCC AAC TGA GGA AGC AAA GTT 
TAA ATT CTA CTC CCG TCT TAT TTC CAA CTT TG-3’.
6. Isolation of poIyA+ RNA from SV5-P-k hybridoma and generation 
of cDNA.
SV5-P-k hybridoma cells were harvested by centrifugation and washed with 
phosphate-buffered saline (PBS). The cell pellet (approximately 200 mg) was 
resuspended in 2.4 ml of GSS solution (5.5 M guanidinium isothiocyanate, 25 mM 
sodium citrate, 0.5% (w/v) sodium lauryl sarcosine, pH 7.0), the DNA was sheared by 
passing through a 19-gauge needle several times and the lysate was spun in an 
eppendorf centrifuge. 2.5 ml of the resulting supernatant was loaded onto 2.7 ml of 
caesium trifluoroacetate solution [prepared by combining 25.5 ml of caesium 
trifluoroacetate in water, density 2.01 g.ml-1 (CsTFA™ solution; Pharmacia cat. no. 
17-0847-02) and 23.5 ml of 0.25 M EDTA pH 7.0] and separated by centrifugation at 
31,(XX) rpm in Beckman SW 50.1 rotor at 15 °C for 24 hours. The total-RNA pellet 
was resuspended in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.0) and the 
polyA+ subpopulation was isolated on a oligo(dT) column using a Pharmacia 'mRNA 
Purification Kit' (cat. no. 27-9258-01). An oligo(dT) primer and avian myoblastoma 
virus (AMV) reverse transcriptase (Promega cat. no. M5101) were used for the first- 
strand DNA synthesis as recommended by the vendor.
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7. Polymerase chain reaction.
A 50-fxl PCR reaction mixture consisted of PCR buffer (final concentration:
50 mM KCl, 10 mM Tris-HCl pH 8.8,1.5 mM MgCh, 0.1% (v/v) Triton X-100),
0.2 mM of each dNTP, 0.5 |xM of each primer. The amount of template varied from 
approximately 0.1-10 ng of DNA. For the amplification of immunoglobulin variable 
regions, the PCR reaction mixture was briefly irradiated prior to addition of the 
cDNA template in order to inactivate any possible contaminating large-size DNA.
The reaction mixture was overlayed with 2-3 drops of liquid paraffin and incubated 
for 3 min. at 94 °C before addition of the Tag DNA polymerase (Promega).
Typically, 35 cycles of 94 °C for 1-2 min., 40-60 °C for 1-2.5 min. and 65-74 °C for 
1.5-3 min. were carried out with the last cycle being 60 ®C for 5 min.
8. Processing of PCR products for ligation.
After PCR amplification, the top liquid paraffin layer was removed and the 
reaction mixture volume increased to 1(X) pi witli TE buffer. The PCR product was 
extracted with 100 pi of chloroform, precipitated by addition of 10 pi of 3 M sodium 
acetate and 250 pi of ethanol in -20 °C for 30 min., collected by centrifugation at 
12,0(X)g at 4 °C for 10 min., dried and resuspended in 20 pi of sterile water. The 
PCR-amplified DNA was digested with appropriate restriction endonuclease enzymes 
according to manufacturer's instructions for 1 to 16 hours. The digestion products 
were gel-purified (above) and used for ligation.
9. DNA ligation.
Approximately 400 ng of vector DNA and 40-400 ng of insert were combined 
in total of 20 pi of ligation buffer (50 mM Tris-HCl pH 7.8,10 mM MgCli, 10 mM 
dithiothreitol, 1 mM ATP, 25 mg.ml’  ^bovine serum albumin) containing 2(X) U of
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T4 DNA ligase (NEB) and incubated at 16 °C for 1 hour. The ligation mixture was 
used directly for transformation of competent E. coli.
10- Preparation of competent bacteria.
Escherichia coli strains DHl, JMlOl, M15, SG 13009, TGI or RZ1032 were 
made competent using the modified RbCl method of Kushner (1978). Briefly, a 60-ml 
bacterial culture was grown to ODeoo = 0.3-0.5, cooled on ice and spun at 756g for 
10 min. The pellet was resuspended in 20 ml of ice-cold MOPS I solution (1 M 
MOPS pH 7.0,100 mM RbCl), spun as above and resuspended in 20 ml of ice-cold 
MOPS II solution (1 M MOPS pH 6.5,7(X) mM CaCl2, 100 mM RbCl), spun as 
above and resuspended in 2 ml of MOPS II solution. Competent bacteria were used 
immediately for DNA transformation or stored at 4 ®C for over a week.
11. Transformation of competent bacteria.
One half of the 20-pl ligation reaction or 10 pi of in-vitro mutagenesis 
reaction was combined with 100-200 pi of competent bacteria and incubated on ice 
for 30 min. with occasional end-over-end shaking. The bacteria were then heat- 
shocked at 42 °C for 2 min., returned to ice for 5 min. and plated. When selecting for 
transformants carrying antibiotic resistance-conferring plasmids, the transformation 
mix was diluted in 1 ml of Luria-broth (LB) medium and incubated at 37 °C for 
1 hour, to allow for the expression of resistance-conferring gene, before plating on 
selection plates.
12. Preparation of single-stranded DNA.
Bacteriophage was added into 2-ml bacterial inoculum and the becteriophage- 
infected bacteria were grown for 6 to 16 hours at 37 °C. The bacteria were pelleted 
and 1.2 ml of the culture supernatant was transferred into a new eppendorf tube
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containing 200 pi of 20% (w/v) polyethylene glycol 8,000 (PEG), 2.5 M NaCl 
solution, the tubes were vortexed and incubated at 20 °C for 15 min. The 
bacteriophage was pelleted in an eppendorf centrifuge, the supernatant was discarded 
and residual traces of PEG supernatant were removed after a re-centrifugation. The 
pellet was resuspended in 100 pi of TE buffer, thoroughly phenol/chloroform 
extracted, ethanol precipitated and dried. The ssDNA pellet was resuspended in 35 pi 
of water and its concentration was estimated by agaiose-gel electrophoresis, as 
described earlier.
13. Oligonucleotide-directed mutagenesis of heavy and light chain 
variable regions.
Oligonucleotide-directed mutagenesis was described in detail by Kunkel and 
co-workers (1987). Briefly, bacteriophages M13mpl8 containing human variable 
regions were grown in dut ung~ E. coli, strain RZ1032, in order to prepare uridine- 
containing ssDNA. (The incorporation of uridine into templates destabilizes the DNA 
when propagated in dut^ ung~^  E. coli strains.) The extent of uridine incorporation 
into templates was estimated by the difference in plaquing efficiencies on dut ung~ 
RZ1032 and dut^ ung'  ^ TGI strains and only phages giving 10^-10  ^less plaques on 
a TGI bacterial lawn were used for preparation of templates. Three end- 
phosphorylated oligonucleotides corresponding to the murine complementarity- 
determining region DNA sequences were mixed with uridine-containing ssDNA 
template at ratios 10:10:10:1, allowed to anneal in a water-bath cooling from 70 °C to 
room temperature over 3 hours and transferred to ice for at least 10 min. To the 
annealing mixture, the following reagents were added: T7 DNA polymerase buffer 
(final concentration of 20 mM Tris-HCl pH 7.5,10 mM MgCl^, 1 mM dithiothreitol), 
1 mM ATP, 0.2 mM dNTPs, 1 U of T7 DNA polymerase and 1 U of T4 DNA ligase 
in final volume of 100 pi. The extension reaction was carried out first on ice for 
5 min., at room temperature for 5 min., at 37 for 30 min. and at 42 °C for 15 min. 
One fifth of the reaction volume was then used to transform competent TGI bacteria
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as described previously and plated. M13-containing plaques were picked and the 
bacteriophage DNA sequenced. The frequency of triple mutants, i.e. all 3 CDRs 
grafted in one reaction, was, on average, lO'i.
14. DNA sequencing.
Single-stranded DNA templates were sequenced using tlie dideoxy chain- 
termination reaction. Sequenase® (Version 2.0) sequencing kit (United State 
Biochemicals) and [a^^SJdATP (10  ^Ci.mmok^; Amersham International) were used 
exactly according to the vendor's recommendations.
15. Production of stably transfected cell lines expressing heavy and 
light chains derived from the SV5-P-k antibody.
Approximately 1 million CHO cells was resupsended in 1 ml of serum-free 
G-MEM (GIBCO-BRL) medium. 15 pg of plasmid DNA was added to the cell 
suspension, the mixture was transferred to an electroporation cell and exposed to 
250 V at 1180 pF capacitance using a Cell-Porator™ (BRL). Immediately after 
electroporation, the cells were placed into 10 ml of G-MEM + 10% (v/v) foetal-calf 
serum (FCS) in a 90-mm petri dish. The appropriate selection drugs were added after 
1 day, i.e. 400 U.ml'l of hygromycin B (Sigma cat. no. H-8272) for the light chain 
plasmids and 25 mg.ml-l of mycophenolic acid (Sigma cat. no. M-3536) 
supplemented with 250 mg.ml-l Qf xanthine (Sigma cat. no X-2001) for the selection 
of the heavy chain plasmids. In 10-14 days, individual colonies of resistant cells were 
ring-cloned, expanded and assayed for the expression of proteins of interest. Initially, 
stable cell lines expressing the light chains were isolated. The expression light chains 
were confirmed by a dot blot analysis of both the cell lysates (below) and tissue 
culture supernatants using horse radish peroxides (HRP)-conjugated anti-human 
kappa light chain antibodies (Sigma cat. no. A-7164) followed by ECL (Amersham 
International). Cell clones expressing the highest levels of light chains were then
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transformed with the heavy chain genes, the expression of which was confirmed using 
HRP-conjugated protein A (Amersham International cat. no. NA9120) followed by 
ECL.
16. ELISA for detection of antibody H and L chain association, and 
cloned antibody or antibody fragment specificities.
ELISA plates were coated with approximately 2 pg of Pk tag-linked antigen in 
100 pi phosphate-buffered saline (PBS) overnight at 4 °C. The wells were blocked 
with PBS + 10% (w/v) Marvel at room temperature for 1 hour, incubated with 
bacterial (for Fab and scFv fragments) or tissue culture (for recombinant antibodies) 
supernatants at room temperature for 1 hour and positive binding was detected with 
HRP-conjugated anti-human kappa light chain antibodies or HRP-conjugated protein 
A and solution of ImmunoPure® ABTS (2,2-azino bis(3-ethylbenzthiazoline- 
6-sulphonic acid) diammonium salt) tablets (Pierce cat. no. 34026) and diluted 
hydrogen peroxide.
To confirm the association of light and heavy chains, the plate was coated 
with monoclonal anti-human IgG (Fc-specific) antibody (Sigma cat, no. 1-6260), 
blocked as above and incubated with tissue culture supernatant followed by HRP- 
conjugated anti-human kappa light chain antibody and ABTS/hydrogen peroxide 
solution.
17. Isolation of recombinant baculovirus expressing SIV gpl60.
Baculovirus expressing SIV gpl60-Pk was generated by a co-transfection of 
B^w36I-digested viral DNA and transfer vector pVLl393160Pk containing the SIV 
env gene into Spodopterafrugiperda cells IPLB-SF-21 (Sf 21) cells using lipofection. 
Briefly, approximately 10  ^Sf 21 cells from a spinner culture were placed into 
a 25-cm^ flat in TCI00 medium supplemented with 10% (v/v) FCS and allow to 
adhere for 90 min. The monolayer was washed 2x with 5 ml of OPTIMEM medium
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(BRL-GIBCO) and 3 ml of the same medium was added to the cells. 0.5 |ig of 
digested viral DNA was mixed with 2 pg of the transfer vector in 50 pi of water, the 
resulting mix was combined with an equal volume of Lipofectin (BRL cat no. 
8292SA), incubated at room temperature for 10 min. and the 1(X) pi Lipofectin/DNA 
solution was then added dropwise onto the cell monolayer. After 4 hours at 28 ^C, the 
medium was replaced with TClOO + 10% (v/v) FCS and the cells were incubated at 
28 ®C for 4 days. Serial dilutions ranging lO^-lO'^ of the 4-day supernatant were used 
to infect Sf 21 cell monolayers for plaque purification of the virus. As described by 
O'Reilly and co-authors (1992), infected cell monolayers were overlayed with soft 
agar, stained with Neutral Red at 5 days post-infection and plaques were observed 
approximately 7 days later. Twenty plaques were picked and the viruses assayed for 
expression of the Pk tag in a Western blot analysis using SV5-P-k mAb. Virus stocks 
of two expressing isolates were gradually scaled up.
IS. Antibodies and cells.
Monoclonal antibody SV5-P-k recognizing an epitope on SV5 phospho (P) 
and V proteins was isolated (Randall et aL, 1987) and its specificity was determined 
(Southern et al., 1991) in our laboratory. Monoclonal antibodies KK33 (anti-SIV 
p27), KK7 (anti-SIV gp41/gpl60) and KK8 (anti-SIV gpl20/gpl60) were obtained 
from K Kent [Medical Research Council AIDS Reagent Project (MRC ADP)]. Pooled 
antisera to SIVmac251(32H) from cynomolgous macaques were obtained from
E.J. Stott (Potters Bar, U.K.) through the MRC ADP (ADP416). Serum from 
SrVmac251(32H)-infected macaques rhesus and C8166 cell lysate infected with the 
same virus were generous gifts from M. Cranage (CAMR, Port Down, U.K.), Chinese 
hamster cells (CHO-Kl) cells (Kao and Puck, 1968) were grown in G-MEM medium 
(GIBCO-BRL) supplemented with 10% (v/v) FCS and insect Sf 21 cells were grown 
in TClOO medium (GIBCO-BRL) supplemented with 10% (v/v) FCS.
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19. Screening for pQ9SIVPk recombinants by detection of expressed 
Pk tag on agar plates.
The gene for the Pk tag was positioned in plasmid pQ9cPk in such a way, that 
the Pk tag gene was out of the N-terminal His tag reading frame. This enabled 
screening for transformants carrying successfully inserted SIV gene by detection of 
the Pk tag. Thus, after ligation and transformation, individual bacterial colonies were 
induced by IPTG and screened directly on agar plates for the expression of the Pk 
tag. Plates with 18-hour-old colonies were covered with one sheet of nitrocellulose 
filter and two 3MM papers soaked in LB medium containing 100 pg.ml-l of 
ampicillin, 50 pg.ml'l of kanamycin and 1 mM IPTG, and incubated at 37 °C for 
2 hours. Bacterial colonies attached to the nitrocellulose filter were disrupted by 
a 30-min. incubation in disruption buffer [4x concentrated: 20% (v/v) glycerol,
2(X) mM Tris-HCl, pH 7,20% (v/v) 2-mercaptoethanol, 8% (w/v) sodium dodecyl 
sulphate (SDS)], the nitrocellulose filter was blocked with PBS + 20% (w/v) Marvel 
and processed as described for Western blots. After removal of the nitrocellulose 
filter, the plates were incubated at 37 °C for 2-3 hours in order to regenerate the 
bacterial colonies.
20. Expression and two-step purification of GST-SIV-Pk proteins.
GST fusion proteins were purified as described by Smith and Johnson (1988) 
with minor modifications. Briefly, bacteria carrying plasmids were grown to 
OD600 = 0.7 and the expression of the fusion proteins was induced by 1 mM IPTG at 
20 °C for 3-6 hours. Bacteria were pelleted, washed in ice-cold TN buffer (20 mM 
Tris-HCl pH 7.8, 300 mM NaCl) and treated with 10 mg.ml-I of lysozyme on ice for 
15 min. Triton X-100 was then added to final concentration of 1% (v/v) and the 
lysates were sonicated. The bacterial lysates were spun at 25,0(X)g for 30 min. The 
supernatants were incubated with glutathione-agarose beads (sulphur linked. Sigma) 
rotating end-over-end at 4 °C for 1 hour. The beads were then transferred to a column,
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washed with PBS and incubated with human thrombin (Sigma) to cleave off SIV-Pk 
antigens. Thrombin-released proteins were washed from the column by 2 column 
volumes of PBS and incubated with SV5-P-k-saturated particles of S. aureus on 
a rocking table at 4 °C for 1 hour and washed 4x with PBS.
21. Expression and two-step purification of His-SIV-Pk proteins.
His-SrV-Pk proteins were induced with 50 p.M IPTG at 26 °C for 1-3 hours. 
Two procedures were used for protein purifications depending on whether the protein 
was soluble or insoluble.
i) Soluble proteins. Bacteria were pelleted, the pellet was washed in TN 
buffer, resuspended in the same buffer supplemented with 10 mg.ml'l of lysozyme 
and incubated on ice for 15 min. Triton X-100 was then added to final concentration 
of 1% (v/v), the lysates were sonicated and spun at 25,000g for 30 min. The 
supernatant was incubated with NP+-nitiilotriacetic acid (NTA) resin and an excess 
of mAb SV5-P-k at 4 for 1-2 hours. The resin was transferred to a column, washed 
with 10 column volumes of TN buffer 4-1% (v/v) Triton X-100 and eluted with
1 volume of the TN buffer 4-1% Triton X-100 supplemented with 250 mM imidazole. 
Eluted material was incubated with protein A-sepharose beads at 4 for 1 hour, 
washed with TN buffer 4-1% (v/v) Triton X-100, resuspended in disruption buffer 
containing 0.25% (w/v) bromophenol blue and analyzed on 17% (w/v) SDS- 
polyacrylamide gels.
ii) Insoluble proteins. For His-vif-Pk, which was insoluble under the above 
conditions, the bacterial pellet was resuspended in buffer A [6 M guanidine 
hydrochloride (GuHCl), 0.1 M NaH2P0 4 , 10 mM Tris, 0.1% (v/v) Triton X-100, pH 
adjusted to 8.0 with NaOH] and stirred at room temperature for 1 hour. The lysate 
was then sonicated, spun at 25,000g for 30 min., the supernatant was incubated with 
a Ni^+-NTA resin at 4 °C for 1-2 hours and the resin was transferred into a column. 
The column was washed with 10 column volumes of buffer A, 10 volumes of 
buffer B (8 M urea, 0.1 M NaH2P04,10 mM Tris, 0.1% (v/v) Triton X-100, pH
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adjusted to 8.0 with NaOH immediately before use) and the His-vif-Pk protein was 
eluted with buffer E (same as buffer B, but pH adjusted to 4.5 with HCl immediately 
before use). Fractions containing the desired protein were pooled and dialyzed against 
0.65 M NaCl, 20 mM Tris-HCl pH 7.8 and 0.1% (v/v) Triton X-100 overnight in 
order to remove urea. The amount of nickel affinity-purified protein was estimated on 
a Coomassie blue-stained gel and a 3-fold molar excess (antigen to antibody) of the 
purified His-vif-Pk was incubated with protein A-sepharose beads saturated with 
mAb SV5-P-k at 4 ^C for 1 hour. The beads were washed in TN buffer + 0.1% (v/v) 
Triton X-100, resuspended in disruption buffer containing 0.25% (w/v) bromophenol 
blue and analyzed on a 17% (w/v) SDS-polyacrylamide gel.
22. Expression and two-step purification of SIV gpl60-Pk,
500 ml of Sf 21 suspension culture (approximately 10  ^cells per ml) was 
infected with approximately 6 x 10  ^plaque-forming units of recombinant virus 
AcRP6-160Pk for 2 days, the cells were harvested and lysed in NP 40/DOC buffer 
[50 mM Tris-HCl pH 7.5,100 mM NaCl, 0.5% (v/v) sodium deoxycholate (DOC),
1% (v/v) NonidetP-40 (NP 40)], sonicated and spun at 25,000^ for 30 min. The 
supernatant was mixed with lentile lectin-sepharose beads at 4 °C for 1 hour, the 
beads were washed with NP 40/DOC buffer and loaded into a column, washed again 
with NP 40/DOC buffer and the bound glycoproteins were eluted with a high-sugar 
solution (5(X) mM methyl a-D-glucopyranoside, 500 mM methyl 
a-£>-mannopyranosid in NP 40/DOC buffer). The eluate was directly incubated with 
mAb SV5-P-k complexed to a solid matrix for the second-step purification.
23. Construction of SMAA complexes.
SMAA complexes were prepared as described before (Randall and Young,
1988). Briefly, a 10% (w/v) suspension of 'fixed' and killed Cowan A strain of 
Staphylococcus aureus (Kessler, 1975) was incubated with an equal volume of
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SV5-P-k antibody-containing ascitic fluids at 4 °C for 1 hour. Unadsorbed antibodies 
were removed by 3 consecutive pelletings (2,500g for 2 min.) and resuspensions in 
PBS. Antibody-saturated S. aureus particles were mixed with partially purified 
SIV-Pk or GST-SIV-Pk antigens at 4 °C for 1 hour and washed as above. 
Alternatively, particles of 'fixed' and killed S, aureus were incubated with SV5-P-k- 
His-SrV-Pk complexes eluted from the nickel-chelating column at 4 °C for 1 hour 
and the resulting SMAA complexes were washed with PBS as above.
24. SDS-PAGE and Western blot analysis.
Protein samples were suspended in disruption buffer containing 0.25% (wA^ ) 
bromophenol blue, boiled for 2 min. and individual polypeptides were separated on 
SDS-polyacrylamide gels crosslinked with 15% (w/v) iV,V-diallyltartardiamide 
(DATD) using thin (0.75 mm) mini-slab gels of the Bio-Rad electrophoresis system. 
Separated polypeptides were either stained with Coomassie brilliant blue R-250 or 
transferred onto a nitrocellulose filter using a semidry gel electroblotter (LKB). The 
filters were blocked with PBS + 20% (w/v) Marvel and incubated with monoclonal or 
polyclonal antibodies ni PBS + 1% (w/v) Marvel. Bound antibodies were detected 
using either [I^^I]protein A (Amersham International) in PBS + 1% (w/v) Marvel 
followed by autoradiography, or HRP-conjugated protein A (Amersham 
International) in PBS + 1% (w/v) Marvel followed by enhanced chemüuminiscence 
(ECL; Amersham International).
25. Dot blot analysis.
For testing the specificity of immune sera, nitrocellulose sheets were 
incubated with immunoaffinity-purified antigen (10-20 p.g per 7x5 cm sheet) at room 
temperature for 1 hour and sandwiched between 84-well Terasaki plates containing 
10 pi of diluted sera per well at room temperature for 30 min. The filters were then 
incubated with [l^Ijprotein A in PBS + 1% (w/v) Marvel followed by
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autoradiography. Alternatively, PBS-soaked nitrocellulose filters were sandwiched 
between Terasaki plates containing 10 pi of transfected cell clone lysates in order to 
detect the expression of the immunoglobulin light chains. After a 30-min. incubation 
at room temperature, filters were blocked in PBS + 10% (w/v) Marvel and incubated 
with HRP-conjugated human k light chain-specific mAb followed by ECL.
26. Immunization of mice.
To test the immunogenicities of recombinant SIV antigens assembled into 
SMAA complexes, mice were injected intraperitoneally with 200 pi aliquots of 0.5% 
(w/v) suspension of SMAA complexes, which contained 2-5 pg of recombinant SIV 
antigens. The immunizations were repeated after 2 to 3 weeks. 10 days after me 
second injection, mice were bled and the sera assayed for the presence of anti-SIV 
antibodies in ELISA or dot blot using recombinant SIV proteins and/or against 
Western blotted SIV-infected cell lysates.
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RESULTS
A. Construction of SMAA complexes using  a Tag-Specific 
MAB and Tag-Linked S iv  P27.
Monoclonal antibody S V5-P-k was isolated in our laboratory, (Randall et al, 
1987) the binding of which to the original antigen, the phospho (P) protein of simian 
virus 5 (SV5), could be successfully competed with a nonapeptide (Southern et ah, 
1991). The work presented in Part A of the Results demonstrates, that a short oligo­
peptide tag, the core sequence of which coiTesponds to the originally competing nona­
peptide, retained its antigenicity when attached to the C-terminus of SIV p27 and that 
the tag-linked p27 could be assembled into SMAA complexes using SV5-P-k mAb.
A.I. Construction of expression vector pGEX27Pk.
An E, coli expression vector pGEX-2T (Fig. 8) described by Smith and 
Johnson (1988) was chosen for the expression of Pk tag-linked p27 of simian 
immunodeficiency virus (SIV). In the pGEX-2T system, recombinant proteins are 
expressed as a fusion protein linked to the C-terminus of glutathione S-transferase and 
can be easily purified by affinity chromatography on immobilized glutathione. The 
GST gene is under control of the lac promoter and can therefore be induced by IPTG. 
The pGEX-2T vector was also designed so that the GST carrier polypeptide can be 
cleaved from the fusion protein by thrombin.
A region of the SIV gag gene encoding the major core protein p27 was 
amplified from plasmid pBK28-SIV DNA (Komfeld et al., 1987) using the
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ser gly lys pro iia pro asn pro iau lS22
GA TCG GGA AAG CCG ATC CCA AAC CCT TTG CTGC CCT TTC GGC TAG GGT TTG GGA AAC GAC
a&B ser thr AMB OPA
GGA TTG GAC TCC ACC TAG TGA ATT CCCC AAC CTG AGG TGG ATC ACT TAA GAG CT
Figure 9. DNA linker coding for the Pk tag.The schematics shows sequences of positive and negative strand oligonucleotides, which were designed to give after annealing BamHI-compatible mà Xhdi cohesive ends. The Pk tag linker codes for amino acids 95-108 derived from SV5 P and V proteins (bold). Underlined region corresponds to the synthetic nonapeptide, which competed with P and V proteins for binding to SV5-P-k antibody in a radioimmunoassay (Southern et a/., 1991).
Figure 8. Construction of pGEX27Pk expression vector.(Next page) The gene coding for SIV p27 was amplified in a polymerase chain- reaction from pBK28-SIV plasmid. The PCR product was treated with polynucleotide kinase and the Klenow fragment of DNA polymerase, digested with BcH and the Bc/I/blunt fragment was ligated between the unique BamBl and Smal sites of the pSV2X3 polylinker (Hanke et al., 1990). Resulting plasmid pSV27 was cleaved with Bam\H and Xho\ for the ligation of the tag linker (Fig. 9). In order to regenerate BcB site at the 5’-end of the hybrid gene, p27-Pk DNA was amplified by PCR from pSV27Pk using 27BACK and the negative strand of the Pk tag linkr as primers. Amplified p27-Pk DNA was digested with Bcïl and EcoRI restriction endonucleases and inserted into BamHl and EcoRl sites of pGBX-2T yielding pGEX27Pk. Plasmid pGEXPk was constructed by an insertion of an EcoRI-digested Pk tag linker between the unique BaniHl and EcoRl sites of pGEX-2T.
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polymerase chain reaction (PCR) and the p27 PCR product was ligated into vector 
pSV2X3 resulting in plasmid pSV27 (Fig. 8). An oligonucleotide linker encoding the 
tag antigen, i.e. 14-amino acids of SV5 P and V proteins (Fig. 9) recognized by 
monoclonal antibody SV5-P-k (Southern et al.^  1991), was inserted at the 3*-terminus 
of the p27 gene, yielding plasmid pSV27Pk. In order to insert the hybrid gene into 
pGEX-2T, the Bctt. site at the 5'-end of the p27-Pk gene had to be regenerated by 
PCR amplification from pSV27Pk using 27BACK primer and the negative strand of 
the Pk DNA linker as primers. The amplified sequences were inserted into 
and EcoBl sites of pGEX-2T.
The Pk tag DNA linker was also inserted alone into pGEX-2T for the 
production of GST-Pk (not shown).
A.2, Expression of SIV p27-Pk and construction of SMAA complexes.
SIV p27-Pk was expressed in E. coli as a fusion protein with glutathione 
S-transferase. The expression of GST-p27-Pk was induced by addition of IPTG into 
bacterial cultures transformed with pGEX27Pk plasmid. Total bacterial lysates 
analysed by ^SDS-PAGE gave a prominent GST-p27-Pk band migrating at about 
52 kDa (Fig. 10, lane L). For the purification of GST-p27-Pk, bacteria were lysed by 
Incubation in TN buffer containing lysozyme followed by vigorous sonication. The 
sonicated lysate was centrifuged and the supernatant used for either glutathione- 
affinity column purification of GST-p27-Pk or constraction of SMAA complexes.
Two approaches were taken to construct SMAA complexes. In the first, 
SMAA complexes were prepared by incubation of SV5-P-k-saturated S. aureus 
particles with the soluble antigen preparation. The resulting SMAA complexes 
containing GST-p27-Pk were washed several times in PBS, and analyzed by SDS- 
PAGE (Fig. 10, lane 1). The Coomassie blue-stained gel shows a highly purified 
GST-p27-Pk protein migrating between the heavy and light immunoglobulin chains 
of S V5-P-k antibody. All three bands are approximately equimolar, confirming that
7 7
IgH
GST-27-Pk —
27-Pk
IgL / ■
97.5
66
Figure 10. Purification of SIV p27-Pk (Coomassie blue-stained SDS- polyacrylamide gel).Coomassie brilliant blue-stained SDS-polyacrylamide gel of a crude bacterial lysate after induction of GST-p27-Pk (lane L), SMAA complexes containing GST-p27-Pk (lane 1) and the same complexes, from which the GST domain was cleaved off with thrombin (lane 2). Also shown is a purified preparation of p27-Pk (lane 3) and SMAA complexes constructed using purified p27-Pk (lane 4). Polypeptides were separated by electrophoresis through a 12% (w/v) SDS-polyacrylamide minislab gel. The positions of immunoglobulin heavy ^gH) and light (IgL) chains, GST-p27-Pk, p27- Pk as well as the Mf markers of 97.4,66,45 and 29 kDa are shown. Note that purified p27-Pk runs as two bands, both of which react with mAb specific for p27 and for the Pk tag (Fig. 11).
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KK33 SV5-P-k
Figure 11. Western analysis of SIV p27-Pk-containing SMAA complexes.The figure shows Western blot analysis of SMAA complexes probed with anti-p27 
(KK33; panel A) or anti-Pk tag (SV5-P-k; panel B) mAbs followed by [^^^I]protein A and autoradiography. SMAA complexes containing GST-p27-Pk are shown in lanes 1, the same complexes after thrombin removal of the GST domain are in lanes 2 and complexes containing a two step-purified p27-Pk (see Materials and Methods) in lanes 4. Lanes 3 contain purified p27-Pk eluted from the glutathione column.
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SV5-P-k antibody in SMAA complexes was saturated with the antigen. In order to 
remove the GST domain of the fusion protein from the surface of the complexes, the 
GST-p27-Pk-containing SMAA complexes were incubated with thrombin and the 
cleaved complexes were analyzed by gel electrophoresis (Fig. 10, lane 2). The gel 
revealed a polypeptide doublet incorporated into the 'shaved' SMAA complexes. The 
reason for obtaining two bands after the thrombin digest of GST-p27-Pk is unclear, as 
amino acid sequence analysis of p27-Pk did not show any other obvious recognition 
sites for thrombin.
To confirm that the polypeptides incoiporated in the SMAA complexes above 
were indeed SIV p27 linked to the oligopeptide Pk tag, disrupted SMAA complexes 
were analyzed by Western blotting. Incubation with both anti-Pk (SV5-P-k) and anti- 
p27 (KK33) mAbs resulted in a strong signal on the autoradiogram corresponding to 
the Mf. of p27-Pk (Fig. 11, lanes 2). Shorter exposure of the same transfer showed that 
both bands of the doublet were recognized by both mAbs (not shown). The Western 
blot also revealed distinct faster-migrating bands detected with SV5-P-k (Fig. 11, 
right panel, lanes 1 and 2) and partially with KK33 (Fig. 11, left panel, lane 1) mAbs. 
These bands were products of proteolytic degradation, which had assembled into 
SMAA complexes via the oligopeptide tag. Taking advantage of the affinity of GST 
for its natural substrate glutathione, the contamination of SMAA complexes with 
degraded p27-Pk could be avoided by prior purification of GST-p27-Pk fusion protein 
on a glutathione affinity column. Crude bacterial lysate was incubated with 
glutathione coupled to agarose beads. Beads with adsorbed GST-p27-Pk were loaded 
into a column and thoroughly washed with PBS. As GST-p27-Pk bound to the beads 
via the GST end of the fusion protein, the washes removed all degradation products 
lacking the GST domain. p27-Pk was then released from the column by cleavage with 
thrombin (Fig. 10, lane 3). Note, that the thrombin cleavage of GST-p27-Pk adsorbed 
to the column again released a p27-Pk doublet. Purified p27-Pk readily assembled 
into SMAA complexes (Fig. 10, lane 4), this time without contamination from the 
degraded species (Fig. 11, lanes 4). Thus, a straightforward procedure has been
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developed for producing relatively large amounts of tag-based SMAA complexes 
using SV5-P-k mAh and a bacterially expressed Pk-linked antigen.
A.3. Isolation of p27-specific monoclonal antibodies.
SMAA complexes containing recombinant SIV p27-Pk were used to 
immunize mice for the production of p27-specific monoclonal antibodies. Sera taken 
from immunized mice were tested for the presence of antibodies binding to p27-Pk 
and GST-Pk in a radioimmunoassay. The antibody titre against p27-Pk was much 
higher than tliat against GST-Pk (Fig. 12) demonstrating, that serum antibodies 
recognized the p27 portion of p27-Pk fusion protein rather than the Pk tag itself. 
Indeed, it was previously shown that immunization with SMAA complexes resulted 
in relatively fewer antibodies being produced to the epitope interacting with the 
antibodies in SMAA complexes compared with the other antigenic determinants on 
the incorporated protein (Randall and Young, 1988).
In experiments cairied out by P. Szawlowski, splenocytes from immunized 
mice were isolated and used for the generation of hybridoma cells secreting SIV p27- 
specific antibodies. Seven independent cell lines producing antibodies to p27 were 
isolated in this manner. Fig. 13 shows the reactivates of these mAbs on a Western blot 
transfer of SIV-infected cell lysates. All mAbs recognized authentic p27 and were, 
apart from SIV-27-d, detected by [125i]protein A. mAb SIV-27-d appeared negative, 
because it was of the IgGl isotype and murine IgGl isotype has a low affinity for 
protein A. Positive binding of SIV-27-d was demonstrated using polyclonal rabbit 
anti-mouse antibodies followed by [I^Sijprotein A (data not shown). Isotypes of the 
other p27-specific mAbs were: IgG2a (a, b, e and f), IgG2b (c) and IgG3 (g) (data not 
shown). The Western blot of p27-specific mAbs also showed weakly reacting bands 
migrating both slower and faster than p27, which probably correspond to other 
products of the gag polyprotein processing (Ferns et ai, 1987). The banding patterns 
suggest that there were three groups of mAbs (b and c grouped with KK33; e and f; 
and a and g), although this remains to be confirmed. None of the p27-specific mAbs
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GST-27-Pk GST-Pk
Figure 12. Immunogenicity of the Pk tag.Nitrocellulose filters were coated with purified either p27-Pk or GST-Pk and 
incubated with immune sera from 4 individual mice followed by ['^^Ijprotein A and autoradiography. As controls, single dots on the bottom row were reacted with p27- specific mAb (middle), S V5-P-k fright centre) and an irrelevant antibody (extreme right). The amounts of antigens bound to the nitrocellulose filters and times of exposure can be compared by the intensities of the SV5-P-k signals.
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Figure 13. Reactivity of mAbs to authentic SIV p27.A panel of seven mAbs induced by immunization with SMAA complexes containing recombinant SIV p27-Pk was assayed against SIVmac251-infected cell lysates. SIV- infected cell lysates were electrophoresâ through a 15% (w/v) SDS-polyacrylamide minislab gel, transferred onto a nitrocellulose filter and incubated witii corresponding 
ascitic fluids. The presence of bound mAbs was detected by [^^IJprotein A followed by an autoradiography. p27-specific (KK33) mAb was used as a positive control, and SV5-P-k and irrelevant IgG2a mAbs served as negative controls.
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reacted with S V5 proteins, i.e. did not recognize the tag peptide (data not shown). The 
isolation of p27-specific mAb demonstrates the general use of tag-based SMAA 
complexes for producing immunological reagents.
B, C lo n in g ,  e x p r e s s io n  a n d  t w o - t a g  p u r i f i c a t io n  o f  n o n -
GLYCOSYLATED SIV ANTIGENS.
In Part A, (i) a 14-amino acid Pk tag was identified, which retained its 
antigenicity when coupled to larger proteins, for example when attached to the 
C-terminus of simian immunodeficiency virus (SIV) p27. It was shown that (ii) 
a two-step purification protocol using N- and C-terminal affinity tags yields pure full- 
size p27-Pk. In part B, these observations were extended and further exploited for the 
incorporation of other non-glycosylated proteins of SIV into SMAA complexes.
B .l. Construction of universal pGEX-2T-derived vectors for addition 
of Pk tag
In order to facilitate the cloning and expression of other SIV proteins, two 
vectors, pGEXnPk and pGEXcPk, were constructed for attachment of the Pk tag at 
the N- and C-termini, respectively, to recombinant proteins. Both vectors were 
derived from the original pGEX-2T plasmid (see Fig, 34 and Table 2 for a schematic 
description of the resulting vectors). pGEXnPk was constructed by an insertion of a 
DNA linker coding for the Pk tag oligopeptide into the BamHl site of the pGEX-2T 
polylinker in such a way, that the BaniHl site at the 5-end of the tag linker was 
mutated while the 3’-end site was preserved for cloning. Thus the only restriction for 
the inserted genes is that they must have a 5' BaniHl site in a position which keeps the 
reading frame of GST-Pk. Similarly, pGEXcPk was constructed by inserting the tag 
linker into the EcoRI site of the pGEX-2T polylinker abolishing the 3'-end EcdBl 
recognition site, so that genes could be cloned between BaniHl and EcoBl. In the
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pGEXcPk case, the amino acid codons of the Pk tag were immediately followed by 
a stop codon.
B.2. Cloning of SIV genes into pGEX-2T-derived expression vectors
The SIV genes encoded by a continuous open reading frame (ORF) were PCR 
amplified from plasmid pBK28-SIV (Komfeld et ai, 1987). The BACK (5') PCR 
primers contained a recognition site for restriction endonuclease BaniHl and, if not 
already present in the gene sequence, an ATG codon was added at the beginning of 
the genes. The start codon was added for the possible future expression of the SIV 
genes in the absence an N-terminal tag. The ;*e/gene contained an internal BaniHl 
site, so nefBACK primer carried a recognition sequence for BcH. The polBACK 
primer annealed to the beginning of the pol ORF. The FOR (3*) primers created an 
EcoBl site. The gene for tat was derived from SIVmac(32H)(pJ5) proviral DNA 
(Rud, 1991; Rud et aL, 1992) and was PCR amplified from already cloned and 
spliced tat sequences in pBluescript. The resulting pGEX-2T-derived vectors carrying 
SIV genes are schematically described in Table 2.
B.3. Purification of recombinant Pk-linked SIV proteins expressed 
from pGEX-2T-derived vectors.
Expression of the recombinant proteins of the general structures GST- 
(thrombin site)-Pk -SIV or GST-(thrombin site)-SIV-Pk from the corresponding 
vectors were confirmed by a Western blot analysis using mAb SV5-P-k (Fig. 14). 
However, although successful purification of vpr-Pk and vpx-Pk was also achieved 
using this system (Fig. 15), the purification of most other SIV Pk-linked antigens 
proved problematic for a variety of reasons. In particular, difficulties were 
encountered in removing the GST domain with thrombin. For example, there was 
a thrombin cleavage site near the C-terminus of pl7 (Randall et ah, 1993a). Other
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Table 2. Construction of bacterial vectors expressing GST-SIV-Pk fusion 
proteins*.
pGEXnPkb GST-{BaniHl)-Vk-BamHl,Smal,EcoRl
pGEXcPkc GSr-Bamm,Smal,EcoRl-Vk-iEcoRÎ)
pGEXnefPk GST-(BflmHI/5c/I)-nef-EcoRI-Pk
pGEXnucPk GST-BûmHI-nuc-EcoRI-Pk
pGEXNpolPkd GST-J5amHI-Npol-EcoRI-Pk
pGEXlSPk GST-BamHI-pl5-EcoRI-Pk
pGEX17Pk GST-5flmHI-pl7-EcoRI-Pk
pGEX27Pk® GST-(BawHI/Bc/I)-p27-Pk-EcoRI
pGEXrtPk GST-EamHI-rt-EcoRI-Pk
pGEXPktat GST-(BflwHI)-Pk-jBflmHI-tat-BamHI,SmflI,Ecr>RI
pGEXvifPk GST-BamHLMf-EcoRl-Vk
pGEXvprPk GST-BamHl-vpr-EcoRI-Pk
pGEXvpxPk GST-BamHI-vpx-EcaRI-Pk
i) Where not already present, ATG was added at the beginning of the SIV gene.ii) All sequences coding for the C-terminal Pk tag are immediately followed by a stop codon, iii) DNA between the 3'-end of the GST domain and BaniHl site codes for a thrombin recognition site.Plasmid pGEXnPk was derived from pGEX-2T (Smith and Johnson, 1988) by inserting a DNA linker coding for the Pk tag into the BaniHl site. The Pk tag sequence is in the frame with GST.Plasmid pGEXcPk was derived from pGEX-2T (Smith and Johnson, 1988) by inserting a DNA linker coding for the Pk tag into the EcoRI site. The EcoRl site 3' of the Pk tag gene was mutated during the insertion, while the 5’ EcoRI site was preserved for cloning. The Pk tag sequence is in the frame with GST. pGEXNpolPk contains DNA sequences from the very 5’-end of SIV pol ORF to the 3*-end of protease [nucleotides 2216 to 2827 of SIVmac251, clone BK28 as in the GeneBank database (Donahue et <%/., 1988), i.e. the expressed protease domain contains Met plus 104 amino acids added to the N-terminus of the 100-amino acid viral protease.The construction of pGEX27Pk was described in Part A of Introduction.
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Figure 14. Western blot of bacterial lysates containing GST-SIV-Pk proteins.Bacterial cultures were grown to OD500 = 0.7 and induct with IPTG. Harvested 
bacteria were lysed, sonicated, boiled and loaded on a 15% (w/v) SDS- polyacrylamide gel. Separated polypeptides were transferred onto a nitrocellulose filter and the GST-SIV-Pk proteins detected using SV5-P-k mAb followed by 
[^^IJprotein A and autoradiography. The Mr of the SIV proteins predicted firom their amino acid sequences are: nef - 28.4 kDa, endonuclease (nuc) - 33.5 kDa, pl5 -16.0 kDa, pl7 - 14.9 kDa, p27 - 25.5 kDa, N-terminalpo//protease - 21.9 kDa, rev - 13.4 kDa, reverse transcriptase (it) - 64.6 kDa, tat -14.7 kDa, vif - 25.3 kDa, vpr -11.0 kDa and vpx -12.9 W)a. Mr of the GST domain and the Pk tag are 26 kDa and2.0 kDa, respectively. The positions of Mj- markers in kDa are indicated.
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Figure 15, SMAA complexes containing vpr-Pk and vpx-Pk (Coomassie blue- stained SDS-polyacrylamide gel).Recombinant GST-SIV-Pk proteins were first purified from crude bacterial lysates on a glutathione column via their N-terminal GST, digested with thrombin between the GST and SIV domains and the released SIV-Pk proteins were purified via the Pk tag during their assembly into SMAA complexes. The resulting SMAA complexes were analyzed on a 15% (w/v) SDS-polyacrylamide gel. On this percentage of gel, the vpr- Pk and vpx-Pk proteins migrated very similarly, but difference in their electrophoretic mobilities can be seen comparing the distances of their protein bands from the dye front. Also shown are the positions of the heavy (IgH) and light (IgL) chains of SV5-P-k mAb.
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difficulties included low levels of expression (nef, nuc, pl5 and rt) and protein 
insolubility (vif and, after removal of GST, endonuclease).
B.4. Cloning and expression of His-SIV-Pk proteins.
The main obstacles in the preparation of Pk-linked SIV antigens using pGEX 
vectors were low levels of expression in bacteria, proteolytic removal of the GST 
domain from the GST-SIV-Pk fusion proteins and insolubility. In an attempt to 
overcome some of these problems, the N-terminal GST domain was substituted by a 
histidine affinity tag (His). Histidine residues have a high affinity for metal cations, 
thus enabling the purification of proteins fused to a His tag by chelating immobilized 
metal ions (Smith et aU 1988). Moreover, His-linked proteins may be purified under 
strong denaturing conditions, e.g. 8 M uiea or 6 M guanidine hydrochloride, which 
helps to overcome protein insolubility problems. The affinity tag used in this work 
was a short 12-amino acid-long peptide containing 6 histidine residues.
The cloning of SIV genes into bacterial vectors expressing His-SIV-Pk fusion 
proteins is schematically represented in Table 3. Initially, a universal primer, 
GEXFOR, was designed containing a HindlJl site, which annealed to the 
pGEXSrVPk plasmids immediately downstream of the Pk sequence. Using the 
GEXFOR primer and the respective BACK primers described above, genes for nef- 
Pk, nuc-Pk, pl5-Pk, pl7-Pk, rev-Pk, rt-Pk, vif-Pk and vpx-Pk were PCR amplified 
from the pGEXSIVPk vectors and inserted between RtiwHI and //indlll sites of the 
pQE-9 (QIAGEN) plasmid polylinker (Table 3).
In order to simplify the addition of His and Pk tags at antigen termini, plasmid 
pQ9cPk was also constructed. The EcoRl site in the promoter region of pQE-9 was 
first mutated and a synthetic DNA linker coding for the Pk tag was inserted between 
the BaniHl and Pstl sites of the polylinker, generating plasmid pQ9cPk. In this vector, 
the Pk and His tag coding sequences are in different reading frames and are only 
brought into the same reading frame by insertion of the appropriate genes between the 
BomHI and EcoRI sites. Thus the expression of the Pk tag can be used as a marker for
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Figure 16. Screening of pQ9SIVPk clones by IPTG-induction of Pk tag-linked proteins on agar plate.The Pk tag gene in pQ9cPk plasmid was out of the His tag reading frame, so the insertion of a SIV gene could be screened for by an expression of the Pk tag. Induced bacterial colonies were lifted onto a nitrocellulose filter, disrupted and p ro l^  with 
SV5-P-k mAb followed by [I^^IJprotein A and autoradiography.
screening bacterial colonies containing properly inserted His-SIV-Pk genes using 
mAb SV5-P-k (Fig. 16). Plasmid pQ9cPk was used for cloning of the p27, rev, tat 
and vpr genes. Because the expression level of GST-Npol-Pk was very low and one 
possibility was, that the protease cleaved itself out of the fusion protein and thus 
rendered the protein undetectable by SV5-P-k mAb, the protease enzymatic activity 
was inhibited by a substitution of Asp25->Asn in the active site of the enzyme 
(Swanstrom et al., 1990). The mutated gene now designated as Npol^ was also cloned 
into the pQ9cPk vector (Table 3). The inactivation was achieved using mutagenic 
positive and negative sense PCR primers hybridizing across the active site region and 
a PCR assembly. All the above His-SIV-Pk proteins were induced by addition of 
IPTG to bacterial cultures and the crude lysates were analyzed on a Western blot 
using mAb SV5-P-k (Fig. 17). Non-degraded His-SIV-Pk proteins migrated at 
mobilities predicted from their amino acid sequences (see above), taking into account 
the addition of 1.4 kDa of His and 2 kDa of Pk tags. His-nef-Pk and His-nuc-Pk
88
Table 3. Construction of bacterial vectors expressing His-SIV-Pk fusion 
proteins .^
pQE-9b m s-Bam m ,SaBrstlM nm i
pQE9nefPk His-(ôûmHI/fîc/I)-nef-EcoRI-Pk-//mdni
pQE9nucPk His -BflwHI-nuc-Ec<?RI-Pk-//mdIII
pQE915Pk His -BamHI-pl5-EcoRI-Pk-//mdIII
pQE917Pkc His -5flmHI-pl7-£coRI-Pk-//mdIII
pQE9rtPkc His -RawHI-rt-EcoRI-Pk-//mdIII
pQE9vifPk His -fiamHI-vif-Ec<?RI-Pk-//wdIII
pQE9vpxPk^ His -BamHI-vpx-EcoRI-Pk-ffmdlll
pQ9cPk^ His-5nmHI,5fl/I/*srI,Ec<3RI-Pk-///rtdni
pQ927Pk His-(BnwHl/fic/I)-p27-Pk-EcoRI-Pk-//mdra
pQ9NpoPPk® His -5amHI-Npoli-Ec<?RI-Pk-//mdin
pQ9prot‘Pk His -5awHI-prot*-EcoRI-Pk-//mdIII
pQ9revPk His -Bamffl-rev-EcoRI-Pk-Z/mdll
pQ9tatPk His -BflwHI-tat-FcoRI-Pk-//mdIII
pQ9vprPk His -BamHI-vpr-Ec^?RI-Pk-//mdin
i) Where not already present, ATG was added at the beginning of the SIV gene.ii) All sequences coding for Pk tag are immediately followed by a stop codon. QIAGEN catalogue number 32049. SIV genes already linked to the Pk tag were inserted into pQE-9 vector using the B arr^  and //mdin sites of the polylinker. Genes coding for pl7-Pk, rt-Pk, vpr-Pk and vpx-Pk were inserted into plasmid pQE-9 by J. Southern and R.E. Randall.Plasmid pQ9cPk was constructed by first mutating the EcoRI site in the promoter region of pQE-9 followed by an insertion of the Pk tag DNA linker between Pstl and //indin sites. The Pk tag sequence is out of the His tag frame and is brought into the frame by cloning in the gene of a desired recombinant protein. SIV genes were cloned into pQ9cPk using the BaniHl and EcoRI sites of the polylinker. 
NpoP is the same protein as Npol in Table 2, except that the protease activity was 
inhibited by Asp25->Asn (in NpoP amino acid 130) substitution.
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showed significant levels of degradation^ while His-NpoP-Pk gave a major band 
corresponding to the full-size protein suggesting that the inactivation of protease was 
indeed successful. Similarly to Fig. 14, the band intensities in Fig. 17 do not reflect 
the levels of expression of individual His-SIV-Pk proteins.
B.5. Optimization of His-SIV-Pk expression.
All the His-SIV-Pk proteins were initially induced by the addition of 
1 mM IPTG at 26 °C for 3 hours. Their levels of expression varied remarkably, but 
were similar to those observed for their GST-SIV-Pk counterparts. While some 
proteins, such as His-pl7-Pk and His-vpx-Pk, were abundantly expressed giving 
prominent bands on a Coomassie blue-stained gel of total cellular proteins, others, 
such as His-NpoP-Pk, were barely detectable by Western blotting. It was, therefore, 
attempted to optimize the expression of individual proteins by adjusting the IPTG 
concentration, time of induction and temperature. Firstly, the effect of IPTG 
concentration and temperature on the levels of expression was tested by inducing the 
cultures for 1 hour at 37 °C and 26 °C with doses ranging from 10 |iM to 1 mM. 
Although for a number of proteins no difference in the levels of induction was 
observed, in general the optimum induction was achieved by addition of 10-50 pM 
IPTG at 26 °C. Examples of dose-responses for His-NpoP-Pk, His-pl5-Pk and 
His-tat-Pk are shown in Fig. 18. The time of induction was also varied from 
0.5 to 3 or 6 hours after addition of 50 pM IPTG at 26 °C. For His-nuc-Pk, 
His-rev-Pk, His-vpr-Pk and His-vpx-Pk, the amounts in total cell lysates remained 
unchanged over the tested period. The levels of His-nef-Pk and His-pl5-Pk decreased 
with time, while the amounts of the remaining His-SIV-Pk proteins increased. 
Representative examples of His-NpoP-Pk (decrease), His-vpr-Pk (constant) and 
His-tat-Pk (increase) are shown on Fig. 19. The data are summarized in Table 4. The 
supposedly higher producing E. coli strain SG 13009 (Gottesmann et al., 1981) was 
also used to express the low-expression-level proteins, but in this host, the
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Figure 17. Western blot analysis of bacterial lysates containing His-SIV-Pk proteins.Bacterial cultures were induced with IPTG, harvested, lysed, sonicated and boiled before loading onto a 17% SDS-polyacrylamide gel. Separated polypeptides were transferred onto a nitrocellulose sheet and probed with SV5-P-k mAb followed by 
[125i]protein A and autoradiography. The positions of markers in kDa are 
indicated.
expression was similar to that found with strain M15 (Villarejio and Zabin, 1974) 
(data not shown).
The levels of expressed His-NpoP-Pk protein were consistently low, 
irrespective of which induction conditions or bacterial strains were used. It is possible 
that the translated, but non-functional N-terminal portion of the SIV pol polyprotein 
was inherently unstable. Therefore, using protBACK and protPOR primers, the gene 
of the inactivated protease ipro^) was PCR amplified, cloned into the pQ9cPk vector 
(Table 3) and expressed as His-prot*-Pk. However, the expression level of His-prot*- 
Pk was not significantly increased (Table 4).
B.6. Purification of His-SIV-Pk proteins.
Bacterial cultures expressing individual His-SIV-Pk proteins were optimally 
induced with IPTG and the proteins were purified using a two-step purification
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Figure 18. IPTG dose-response of His-SIV-Pk induction.
The figure shows 1-hour inductions of His-NpoP-Pk (lanes 1-5 and 16-20), His-pl5-Pk (lanes 6-10 and 21-25) and His-tat-Pk (lanes 11-15 and 26-30) at either 
37 OC (lanes 1-15) or 26 ®C (lanes 16-30) with the final concentration of IPTG of 
10 pM (lanes 1, 6, 11, 16, 21 and 26), 50 mM (lanes 2,7, 12, 17, 22 and 27), 100 pM
(3, 8, 13, 18, 23 and 28), 500 pM (lanes 4, 9, 14, 19, 24 and 29) and 1 mM (lanes 5, 
10, 15, 20, 25 and 30). His-SIV-Pk proteins were detected using SV5-P-k mAb 
followed by [I^^Ijprotein A and autoradiography.
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Figure 19. Time-course of His-SIV-Pk induction.
The figure shows inductions of His-Npol^Pk (lanes 1-6), His-vpr-Pk (lanes 7-12) and 
His-tat-Pk (lanes 13-18) with 1 mM IPTG at 28 °C for 1/2 hour (lanes 1, 7 and 13),1 hour (lanes 2, 8 and 14), 2 hours (lanes 3, 9 and 15), 3 hours (lanes 4, 10 and 16),4 hours (lanes 5,11 and 17) and 6 hours (lanes 6,12 and 18). His-SIV-Pk proteins 
were detected using SV5-P-k mAb followed by [^^^Ijprotein A and autoradiography.
Table 4. Expression levels of His-SIV-Pk fusion proteins.
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50 pM IPTG 
26 oC 0.5-3 hours
optimum time (hour) amount in total lysate at best
His-nef-Pk dec 0.5 +++
His-nuc-Pk const 0.5-3 +++
His-pl5-Pk dec 2 ++
His-pl7-Pk inc 3 4-+-H-+
His-p27-Pk inc 2-3 +++
His-NpoP-Pk dec 0.5-1 +
His-proti-Pk const 3 +
His-rev-Pk const 3 +++
His-rt-Pk inc 3 +++
His-tat-Pk inc 3 +++
His-vif-Pk inc 3 ++
His-vpr-Pk const 2-3 +++
His-vpx-Pk const 0.5-3
a const - constant level; inc - increasing level over time; dec - decreasing level over timeb estimated levels of expression of fusion proteins in total bacterial lysates (protein 
mass per 1 litre of bacterial culture induced at OD^oo = 0.7): + <10 pg.l’ ;^
++ 10-200 pg.1'1; +++ 200-700 pg.l’l; ++++ 700 pg.l'l - 2 mg.l-l;
+-H-++ lOmg.l’^
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Figure 20. Two-step purification of His-rt-Pk and His-17-Pk (Coomassie blue- stained SDS-polyacrylamide gel).The figure demonstrates a two-step affinity purification of His-rt-Pk (left) and His-17-Pk (right). Lanes 1: total bacterial lysates; lanes 2: insoluble fractions; lanes 3: soluble fractions; lanes 4: nickel column eluate; and lanes 5: SMAA complexes. The positions of both His-SIV-Pk proteins, the heavy (IgH) and light (IgL) chains of SV5-P-k mAb and lysozyme used to digest the bacterial wall are indicated. (The experiment was performed by R.E. Randall).
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Figure 21. SMAA complexes containing His-SIV-Pk fusion proteins (Coomassie blue-stained SDS-polyacrylamide gel).His-SrV-Pk proteins were purified using the two-step purification protocol and the resulting antigen-antibody complexes were visualizW on a 17% (w/v) SDS- polyacrylamide gel stained with Coomassie brilliant blue. The heavy (IgH) and light (IgL) chains of SV5-P-k mAb are designated and the positions of His-SIV-Pk are indicated by diamonds.
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protocol. For soluble proteins, bacterial lysates were incubated with an excess Pk- 
specific mAb SV5-P-k and the Ni^+-NTA resin was added to the mixture. The beads 
were then loaded into a column and the unbound proteins (including the unreacted 
mAb SV5-P-k) were removed by washing. Bound antibody-antigen complexes were 
eluted with 250 mM imidazole. The eluates were then incubated with protein A- 
sepharose beads and the bound material analyzed on a Coomassie blue-stained 17% 
(w/v) SDS-polyacrylamide gel. The two-step purification of proteins for 
immunization purposes is illustrated for His-rt-Pk and His-17-Pk in Fig. 20.
A modified procedure was used for the purification of the insoluble His-vif-Pk 
protein. The first purification step on the nickel affinity column was carried out under 
denaturing conditions. His-vif-Pk was transferred to the column in 6 M guanidinium 
hydrochloride, this was exchanged for 8 M urea, in which the protein was eluted by 
lowering the pH. Nickel-purified His-vif-Pk was dialyzed overnight to remove urea, 
incubated with SV5-P-k-saturated protein A-sepharose beads and the antibody- 
antigen complexes were analyzed by SDS-PAGE. The composite of SMAA 
complexes containing all of the His-SIV-Pk proteins is shown in Fig. 21,
B.7. Analysis of antibodies to non-glycosylated SIV proteins in sera 
of SlV-infected macaques.
Sera taken from SIV-infected monkeys were tested in a Western blot against 
approximately equimolar amounts of individual recombinant proteins (as judged by 
Western blot analysis using the mAb SV5-P-k). The result using pooled sera 
(ADP416) from cynomolgus macaques infected with live SIVmac251(32H) is shown 
in Fig. 22. Antibody responses could be readily detected to endonuclease, pl5, pl7, 
p27, rt, and vif. Weak responses were also detected against vpx and protease (Fig. 22, 
right panel), but no reactivity was noted against nef, vpr, rev or tat. In contrast to the 
results presented in Fig. 22, there appeared to be similar levels (relative to each other) 
of antibodies to pl5, pl7 and p27 (data not shown), in addition to antibodies specific
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Figure 22. Analysis of sera from SIV-infected macaques.The gel shows the reactivity of pooled sera taken from SIV-infected macaques with total E. coli cell lysates expressing individual recombinant SIV proteins. Antibodies were detected by HRP-conjugated protein A followed by ECL. Approximately equimolar amounts of the SIV proteins (as estimated by previous Western blot analysis using SV5-P-k mAb) were separated by electrophoresis through a 17% (w/v) SDS-polyacrylamide gel. The right hand panel shows a longer exposure of two lanes from the left panel, where specific bands corresponding to the appropriate His-SIV-Pk proteins are designated by diamonds.
to rt and vif, in a serum taken from macaque rhesus infected with SIVmac251(32H), 
but again no antibodies were detected to nef, vpr, rev or tat.
C. Cl o n in g , Ex pr essio n  a n d  Tw o -St e p  a f f in it y
PURIFICATION OF SIV ENVELOPE GLYCOPROTEIN IN INSECT
Ce l l s .
Part C of the Results describes expression of recombinant SIV envelope 
glycoproteins linked at their C-termini to the Pk tag. After abortive attempt to express 
the gpI20-Pk gene in bacteria, the gpl60-Pk gene was inserted into a baculovirus 
vector and expressed in insect cells. This insect cell-produced glycoprotein was 
purified in a two-step purification protocol. The first step employed binding of 
gpl60-Pk to a lectin column via its polysaccharide moieties followed by assembly of
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Figure 23. Western blot analysis of total cellular lysates of bacteria expressing SIV gpl20Pk gene.Four cultures of independent bacterial clones carrying plasmid pGEX120Pk were induced by addition of IPTG, the bacteria were lysed, die lysates were Western 
blotted and probed with SV5-P-k mAb followed by protein A and autoradiography. The position of GST-gpl20-Pk is indicated.
the partially purified glycoprotein into SMAA complexes via the Pk tag and mAb 
SV5-P-k.
C.l. Expression of the SIV env gene in bacteria.
The sequence coding for the glycoprotein gpl20 of SIV env was PCR 
amplified from pBK28-SIV plasmid, coupled to the Pk tag linker and inserted into 
pGEX-2T vector in a similar fashion as described in Fig. 8 for p27. However, when 
bacterial cultures transformed with the pGEX120Pk plasmid were induced with 
IPTG, the expression of GST-gpl20-Pk did not result in a prominent band on 
Coomassie blue-stained SDS-polyacrylamide gels (not shown). Western blot analysis 
of four independent clones carrying pGEX120Pk using mAb SV5-P-k showed that 
the vast majority of GST-gpl20-Pk was proteolytically degraded (Fig. 23). The 
absence of glycosylation in prokaryotic cells presumably had affected the gpl20 
folding and consequently protein stability and protease resistance.
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C.2. Construction of a recombinant baculovirus expressing SIV |
gpl60-Pk.
A recombinant baculovirus carrying hybrid gplôOPk gene in the position of 
the polyhediin gene was constructed as follows. A DNA linker containing 5amHI and 
Sad  restriction endonuclease sites and a coding sequence for the Pk tag was first
inserted between the BaniHl and Pstl sites in the polylinker of transfer vector I
!
pVL1393, generating plasmid pVL1393cPk. The env gene of SIVmac251(32H)(J5) i
I
was excised from a pBluescript plasmid-based construct (Rud, 1991) using BamHl
and Sad  endonucleases and cloned into the corresponding sites in the pVL1393cPk |
I
plasmid. The Sad site lay just within the env gene so that the DNA coding for the last '
three C-temiinal amino acids (ThrLeuLeu) of gpl60 was deleted. The resulting
plasmid pVL1393-160Pk was co-transfected with AcRP6-SC baculovirus DNA,
linearized by Bsu361 endonuclease digest into Sf 21 cells as described by Kitts and
colleagues (1990). Clearly separated plaques on the cell monolayer were selected and
the virus clones were used for subsequent infections. To test for the expression of
gpl60-Pk, Sf 21 cell monolayers were infected with the individual virus clones.
Two days post-infection, the cells were lysed and the cell lysates analyzed on a dot 
blot using mAb SV5-P-k to detect the Pk tag-linked env. All the virus clones tested 
expressed gpl60-Pk and the infection of one, designated AcRP6-160Pk, was 
gradually scaled up to 500-ml suspension culture. The highest levels of gpl60-Pk in 
both adhered and suspension cell culture were found at two days post-infection 
(Fig. 24). On this Western blot, mAb SV5-P-k readily detected two bands in total 
cellular lysates. One band was broader and migrated at around 160 kDa, which is in 
a good agreement with the expected glycosylated form of env. The faster-migrating 
band is of uncertain origin, but is probably a partially degraded species, as it seemed 
to migrate much slower than the unglycosylated env precursor, which, from its amino 
acid sequence, has a predicted Mr of 53 kDa.
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Figure 24. Time-course of SIV gpl60-Pk expression in 500-ml culture of Sf 21 cells.An Sf 21 cell monolayer (left) or a 5(X)-ml suspension culture of Sf 21 cells at 
approximately 10  ^cells per ml (right) were infected at m.o.i. of 1-10 for 1 to 4 days (lanes 1 to 2). At each time point, cells were harvested, lysed and analysed on a Western blot using SV5-P-k mAb followed ECL.
C 3. Two-step purification of SIV gpl60-Pk.
It is imperative for the induction of neutralizing antibodies, that the fidelity of 
surface structures presented by vaccines is preserved during the purification 
procedure. The affinity of lectins for polysaccharides and the elution of bound 
material from the lectin column by monosaccharides represent a suitable system for 
the first purification step, which avoids 'harsh' treatments of purified proteins, such as 
changes of pH or red-ox conditions, often needed for elution from other affinity 
matrices, that could alter the protein structure. The potential of different lectins for the 
first-stage purification of gpl60-Pk was therefore examined.
A 500-ml suspension culture of insect cells was infected with virus AcRP6 - 
160Pk at 1 to 10 multiplicity of infection and the cells were harvested after 2 days.
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Figure 25. Western blot analysis of antigenicity and immunogenicity of baculovirus-expressed SIV gpl60-Pk.Polypeptides from total cell lysate of recombinant baculovirus AcRP6-160Pk-infected Sf 21 insect cells (lanes 1), insect cell-produced lentile lectin-purified SIV gpl60-Pk Ganes 2) and total cell lysates of SIV-infected C8166 cells (lanes 3) were separated through a 10% (w/v) SDS-polyacrylamide gel, transferred onto a nitrocellulose filter and incubated with anti-Pk tag (panel A), anti-^120/gpl60 (panel B), anti- gp41/gpl60 (panel C) mAbs, serum from SIV-infected macaque (panel D) or pooled sera from mouse immunized with SMAA complexés containing gpl60-Pk (panel E) followed by HRP-conjugated protein A and ECL. Although the quantitative estimations of proteins are limited using ECL, panel C is a 5x-longer exposure relative to the other panels. The position of gpl60 monomer is inchoated.
The cells were lysed and the expressed SIV gpl60-Pk in the soluble fraction was 
tested for carrying polysaccharide moieties by employing several types of lectin 
columns. These included lentile lectin (L), wheat germ agglutinin (WGA), 
succinylated wheat germ agglutinin (sWGA) and concanavalin A (ConA). Bound 
material was eluted using a combination of two monosaccharides, 500 mM methyl 
a-D-glucopyranoside and 500 mM methyl a-D-mannopyranoside. Although WGA 
appeared to bind the highest level of Pk tag-linked species, the greates yield, resulting 
from the most efficient release of gpl60-Pk from the lectin column, was achieved 
using the lentile lectin (data not shown). Thus, the yield of purified gpl60-Pk after the 
first purification step was approximately 4(X) p.g per 5(X) ml of suspension culture.
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Figure 26. SIV gpl60-Pk in SMAA complexes (Coomassie blue-stained SDS- polyacrylamide gel).The first purification step of insect cell-produced SIV gpl60-Pk on lentile lectin co­purified other glycosylated species (lane 1). These were removed during the second purification step, which incorporated gpl60-Pk into SMAA complexes (lane 3). Monoclonal antibody SV5-P-k-saturated particles of S. aureus were analyzed on lane 2. The samples were separated through a 12% (w/v) SDS-polyacrylamide gel. The positions of gpl60-Pk, and the heavy GgH) and light (IgL) chains of SV5-P-k are indicated.
The gpl60-Pk purification using a lentile lectin column was analyzed by 
a Western blot analysis (Fig. 25). The soluble fraction of the total baculovirus- 
infected insect cell lysates (lanes 1) was compared with the lentile lectin column 
eluate Ganes 2) and an SIV-infected cell lysate (lanes 3). These blots were probed 
with SV5-P-k, anti-gpl20/160 and anti-gp41/gpl60 mAbs in panels A, B and C, 
respectively, and with serum from an SIV-infected macaque (panel D). As is clearly 
demonstrated in panel A, the soluble fraction of total insect cell lysate was heavily 
contaminated with degraded gpl60-Pk species, which were largely, but not entirely 
(panels B, C and D), removed during the lectin purification step.
In the second purification step, the gp 160-Pk-containing eluate from the 
lentile lectin column was purified via its C-terminal Pk tag. Because the relatively 
high concentration of monosaccharides present in the elution buffer did not appear to
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interfere with antibody binding, the eluate was directly incubated with ’fixed' and 
killed S. aureus particles saturated with S V5-P-k mAb. The second purification step 
resulted in assembly of SIV gpl60-Pk into SMAA complexes (Fig. 26). The lectin 
eluate contained a number of species that co-purified with gpl60-Pk from the affinity 
column (lane 1), however, the incorporation into SMAA complexes specifically 
selected for gpl60-Pk (lane 3).
C.4. Fidelity of insect cell-produced SIV gpl60-Pk.
To evaluate the immunogenic potential of the insect cell-produced SIV gpl60, 
gpl60-Pk was assembled into SMAA complexes and used for the immunization of 
mice. The immune sera were pooled and tested against both insect cell-produced 
gpl60-Pk and SIV-infected cell lysates on a Western blot (Fig. 25, panel E). The 
mouse serum readily reacted with the immunogen, but there was only very weak 
recognition of the authentic envelope monomer in SIV-infected C8155 cells (panel E, 
lane 3). In addition to the monomeric form, there were also two slowly-migrating 
bands (indicated by arrows) in both insect and mammalian cell lysates, which might 
correspond to the glycoprotein dimers and tetramers. The notion, that these bands 
corresponded to ordered structures rather than protein aggregates, was further 
supported by the fact, that these species were detectable in insect cell-lysates using 
monkey immune serum (panel D), and Pk tag- (panel A) and gp41- (panel C), but not 
gp 120-specific mAbs (panels B). Ordered complexes may completely hide an 
epitope, but a 'random' protein aggregate would probably leave at least some of the 
gpl20 epitopes available for antibody recognition. If this was indeed the case and the 
bands represented dimers and tetramers, then incubation with mouse immune sera 
gave a much stronger signal with the tetramer compared to the dimer in insect cell 
lysates (panel E, lane 1), but the opposite was found for the mammalian-produced 
gpl60 (panel E, lane 3), which gave a fainter tetramer signal. Differences in signal 
intensities most likely reflect the relative amounts of glycoprotein present in dimers 
and tetramers in the lysates, rather than reflecting differences in the induced antibody
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specificity or the availability of a particular epitope on these oligomeric structures.
The prevalence of the gpl60-Pk tetramer over dimer in insect cell lysates is also 
suggested using S V5-P-k mAb and immune monkey serum (panels A and D, lanes 
1 and 2).
An additional observation from this series of Western blots was, that gp41-Pk 
was not detected at all among lectin-purified glycoproteins and in insect cells 
(panel A, lane 2 and panel C, lanes 1 and 2). Gp41 was present in small amounts in 
mammalian cells, but was visualized only after a prolonged exposure (panel C, lane 
3). Together with the failure to detect any gpl20 (panel B, lane 3), this may suggest 
an inefficient proteolytic processing of SIV gpl60-Pk/gpl60 to gpl20 and 
gp41-Pk/gp41 in insect cells and, at least, in the sample of SIV-infected C8166 cells 
used in this experiment. As for the insect cells, it was reported previously, that the 
inefficient cleavage of insect cell-produced HTV gpl60 was due to a lack of the furine 
protease in this system (Morikawa et ah, 1993). In mammalian cells , tlie proteolytic 
cleavage of gp 160 is a late processing event in the glycoprotein biogenesis and, as 
such, may account for the low proportion of cleaved gpl60 in SIV-infected cells 
(Hallenberger et al., 1992). However, there may be another indication, that the SIV- 
infected cell lysate was indeed a poor sample. Although a strongly-detected fast- 
migrating band was identified for the gag gene products, there was no apparent signal 
corresponding to rt (panel D, lane 3), an antigen normally detected in SIV-infected 
cell lysates by Western blotting. Also, it can be noted on the Western blot probed with 
the gp41/gpl60-specific mAb, that this antibody recognized only very weakly the 
gpl60- Pk monomer in insect cell lysates (panel C, lane 1), but did give slightly 
stronger signal, corresponding to the full-size protein, after lectin purification (panel
C. lane 2). This may be a result of gpl60-Pk concentration following lectin column 
chromatography. Of course, the limitation of a Western blot analysis is, that it detects 
only structures present on linear stretches of the protein backbone, while all 
discontinuous epitopes are lost. Nevertheless, SMAA complex-generated murine 
antibodies did recognize a band possibly corresponding to the dimer of authentic SIV
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envelope. The weak signal against authentic monomeric SIV gpl60 may reflect 
differences in insect vs. mammalian glycosylation patterns of proteins.
D. HUMANIZING OF PK TAG-SPECIFIC MAB SV5-P-IC
Part D of the Results describes humanizing of the murine Pk tag-specific 
monoclonal antibody SV5-P-k. In the first stage, the genes for the SV5-P-k heavy and 
light variable regions were cloned from the appropriate hybridoma cells and their 
sequences were determined. In the second stage, only the SV5-P-k complementarity- 
determining regions were grafted onto human immunoglobulins. The production of 
stably transfected CHO cells expressing the whole humanized Pk tag-specific mAb is 
currently under way.
D .l. Cloning of the SV5-P-k variable regions and expression of Pk 
tag-specific Fab and scFv fragments of antibody in E. coli.
In the first stage of the Pk tag-specific mAb reshaping, genes for the variable 
regions of the heavy and light chains were cloned and their DNA sequence 
determined. The immunoglobulin variable regions were PCR amplified from cDNA 
made from SV5-P-k murine hybridoma polyA+ RNA. Primers used in the PCR 
reaction were a mixture of upstream primers specific for the leader sequences of 
heavy and light chains (61 and 405 primers, respectively; Jones and Bendig, 1991) 
and one downstream primer hybridizing to conserved nucleotide sequences of the 
constant regions of IgG2a and kappa. Amplified variable sequences were initially 
cloned into M l3 phage for sequencing. Once the nucleotide sequences were 
determined (Fig. 27), specific PCR primers were designed, that only amplified the 
variable regions and generated the correct restriction endonuclease sites for cloning 
the genes into chimeric Fab (murine variable/human constant domains) and single- 
chain-Fv antibody fragment expression vectors (Fig. 28). Both Fab and scFv 
fragments were expressed in E. coli and their positive binding of the Pk tag, tested in
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1/1 31/11
GTC GAC atg agg tgc ttt get cag ctt ctg ggg CTG CTT GTG CTC TGG ATC CCT GGA TCC
val asp met arg cys phe ala gin leu leu gly leu leu val leu trp lie pro gly ser
5'-gat att GAG CTC acg cag get g-3'
61/21 91/31
ACT GCA GAT ATT GTG ATG ACG CAG GCT GCA TTC TCC AAT CCA GTC ACT CTT GGA ACA TCA
thr ala asp lie val met thr gin ala ala phe ser asn pro val thr leu gly thr ser
121/41 151/51
GTT TCC ATC TCC TGC AGG TCT AGT AAG AGT CTC GTA CAT AGT AAT GGC ATC ACT TAT TTG
val ser lie ser eys arg ser ser lys ser leu val his ser asn gly.lie thr tyr leu
181/61 211/71
TAT TGG TAT CTG CAG AAG CCA GGC CAG TCT CCT CAC CTC CTG ATT TAT CAG ATG TCC AGC
tyr trp tyr leu gin lys pro gly gin ser pro his leu leu ile tyr gin met ser ser
241/81 271/91
CTT GCC TCA GGA GTC CCA GAC AGG TTC AGT GGC AGT GGG TCA GGA ACT GAT TTC ACA CTG
leu ala ser gly val pro asp arg phe ser gly ser gly ser gly thr asp phe thr leu
301/101 331/111
AGA ATC AGC AGA GTG GAG GCT GAG GAT GTG GGT GTT TAT TAG TGT GGT CAA ATT CTA GAA
arg ile ser arg val glu ala glu asp val gly val tyr tyr cys gly gin ile leu glu
3 '-go ccc tgt ttc GAG CTC tat tct-5'
361/121 391/131
CTT CCA TTC ACG TTC GGC TCG GGG ACA AAG TTG GAA ATA AGA CGG GCT GAT GCT GCA CCA
leu pro phe thr phe gly ser gly thr lys leu glu ile arg arg ala asp ala ala pro
421/141
ACT GTA TCc ate ttc oca cca tee aCC CGG G
thr val ser ile phe pro pro ser thr arg
Figure 27a. Sequences of the light chain PCR product amplified from SV5-P-k hybridoma cDNA.The lower case in the DNA sequences indicates the primer-annealing regions, thus, although the primers specific for the leader sequences were degenerate, the sequence may not necessarily be genuine. PCR primers used for cloning of the variable regions into E, coli vectors expressing Fab and scFv fragments of antibody are shown above 
the sequences.
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1 / 1  3 1 / 1 1
GTC GAC atg gac toe agg etc aat tta gtt ttc ctt GTC CTT ATT TTA AAA GGT GTC CAG
val asp met asp ser arg leu asn leu val phe leu val leu ile leu lys gly val gin
5*--gtg cag CTG CAG gag tea 999 99& ggc tta gtg c~3 '61/21 91/31TGT GAT GTG CAG GTG GTG GAG TCA GGG GGA GGC TTA GTG CAG CCT GGA GGG TCC CGG AAAcys asp val gin val val glu ser gly gly gly leu val gin pro 9iy gly ser arg lys
121/41 151/51
CTC TCC TGT GCA GCC TCT GGA TTC ACT TTC AGT AGT TTT GGA ATG CAC TGG GTT CGT CAGleu ser cys ala ala ser gly phe thr phe ser ser phe gly met his trp val arg glfi
181/61 211/71ACT CCA GAG AAG GGG CTG GAG TGG GTC GCA TAG ATT AAT ACT GAC AGT ACT ACC ATC TACthr pro glu lys gly leu glu trp val ala tyr ile asn thr asp ser thr thr ile tyr
241/81 271/91TAT GGA GAC ACA GTG AAG GGC CGA TTC ACC ATT TCC AGA GAC AAT CCC AAG AAC ACC CTGtyr gly asp thr val lys gly arg phe thr ile ser arg asp asn pro lys asn thr leu
301/101 331/111TTC CTG CAA ATG ACC AGT CTA AGG TCT GAG GAC ACG GCC ATG TAT TAC TGT GCA AGT GCGphe leu gin met thr ser leu arg ser glu asp thr ala met tyr tyr cys ala ser ala
3'-g ccg aaa ctg atg acc ccg gtt ccg tgg tgC CAG TGG caa agg--5*361/121 391/131GGC CCT TAG TAG GGC TTT GAC TAG TGG GGC CAA GGC ACC ACT CTC ACA GTT TCC TCA GCCgly pro tyr tyr gly phe asp tyr trp gly gin gly thr thr leu thr val ser ser ala
421/141 451/151AAA ACA ACA GCC cca teg gtc tat cca etc CCG GGlys thr thr ala pro ser val tyr pro leu pro
Figure 27b. Sequences of the heavy chain PCR product amplified from SV5-P-k hybridoma cDNA.The lower case in the DNA sequences indicates the primer-annealing regions, thus, although the primers specific for the leader sequences were degenerate, the sequence may not necessarily be genuine. PCR primers used for cloning of the variable regions into E. coli vectors expressing Fab and scFv fragments of antibody are shown above the sequences.
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I
Sac I Xho I Eco RI
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PelB MuVh HuCHl PelB MuVl HuCk
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Htndm Pstl
—"Ezlzz
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A
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S a d  Xho I £coRII I
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Figure 28. Constructs for expression of chimeric Fab and single chain Fv fragments of antibody in E. coU.DNA carrying genes for expression of Fab (A) and scFv (B) antibody fragments in bacteria. The HuChI and HuCk regions of the Fab fragment originate from human antibody genes. (B) In the scFv gene fra ie n t, the heavy and light chain variable domains were connected by an oligoglycine linker. mAb epitope derived from the myc protein was attached to the C-teiminus of the scFv fragment to facilitate its detection. The //mdHI - EcoRI DNA fragments were in both cases inserted into the corresponding sites of the plasmid pUC119 polylinker. In addition to the pUC19 sequences, plasmid pUC119 contains an M13 origin of replication, and so its ssDNA can be synthetized and packaged into a helper phage. The expression of antibody fragments was under control of the lacZ promoter and could be induced by addition of IPTG. Pelb is a bacterial leader sequence enabling an efficient transport of nascent proteins into periplasm. The murine V genes of interest were inserted between the indicated restriction endonuclease sites.
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ELISA, confirmed the fidelity of the isolated variable regions. Although the reaction 
of the chimeric Fab fragment yielded a much darker colour than that of the scFv, 
nothing could be inferred about the relative binding affinities of these fragments for 
the Pk tag oligopeptide. These remain to be determined.
D.2. Construction of eukaryotic vectors expressing engineered 
immunoglobulin chains.
D.2.1. Construction of genes for the reshaped V regions.
In the second stage of reshaping SV5-P-k mAb, complementarity-determining 
regions (CDRs) of human heavy and light chains were substituted with those derived 
from SV5-P-k vaiiable regions, so that only about 9% of the total amino acid 
sequences were of a murine origin. This was achieved by oligonucleotide-directed 
mutagenesis (Kunkel et al., 1987). Briefly, three mutagenic kinased primers per 
variable region, each corresponding to one CDR (also see Fig. 4), were annealed to 
single-stranded human gene templates in M l3, which contained incorporated uridine. 
The primers were extended in vitro by T7 DNA polymerase in the presence of 
T4 DNA ligase and the resulting double-stranded DNA species were transfected into
E. coli. Because of the presence of uridine, the original templates in a wild-type 
bacteria were preferentially degraded, while the mutagenized strands generated in 
vitro were selectively replicated (also see Fig. 31).
D.2.1.1. Construction of gene for reshaped heavy chain V region.
The framework region of the human antibody KOL (Kabat et al., 1987) 
inserted in vector M13KOLHuVH (K. Armour, unpublished data) was used as 
a template for engineering of the heavy chain. This M13-derived vector also carried 
approximately 260 bp upstream of the V h  gene, which contained the promoter region 
and two leader sequence exons (plus the intron), and 200 bp downstream of the Vh 
3' splice-donor site (Fig. 29).
The reshaped Vh gene, designated rH, was generated using HI, H2 and H3 
primers corresponding to CDRl, CDR2 and CDR3 sequences, respectively, for the in
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MindHI V V BamHI
Figure 29. Schematic structure of the inserts in M13K0LHuVH and M13VKPCR1 vectors.The figure schematically depicts the Hindlll-BamHl fragments in M13-derived vectors used as templates for the oligonucleotide-directed mutagenesis. Dark boxes represent the leader sequence- and the empty box variable region-coding sequences. 'V indicates splice sites.
vitro synthesis of the second strand. Primer H2 also mutated AGC codon 75 for serine 
to proline codon, CCC. After transformation of bacteria with the in vitro extension 
reaction mixture, one out of eight sequenced M13 clones contained grafted CDRl, 
CDR3 and the proline codon, but not CDR2. Because repeated attempts to graft 
CDR2 using the H2 primer were abortive, a second primer, termed H2.2, was 
designed, which was shorter at the 5'-end and extended at the 3*-end. This primer 
successfully substituted the DNA corresponding to KOL CDR2 with that of SV5-P-k.
In addition to the grafted CDR, the reshaped heavy chain contained two 
substitutions in the framework, Ser75->Pro and Arg98->Ser (see also Table 5). These 
changes had been suggested by B. Harris (Scotgen, Aberdeen) in order to improve the 
binding affinity of the reshaped variable domain. As can be seen in Fig. 30, the 
reshaped heavy chain had two 'accidental' nucleotide/amino acid substitutions just 
upstream of CDRl, but these were assumed to be unimportant for the overall 
structure of the variable domain.
D.2.1.2. Construction of gene for reshaped light chain V region.
The SV5-P-k light chain CDRs were grafted onto the framework region of the 
human myeloma protein REI (Reichman ei al., 1988) inserted in vector M13VKPCR1 
(Orlandi et al., 1989). This vector carried approximately 190 bp upstream sequences 
of the Vk gene, which contained the promoter region and two leader sequence exons 
(plus the intron), and 40 bp of the 3'-end and the 3' non-coding sequences taken from 
human Jk region sequences (Reichman et at., 1988; Fig. 29). After in vitro synthesis
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Reshaped heavy-cliain V-region gene (rH)
1/1gag gtc caa ctg gtg gag age ggt gga ggt
31/11 
gtt gtg caa cct ggc egg tcc ctg cgc ctg
glu val gin leu val glu ser gly gly gly val val gin pro gly arg ser leu arg leu61/21 
tcc tgc tcc teg tot ggc tat acc ttc acc
91/31 
AGT TTT GGA ATG GAG tgg gtg aga cag gca
ser cys ser ser ser gly tyr thr phe thr ser phe gly met his trp val arg gin ala121/41 
cct gga aaa ggt ctt gag tgg gtt gca TAG
151/51 
ATT AAT ACT GAG AGT AGT AGG ATG TAG TAT
pro gly lys gly leu glu trp val ala tyr ile asn thr asp ser thr thr ile tyr tyr
181/61 
GGA GAG ACA GTG AAG GGG aga ttt aca ata
211/71 
teg cga gac aac GGc aag aac aca ttg ttc
gly asp thr val lys gly arg phe thr ile ser arg asp asn pro lys asn thr leu phe241/81 
ctg caa atg gac age ctg aga ccc gaa gac
271/91 
acc ggg gtc tat ttt tgt gca age GGG GGC
leu gin met asp ser leu arg pro glu asp thr gly val tyr phe cys ala ser ala gly301/101 
CCT TAG 
pro tyr
TAG
tyr
GGG
gly
TTT
phe
GAG
asp
TAG
tyr
tgg
trp
ggc
gly
caa
gin
331/111
ggg acc ccg gtc 
gly thr pro val
acc
thr
gtc
val
tcc
ser
tea
ser
Reshaped light-
1/1
chain V-region gene (rL)
31/11
gac ate cag Ctg acc cag age cca age age ctg age gcc age gtg ggt gac aga gtg acc
asp ile 
61/21
gin leu thr gin ser pro ser ser leu ser 
91/31
ala ser val gly asp arg val thr
ate acc tgt AGG TGT AGT AAG AGT GTG GTA GAT AGT AAT GGC ATG ACT TAT TTG TAT tgg
ile thr 
121/41
cys arg ser ser lys ser leu val his ser 
151/51
asn gly ile thr tyr leu tyr trp
tac cag cag aag cca ggt aag get cca aag ctg ctg ate tac GAG ATG TGC AGG GTT GGG
tyr gin 
181/61
gin lys pro gly lys ala pro lys leu leu 211/71
ile tyr gin met ser ser leu ala
TGA ggt gtg oca age aga ttc age ggt age ggt age ggt acc gac ttc acc ttc acc ate
ser gly 
241/81
val pro ser arg phe ser gly ser gly ser 271/91
gly thr asp phe thr phe thr ile
age agC Gtc cag cca gag gac ate gcc acc tac tac tgc GGT GAA ATT GTA GAA GTT GCA
ser ser 
301/101
leu gin pro glu asp ile ala thr tyr tyr 
331/111
cys gly gin ile leu glu leu pro
TTC AGG ttc ggc caa ggg acc aag gtg gTG ate aaa cgt GAG TAG AAT TTA AAG TTT GGTphe thr 
361/121 
TCC TGA 
ser ser
phe
GTT
val.
gly
GGA
gly
gin
TGC
ser
gly thr lys val val ile lys arg glu AMB asn leu asn phe ala
Figure 30. Sequences of reshaped rH and rL variable regions.The figure shows DNA and deduced protein sequences of reshaped variable regions. Nucleotides in the variable regions that differ from the original human chain genes are shown in capitals.
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of the second strand using the LI, L2 and L3 mutagenic primers and transformation, 
one M13 clone, out of twelve sequenced, contained all three murine CDRs.
D.2.2. Construction of chimeric V region genes.
Chimeric heavy (cH) and light (cL) chains were also constructed, which 
consisted of variable murine domains joined to constant human domains. Because 
chimeric Fab expressed in E. coli readily recognized the Pk tag, it was expected that 
the whole chimeric antibody (cLcH) would behave similarly. Furthermore, affinity 
comparison of combined chimeric light and reshaped heavy (cLrH), and reshaped 
light and chimeric heavy (rLcH) chains to the whole chimeric antibody (cLcH) should 
facilitate the identification of possible binding problems to reshaped heavy, light or 
both chains.
D.2.2.1. Construction of chimeric heavy V gene.
For the construction of the chimeric heavy chain (cH), the whole murine V h  
region gene was inserted into the MlSKOLHuVH for addition of the human Vh 
gene-flanking sequences (Fig. 29). To do that, a Pstl site was generated at the 5'-end 
of the KOL Vh gene using H-Pst primer and oligonucleotide-directed mutagenesis. 
The murine Vh gene was then PCR amplified using the same primers as used for the 
cloning of the murine V h  into the Fab and scFv vectors (Fig. 27b). The PCR product 
was digested with Pstl and restriction endonucleases and used to substitute for 
the KOL gene in Pstl- and B^rEII-digested double-stranded replicative form (RF) of 
bacteriophage M13KOLHuVH.
D.2.2.2. Construction of chimeric light V gene.
A chimeric light chain (cL) gene was generated by PCR amplification of the 
murine Vk using primers L-PvuBACK and L-BamFOR, digesting the PCR product 
with PvmII and BflmHI enzymes and inserting it between the same sites in the RF of 
M13VKPCR1. The L-BamFOR primer included DNA sequences beyond the ORF of 
Vk including the necessary 3' splice-donor site (Reichmann et al.^  1988; Fig. 29).
I l l
Table 5. Recombinant heavy and light chains derived from SV5-P-k.
cL chimeric light chain (murine variable/human constant regions)
rL straight CDR graft
cH chimeric heavy chain (murine variable/human constant regions)
rH CDR graft + substitutions of Ser75->Pro and Arg98->Ser
D.2.3. Assembly of complete immunoglobulin genes in eukaryotic 
expression vectors.
In the next step of the construction of recombinant immunoglobulin genes, the 
reshaped and chimeric variable regions (Table 5) were coupled to human IgGl and 
human kappa constant regions for expression in eukaryotic expression vectors.
Eukaryotic vectors expressing complete cH and rH heavy chains were 
constructed as follows. The reshaped and chimeric Vh genes together with the 
appropriate flanking DNA sequences were cut out from the RF of appropriate 
bacteriophage DNAs using //mdlll and FamHI sites and cloned into eukaryotic 
expression vector pSVgpt (Mulligan and Berg, 1981). The gene coding for human 
IgGl heavy chain (Takahashi et al„ 1982) was then transferred from plasmid 
pBSGlS-HuIgGl into pSVgptH vectors using BamHI sites.
cL and rL light chains were expressed using pSVhyg vector (Orlandi et aL, 
1989). Both the chimeric and reshaped Vk genes flanked by appropriated DNA 
sequences were excised from the M13 vectors and inserted into pSVhyg using 
//mdni and BfjimHI sites. As an illustration of the steps involved in the construction 
and assembly of the complete immunoglobulin genes, the cloning of the rL light 
chain is schematically depicted in Fig. 31.
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cAa eA=
Annealing of mutagenic primers
In vitro synthesis of the 2nd strand
Transformation and selective replication of mutagenized strand
Coupling of the reshaped V region gene to the constant region gene in a eukaryotic expression vector
Figure 31. Construction and assembly of the rL light chain gene.(The schematics does not show the leader sequence and other V gene flanking regions described in Fig. 29.)
D.3. Generation of stably transfected CHO cell clones expressing 
recombinant immunoglobulin chains.
Vectors pSVhygL and pSVgptH expressing the light and heavy chains under 
control of immunoglobulin promotors were transfected in Chinese hamster ovary 
(CHO) cells and the successful transfectants were selected by their ability to grow in 
the presence of hygromycin B (pSVhygL) and mycophenolic acid plus xanthine 
(pSVgptH). Hygromycin B inhibits protein synthesis by disrupting translocation and 
promoting mistranslation. The hygromycin B-phosphotransferase gene product
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Figure 32. Principle of the metabolic selection for XGPRT-expressing cells by mycophenolic acid/xanthine.
detoxifies hygromycin B by phosphorylation (Gritz and Davies, 1983). Mycophenolic 
acid blocks the pathway for de novo synthesis of guanylate (GMP) and the expression 
of xanthine-guanine phosphoribosyltransferase (XGPRT or gpt), an enzyme normally 
absent in mammalian cells, allows transfectants to produce guanylate from xanthine 
(Mulligan and Berg, 1981). The relevant metabolic pathways of the mycophenolic 
acid selection are depicted in Fig. 32.
Firstly, pSVhygL vectors expressing either cL or rL light chains were 
transfected into CHO cells using electroporation and the transformants were selected 
for growth in the presence of hygromycin B. Nine individual colonies of each of 
pSVhygcL- and pSVhygrL-transfected cells, designated CHO-cL and CHO-rL, 
respectively, were ring-cloned and expanded. The presence of light chains was tested 
on a dot blot in both the cell lysates and tissue culture supernatants using HRP- 
conjugated antibodies specific for the human k  light chain followed by ECL. Fig. 33 
shows a dot blot analysis of the CHO-rL clones. As judged by the cell lysates, of the
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Figure 33. Expression of the rL light chain by CHO-rL cell clones.Nine clones of pS VhygrL-transfected CHO cells for expression of the rL light chain. Cell lysates (top) or tissue culture supernatants (bottom) were dotted on
a nitrocellulose filter and the filter was probed using HRP-conjugated anti-human k  
light chain mAb followed by ECL. The figure shows a 20-min. exposure.
nine hygromycin B-resistant clones, two did not express any light chain at all and the 
expression levels in the others varied. No significant amounts of the rL light chain 
were detected in the supernatants.
The CHO-cL and CHO-rL clones producing the highest levels of the 
respective light chains were transfected with vectors pSVgptcH or pSVgptrH, so that 
cells expressing all the four possible combinations of heavy and light chains were 
generated. Transformats were selected by growth in the presence of hygromycin B 
and mycophenolic acid/xanthine, ring-cloned and are being currently grown to 
sufficient cell numbers to allow testing for the expression of both the heavy (using 
HRP-conjugated protein A) and light (as above) chains. Recombinant 
immunoglobulin chains produced by 'double-positive' clones will be tested for the 
chain association and binding specificity in ELISA.
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DISCUSSION
1. Pk tag for assembly of SMAA vaccines.
The binding of monoclonal antibody S V5-P-k to the P protein of simian 
virus 5 was successfully competed with a nonapeptide (Southern et al, 1991). This 
nonapeptide, extended by 5 adjacent amino acids from the P protein and designated 
Pk, had a number of properties, which made it attractive for the construction of 
vaccines. It retained its antigenicity when coupled to the C-terminus of larger 
proteins. This was initially demonstrated using the nucleocapsid protein p27 of simian 
immunodeficiency virus both denatured (as shown by a Western blotting in Fig. 11) 
and in a native conformation (as shown by capture and assembly of p27-Pk into 
SMAA complexes in Fig. 10). This finding was subsequently extended for other non­
glycosylated SIV proteins (e.g. Figs. 14 and 17). The Pk tag also remained antigenic 
when attached to the C-terminus of a glycoprotein, SIV gpl60, (Fig. 25) and, in that 
position, did not interfere with transport and post-translational modification/ 
glycosylation of the gpl60 glycoprotein in insect cells. Although this finding may be 
limited to this particular situation, it suggests that the Pk tag may be a valuable 
universal affinity tag for the purification of glycoproteins. Furthermore, the Pk tag 
does not seem to interfere with the transport of proteins across the plasma membrane 
and cellular wall of E. coli. This was demonstrated by a successful secretion of the Fv 
antibody fragment with the Pk tag attached to the C-terminus of its ChI domain from 
bacteria (T. H. and G. Winter, unpublished observation). In the past, this had not been 
the case for all Fv teiminal tags (G. Winter, personal communication). This finding
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may be of significance for the large-scale production of Pk tag-linked antigens. The 
secretion of antigens from bacteria may facilitate immensely the industrial 
purification of antigens and, thus, may lead to more economical methods of vaccine 
production. It is also important to minimize the immune responses directed against 
the non-antigen parts of the vaccine. In this respect, the Pk tag was only weakly 
immunogenic when bound to SV5-P-k mAb in the SMAA complexes (Fig. 12 and 
Randall et al., 1993a),
2, Two-tag purification of proteins.
Three commercially available expression vectors pGEX-2T, pQE-9 and 
pVL1393 were modified (Fig. 34) and used to express SIV proteins with the Pk tag at 
their C-termini. The non-glycosylated SIV proteins also had either glutathione 
S-transferase (GST) or histidine (His) affinity tags attached to their N-termini.
A general purification method was developed, in which the recombinant proteins 
were first purified via their N-terminal His tag on a nickel-affinity column and then 
via their C-terminal Pk tag using SV5-P-k mAb (Fig. 20). Despite lower tlian 
10 pg.l’  ^levels of expression for some SIV proteins (Table 4), analytical quantities of 
all the His-SIV-Pk proteins using a two-tag purification protocol were prepared 
(Fig. 21).
The number of proteins that need to be produced and isolated to a high degree 
of homogeneity increases every day. Purification involving two different tags, each 
attached to one end of a recombinant protein, represents a simple and rapid technique 
for isolation of full-size proteins (Fig. 35). This strategy may be particularly useful for 
the large-scale production of immunogens needed in the construction of subunit 
vaccines. There is an increasing requirement for precisely defined components of 
vaccines and two-tag purification provides proteins that are intact at both their N-and 
C-teimini. However, it should be noted, that even protocols involving tags attached to 
both protein termini occasionally co-purify partially degraded species due to protein
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Figure 34. DNA vectors for expression of tagged proteins.Vectors pGEXnPk, pGEXcPk and pQ9cPk aie designed for a single-cloning-step addition of two purification tails to bacterially expressed proteins. pVL1393cPk is a transfer vector for the construction of recombinant baculoviruses.
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Figure 35. Schematics of a two-step purification of SIV 27-Pk expressed from vector pGEX27Pk.The use of two affinity tags ensures purification of full-size proteins (right).T indicates the site of thrombin cleavage.
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aggregation or on-going proteolytic degradation during the purification procedure. 
Furthermore, two-step purification is less prone to contamination than protocols 
attempting to purify the protein of interest in a single step. This is especially relevant 
for antigens that are difficult to express at high levels in host organisms.
Short tags may also have advantage of low immunogenicity and may not be 
necessary to remove from recombinant proteins, which are intended for use as 
immunogens. As has been demonstrated, both the Pk (Fig. 12) and His (Randall et al, 
1993a) tags induce only weak antibody responses. However, it is difficult to predict 
whether small tags may contain immunodominant T cell sites and thus interfere with 
the induction of cell-mediated immunity. If this is the case, it may be possible to 
reduce the tag size. Indeed, an antigenic sequence as short as three amino acid 
residues has been identified (R.E. Randall, personal communication). Also, 
a chelating N-terminal dipeptide HisTrp was sufficient to purify proinsulin (11 amino 
acids; Smith et al,, 1988). In this case, the binding of HisTrp-proinsulin to an 
immobilized Np+ was probably partially facilitated by the presence of two histidine 
residues in proinsulin. Thus, the use of HisTrp tag and nickel-chelating 
chromatography was a sensible choice of a purification strategy, which suggested that 
even using ’universal' affinity tags, each protein may have to be approached 
individually to select an optimal purification procedure. Thus, one may envisage 
a situation, in which two amino acid residues at the N-terminus and three amino acids 
at the C-terminus may allow a two-step purification of full-size proteins.
3. Levels of protein expression in prokaryotic cells.
Purification protocols involving terminal Pk and His tags worked well for all 
the proteins tested. The major obstacle for the large-scale protein preparations of 
a number of SIV proteins was their level of expression. While the yields of His-17-Pk 
approached 5 -10 mg per litre of induced culture (approximately 2.5 g of wet 
bacterial pellet), proteins such as His-NpoP-Pk and His-prot*-Pk were produced in 
amounts less than 10 pg.l-l. For each of the SIV protein, time-course of expression
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(Fig. 18) and IPTG-induction dose-response experiments at two different 
temperatures (Fig. 19) were carried out, which, however, resulted in only marginal 
increases in expression levels and only for some proteins. Increased protein yields 
may also result from monitoring the physiology of bacteria during the period of IPTG 
induction of protein expression, a factor that was not examined in this work. Among 
the parameters to measure would have been the level of nitrogen in the culture 
medium, the accelerating rate of consumption of initial glucose or the molar fraction 
of CO2 and O2 in the exit gas (Pack et al., 1993).
Large differences in the relative levels of expression between SIV genes were 
observed in both pGEXcPk and pQ9cPk vectors. Thus, the problems appeared to be 
associated with the particular DNA sequences or polypeptide chains expressed rather 
than being dependent on the expression vector system used. There are several 
possible explanations for this observation. An obvious problem in the overproduction 
of proteins in prokaryotic cells is proteolytic degradation. It can be envisaged, that 
foreign proteins would be rapidly degraded, if their conformation or amino acid 
sequence did not offer protection from the host intracellular proteases. Moreover, 
some proteins, e.g. those carrying regulatory functions, may be inherently unstable. 
There is a number of ways how to deal with protein instability. One possibility is to 
use E. coli strains deficient in certain proteases or other strains carrying the so called 
pin (for protease inhibitor) gene of bacteriophage T4 (Simon etal., 1983). 
Alternatively, recombinant proteins may be secreted from bacteria into the growth 
medium, where proteolytic enzymes may be different and/or their levels reduced.
As already mentioned above, proper folding influences protein stability in the 
cell. The proper folding of recombinant proteins in bacteria may be facilitated by 
induction of bacterial cultures at lower temperatures, which probably slows the 
overall translation rate and gives the translated protein time to assume its tertiary 
conformation. Codon usage and distribution in the gene may also affect protein 
folding. It was suggested by Purvis and collègues (1987), that a set of rare codons 
may cause a translational pause at key junctures in protein biosynthesis, which may, 
in turn, allow a discrete domain to fold more efficiently. This fine co-translational
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regulation may be disturbed in hosts, which differ in codon usage from the gene's 
original species. Moreover, high proportion or accumulation of infrequently used 
codons in a gene may cause a limitation of amino acid-charged tRNAs, which may 
significantly increase the frequency of mistranslations or decrease the overall protein 
production (Robinson et al., 1984). The only potential problem-causing codons of 
mammalian genes expressed in prokaryotes are the AGG and AGA codons for Arg. 
However, when the SIV genes were searched for these codons, there was no 
immediate difference in their usage between well and poorly expressed His-SIV-Pk 
proteins.
Many different post-translational modifications of proteins have been 
described in eukaiyotes including glycosylation, phosphorylation, acétylation, 
amidation, sulphation, attachment of fatty acids and formation of unusual amino 
acids, none of which, as far as it is known, occurs in bacteria. These modifications 
may again influence the protein conformation and contribute to protein stability.
Cell toxicity of His-SIV-Pk proteins expressed in bacteria should be also 
considered. This could be partially overcome by a more tightly-controlled inducible 
promotor than the /ûc-based system operating in pGEX-2T and pQE-9 plasmids. An 
example of a tight expression control is the T7-lac double repression system (Studier 
et al., 1993). In these constructs, a lac operator is placed between a T7 promotor and 
the gene of interest. The transcription of the T7 polymerase gene in the same 
bacterium is also controlled by lac operator. Thus, in the presence of lac repressor, 
both transcription of the T7 polymerase gene by E. coli RNA polymerase and that of 
the target gene by T7 polymerase are inhibited. Their normal transcription can be 
restored by addition of IPTG. Alternatively, bacteria could be induced at higher 
temperature than 37 °C, which results in sequestering of proteins into inclusion 
bodies (J. Sedlacek, personal communication). Also, the use of non-bacterial hosts 
such as baculovirus vectors or yeasts is a possibility always worth pursuing.
Finally, mRNA secondary structures may account for the differences seen in 
expression of different SIV proteins from identical plasmids. In particular, the Shine- 
Dalgamo (30S ribosomal subunit-binding site) and more so the AUG sequences have
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to be readily accessible for an efficient translation, i.e. should not be a part of dsRNA 
in secondary mRNA structures (Roberts et al., 1979). For the same reasons, 
reconstruction of the 5'-end of expressed gene has been recommended, that 
maximizes the A+T content, but preserves amino acid sequence (DeLamarter et ah, 
1985).
In essence, there is room for increasing of the levels of SIV protein 
expression, but, as it is with the traditional protocols of protein purification, there is 
not a straightforward method to follow. There are two ways how to pursue the low 
expression levels. The first approach is to take the His-SIV-Pk genes one by one and 
identify in each case the particular problem. Then, according to both the theoretical 
and empirical principals, steps may be taken in attempt to increase their levels of 
expression. Alternatively, bacteria may be exposed to a mutagen and searched for 
high-expression mutants. Both these approaches are labour- and time-intensive and 
are beyond the scope of this thesis.
4. Antigenicities and immunogenicities of recombinant SIV proteins.
One of the reasons for expressing and purifying all of the SIV proteins was to 
produce reagents for immunization/protection experiments in macaques. The idea was 
to prepare SMAA complexes containing all the SIV antigens and use these for 
vaccination of experimental animals, which would be subsequently challenged with 
SIV. However, before the SMAA complexes containing SIV proteins were used in 
monkeys, their immunologic fidelities, i.e. their abilities to induce antibodies and cell- 
mediated immune responses, which could recognize authentic SIV antigens or SIV- 
derived peptides, had been evaluated in smaller and cheaper animals such as mice.
4.1. Bacterially produced non-glycosylated SIV proteins.
All the so-far tested recombinant non-glycosylated SIV proteins assembled 
into SMAA complexes and used for immunizations of mice (His-pl7-Pk, His-p27-Pk, 
His-rt-Pk, His-vpr-Pk, His-vpr-Pk) induced antibodies, which readily recognized
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authentic Western-blotted proteins in SIV-infected cell lysates (Fig. 13 and Randall et 
al, 1993a, 1993b).
Western blotted recombinant SIV proteins were also employed in the analysis 
of the antibody responses in SIV-infected macaques. Using HRP-conjugated 
protein A followed by ECL, clear humoral responses to endonuclease, pl5, pl7, p27, 
rt and vif as well as weak responses against vpx and protease were observed (Fig. 22), 
No antibodies specific for nef, rev, tat or vpr were detected. Although some monkeys 
have previously produced nef-specific humoral responses (M. Cranage, personal 
communication), the negative results in this experiment suggest, when translated to 
humans, that it may be difficult to use antibody responses to nef to distinguish 
between infection with wild-type HIV and any administered attenuated nef-deleted 
virus vaccines. However, the possible reasons for a negative signal in this type of 
assay were several: (i) the antibodies were not present in the monkey serum, 
a genuinely negative results; (ii) the antibodies were present, but not detected, 
because they were specific for structural epitopes on the non-denatured proteins and 
failed to recognize the denatured polypeptides; alternatively, (iii) cross-reacting 
antibodies present in the serum, which were generated by linear epitopes on authentic 
SIV proteins, failed to recognize the same stretch of amino acid residues on 
recombinant proteins, i.e. the recombinant SIV proteins did not have the desired 
fidelity, a situation which is difficult to picture unless some post-translational 
modifications had occurred on either recombinant or mammalian cell-produced SIV 
proteins; finally, (iv) antibodies in the monkey serum did bind the Western blotted 
proteins, but failed to bind the HRP-conjugated protein A.
The ability to induce lymphoproliferative responses has been examined using 
His-rt-Pk (A. Green, personal communication). After immunization with SMAA 
complexes containing His-rt-Pk, murine splenocytes were removed and incubated 
with the recombinant antigens. Incorporation of radiolabel was observed after in vitro 
stimulation with His-rt-Pk, but not His-pl7-Pk, which indicated, that the 
lymphoproliferative responses were specific for the SIV reverse transcriptase rather 
than for the terminal His and Pk tags.
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42. SIV envproduced in insect cells.
Serum from SIV-infected macaques recognized efficiently Western-blotted 
recombinant gpl60-Pk (Fig. 25, panel D, lanes 1 and 2), thus the insect cell-produced 
gpl60-Pk was antigenicly appropriate. In order to evaluate the ability of recombinant 
gpl60-Pk to induce antibody responses capable of recognition of the authetic SIV 
envelope glycoprotein, mice were immunized with gp 160-Pk-containing SMAA 
complexes. Vigorous humoral responses were generated, that readily recognized 
recombinant gpl60-Pk. However, the murine serum reacted only weakly with the 
Westem-blotted authentic gpl60 monomer in SIV-infected mammalian cells (Fig. 25, 
panel E, lane 3). If the slower-migrating band on the Western blot of SIV-infected 
mammalian cell lysates was indeed a gpl60 dimer, as argued earlier, then the 
antibodies induced by immunization recognized the glycoprotein preferentially in 
a dimeric rather than monomeric form.
4J. Protection experiments in macaque monkeys.
As an extension of this work, the preparation of large-enough quantities of 
these SMAA complexes for protection experiments in macaques was attempted. 
However, because of problems with the levels of protein expression in E. coli, 
preparation of only six SIV antigens have been successfully achieved to-date 
(C. Dotting and D. Young, personal communication). Thus, only alum-antibody- 
antigen complexes of His-17-Pk, His-27-Pk, His-rt-Pk, His-vpr-Pk, His-vpx-Pk 
(prepared by eluting the antibody-antigen complexes from protein A-sepharose and 
subsequent precipitation of the complexes into alum), and S. aureus-mûboôy- 
gpl60-Pk complexes have been used for macaque immunizations. In addition to the 
limited number of antigens, there are several potential factors complicating the 
interpretation of a possible negative outcome of this protection experiment. Firstly, all 
the non-glycosylated SIV proteins used for the first protection experiment were 
derived from SIV molecular clone BK28, the precise derivation of which is difficult 
to trace (Fig. 7) and which is not widely used. Consequently, the macaques will be 
challenged with molecular clone SIVmac251(32H)(J5), a virus homologous to the 
gpl60-Pk, but heterologous for the non-glycosylated antigens. Secondly, there has not
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been a single case reported of protection of macaques against SIVmac infection using 
purified recombinant antigens as the only immunogens (Stott, 1993). This may be, 
however, partially due to the fact, that the immunization studies predominantly 
concentrated on the SIV env and gag gene products. Thirdly, alum gels were shown 
by Shearer and Clerici (1993) to preferentially induce the Th2 subset of T helper 
cells, which leads to induction of humoral responses rather than CTL, and, in the past, 
antibodies did not seem to correlate with macaque protection. Finally, if the antibody 
component of SMAA complexes plays a role in the induction of immune responses, 
then it is not clear, how well the murine IgG2a antibody interacts with the simian 
immune system. Thus, a negative result of the protection experiment will have little 
meaning for the evaluation of immunogenic potentials of the involved recombinant 
SrV proteins. On the other hand, a positive outcome of these experiments would 
allow dissecting of the protective immune responses against SIV infection in 
macaques and would enable the correlates of protection to be established.
5. Areas of future investigation.
5.L The nature of solid matrix.
One component of SMAA complexes, that has not been addressed in this 
work, is the nature of the solid matrix. It is clearly an area of SMAA complex 
development, which will require future attention. It may be advantageous, if the solid 
matrix were of a (i) particulate nature, which would facilitate preparation of the 
vaccine especially at the stage of the antigen purification. The (ii) size of particulate 
solid matrixes should be optimized, as it may influence the efficiency of capture of 
SMAA complexes by antigen-presenting cells and thus may influence the 
immunogenicity of SMAA complexes. The solid matrix should also be made of 
a (ii) biodegradable material, which would allow complete clearance of the matrix 
from the organism. Some materials used for incorporation of antigens or antigen- 
antibody complexes may allow (iii) sustained or timed release of the immunogen. 
Finally, the solid matrix should be (iv) inexpensive.
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52. The nature of linkage between antigens and solid matrix.
The availability of cloned variable regions of the tag-specific mAb provides 
a unique opportunity to address the issue of importance of the antibody component of 
SMAA complexes in the immunogenicity of this type of vaccine. For example, 
different immunoglobulin isotypes can be used for the construction, of SMAA 
complexes, some of which do not bind complement or possess weak affinity for 
a certain class of Fc receptor. These experiments may also shed some light on which 
antigen-presenting cells actually process and present SMAA complex-delivered 
antigens. Alternatively, Fab or Fv fragments of antibodies, linked (e.g. via disulphide 
bonds) to particulate beads, may be used for the construction of SMAA complexes.
The antibody component may not be included in the vaccine design at all. 
Attaching tag-linked antigens by a non-covalent, affinity tag-mediated interaction 
directly to beads for vaccination purposes remains to be an attractive possibility. Such 
a strategy would retain the benefits of simplicity, universality and antigen purification 
discussed above for the solid matrix-antibody-antigen complexes, yet it would reduce 
the cost and chance of adverse immune reactions.
5.3. Increasing the immunogenicity of SMAA complexes.
As it was shown by Randall and co-workers (1991), immunization of mice 
with SMAA complexes was less efficient in inducing MHÇ class I-restricted CTL 
than infection of mice with virus. Thus, possibilities of increasing the immunogenic 
potency of SMAA complexes for induction of CTL should be explored. In general, 
proteins of immunostimulating properties, such as the cholera toxin subunit B or the 
subunit B from the heat-labile E. coli toxin, may be incoiporated into SMAA 
complexes. Also, antigens may be included, which would target SMAA complexes to 
particular antigen-presenting cells or selectively stimulate certain aspects of 
immunity, i.e. mucosal immune responses.
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6. SMAA complexes as potential human vaccines.
Monoclonal antibody SV5-P-k has been reshaped as a part of the development 
of SMAA complexes for potential use in humans. Humanization should improve the 
antibody's interaction with the human immune system and minimize its 
immunogenicity in the human milieu. In general, every antibody induces a certain 
level of anti-idiotypic antibodies, in part due to somatic mutations during affinity 
maturation. Thus it may not be surprising, that even reshaped antibodies used in 
a recent clinical trial retained some degree of immunogenicity (Isaacs et al., 1992). 
Obviously, the fewer substitutions in the V region frameworks of the humanized 
antibody, the better. Every amino acid change introduced in vitro has not been seen, 
and therefore 'permitted', by the acceptor's immune system.
The work presented here has demonstrated, that, in general, the assembly of 
tag-based SMAA complexes is indeed a feasible way of constructing multivalent 
subunit vaccines. Taking advantage of this simple approach, multiple antigens, 
including a glycoprotein, have been assembled into SMAA complexes and used as 
immunogens. The cost of production of SMAA complex vaccines should not be 
prohibitive, providing that optimal expression systems for all the protein components 
are found. As for the cost of the antibody, mAbs can be produced at l(X)-mg to 1-g 
quantities per litre of tissue culture supernatant (R.E. Randall, personal 
communication). In conclusion, a universal vaccine core can be envisaged, which 
consists of humanized tag-specific monoclonal antibody attached to a suitable solid 
matrix, to which tag-linked antigens of choice are bound and used for vaccination.
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